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Vaccination continues to represent the most effective means of providing immunological 
protection against infectious disease in human populations. With the World Health 
Organisation (WHO) reporting over 1.2 million AIDS related deaths in 2014, an efficacious 
HIV1 vaccine is urgently needed. The UCT Human Immunodeficiency Virus (HIV) Vaccine 
Development Group has focussed on understanding novel HIV-1 vaccine vectors, such as 
modified BCG, combined with modified vaccinia Ankara in the context of heterologous prime 
boost regimes. The tuberculosis vaccine Bacillus Calmette–Guérin (BCG) has a wellestablished 
safety profile as well as notable adjuvant activity with an estimated 3 billion doses 
administered globally since 1921. The development of modern molecular biology techniques 
in recent times has led to the creation of modified strains of BCG which have been shown in 
many cases to be safer and/or more immunogenic than the wild type strains in terms of 
delivering heterologous antigen.   
This study focuses on exploiting and combining two particular strategies of rBCG modification. 
The first is the development of auxotrophic strains that contain deletions geared towards 
preventing the bacteria from synthesising essential growth compounds or amino acids. An 
example of this is the ΔpanCD auxotroph of rBCG which does not synthesise pantothenic acid 
and thus has limited intracellular replication leading to less pathology. The UCT group has 
previously reported that HIV vaccines vectored by the Pasteur strain of rBCG ΔpanCD induced 
less pathology but improved immunogenicity as compared to Pasteur WT in the murine model 
(when used a prime in conjunction with an MVA boost). A second notable BCG modification 
strategy is the inclusion of exogenous genes to improve the immunogenicity of rBCG as a 
vaccine vector. An example of this is the insertion of the detoxified Clostridium perfringens 
toxin, perfringolysin O (pfo), into the rBCG genome. Upon expression, pfo forms pores in the 
endosome which facilitates translocation of vaccine derived antigen into the cytoplasm. This 
modification has been shown to lead to cross priming of T cells and improve the induction of 





For this study, recombinant BCG (rBCG) based vaccines expressing codon optimized HIV-1 
subtype C Gag, were constructed using three novel BCG strains and a standard strain (kindly 
supplied by AERAS): the Danish wild type strain of BCG (rBCG WT), a pantothenate 
auxotrophic strain of BCG Danish (rBCG ΔpanCD), the Danish strain expressing perfringolysin 
O (rBCG pfo) and a pantothenate auxotrophic Danish strain expressing perfringolysin O (rBCG 
ΔpanCDpfo). We hypothesized that priming with either rBCG ΔpanCD (gag) or rBCG 
ΔpanCDpfo (gag) would lead to less pathology and enhanced T cell responses whilst priming 
with either rBCG pfo (gag) or rBCG ΔpanCDpfo (gag) would lead to improved T cell responses 
(as compared the wild type strain following a SAAVI MVA-C boost).   
A longitudinal study was firstly undertaken to assess the overall pathology which included; 
splenocyte phenotyping, assessment of granuloma formation, iNos activity in the liver and 
disseminated bacterial load in lymph nodes. Mice were vaccinated on day 0 with rBCG 
vaccines (expressing Gag or an empty vector control, 1 x 107cfu/200 µl, i.p injection) and 
sacrificed at multiple time points: days 2, 3, 7, 12, 21 and 28 post vaccination. Mice vaccinated 
with rBCG ΔpanCD (gag/control) as well as rBCG ΔpanCDpfo (gag/control) were able to clear 
the mycobacteria by day 7 post-infection. This clearance could have been due to immune 
responses or alternatively the inability of the mycobacteria to survive in an environment 
limited in pantothenate. In addition to clearance, mice vaccinated with ΔpanCD and 
ΔpanCDpfo (gag/control) presented with significantly fewer liver granulomas (as measured 
by CD3+ staining) and less active granulomas (as measured by iNos) as compared to mice 
vaccinated with the WT and pfo strains. The formation and maintenance of granulomas is 
indicative of the inability of the immune system to clear infection. This data demonstrates the 
superiority of ΔpanCD well as ΔpanCDpfo strains of rBCG in inducing less pathology than the 
WT Danish and the pfo strains.   
Next, the magnitude and quality of vaccine induced HIV specific T cell immune responses 
following ex vivo stimulation of splenocytes was assessed in mice primed with rBCG and 





CD8+ peptide were measured by IFNγ ELISPOT assay, cytokine bead array (CBA) and multi-
parameter flow cytometry. All rBCG (gag) vaccines were able to prime for significant vaccine 
specific boost responses. The response to the two CD4+ peptides tested differed according to 
the rBCG used to prime the MVA response. Whilst rBCG pfo (gag) and rBCG ΔpanCD (gag) 
primed for significant CD4+ (13) and CD4+ (17) boost responses respectively, rBCG ΔpanCDpfo 
primed for a SAAVI MVA-C boost of both CD4+ epitopes. An increased breadth of CD4+ 
responses has been shown to mechanistically improve CD8+ T cell responses and lead to lower 
viral load in chronically infected HIV+ individuals. Multi-parameter flow cytometry indicated 
that the rBCG modifications can work synergistically to induce the greatest collective HIV 
specific bi- and multi- functional CD4+ and CD8+ cells as seen when priming with rBCG 
ΔpanCDpfo (gag). Lastly, mice primed with rBCG pfo (gag) and rBCG ∆panCDpfo (gag) induced 
greater CD8+ TEM and TCM responses as compared to mice primed with rBCG WT (gag) and 
rBCG ∆panCD (gag).  
 
The relative expression of 86 immunologically pertinent genes in ex vivo stimulated and 
unstimulated splenocytes were studied to determine which genes (common and variable) are 
induced in mice primed with the four rBCG (gag) as compared to the corresponding rBCG 
(control) 12 days after the SAAVI MVA-C boost. In a comparison of the different rBCG primes, 
the IL-17 pathway was found to be uniquely up regulated and the IL-18 pathway to be down 
regulated in mice primed with rBCG pfo (gag) and rBCG ∆panCDpfo (gag). After a six hour ex 
vivo stimulation with HIV-1 peptides, mice primed with rBCG ∆panCD (gag) were observed to 
have a 42 fold down regulation of the Th1 transcription factor STAT4 suggesting strong 
suppression of the Th1 immune response 6 hours after the recall response was induced. In 
contrast, the IFNγ pathway was up regulated in mice primed with rBCG pfo (gag) or rBCG 
ΔpanCDpfo (gag) suggesting a persistent Th1 (inflammatory) response is present 6 hours after 
ex vivo stimulation.  
To conclude, we propose systemic models of how the ΔpanCD, pfo and ΔpanCDpfo 





immunogenicity associated with these rBCG Danish vaccines. This work further promotes the 
use of modified rBCG vaccine vectors as HIV-1 vaccines. Furthermore, the systems vaccinology 
approach provides a greater insight into the mechanism of these modifications and we 
suggest that other pre-clinical vaccine studies use such approach to maximise knowledge 
gained from pre-clinical vaccine work. Whilst we have demonstrated these principals in the 
murine model, future work will include assessment of rBCG ΔpanCDpfo expressing Gag and 
combinations of different HIV-1 antigens in non-human primates, including and combining 
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1.1 The importance of vaccination in overcoming the global burden 
of HIV-1/AIDS  
Following the identification of the first case of acquired immunodeficiency disease syndrome 
(AIDS) and its causative agent the human immunodeficiency virus (HIV), in 1981 and 1983 
respectively, there have been in excess of 30 million AIDS related deaths (Barre-Sinoussi et al., 
1983). There are currently an estimated 36.9 million people who are HIV positive (UNAIDS, 
2015). Global data on HIV indicates that there were 2 million new infections as well as 1.2 
million AIDS related deaths in 2014. Sub-Saharan Africa has borne the brunt of the pandemic 
and accounts for 66% of global HIV infections (UNAIDS, 2015). In South Africa, there were an 
estimated 6.8 million people living with HIV in 2015. Currently, a multifaceted approach to 
control South Africa’s HIV epidemic using pre-exposure prophylaxis, improved anti-retroviral 
therapy (ART) and increased public awareness is responsible for decreasing infection rates as 
well as improving life expectancy of HIV infected individuals (Mayosi et al., 2012).   
  
However, the challenges of access to ART as well non-compliance to drug regimes, further 
highlights the need for a vaccine (Derache et al., 2015, Bociaga-Jasik et al., 2014). An effective 
vaccine, in conjunction with prophylactic initiatives and ART, would dramatically enhance the 
decline of the epidemic (Fauci et al., 2014). Vaccination, particularly against viral infections, 
has been the mainstay of infection prevention since Edward Jenner’s smallpox vaccine in 1796 
(Nabel, 2013). The social and economic value of vaccines can be most appreciated with the 
drastic reduction in measles, mumps, influenza, hepatitis B and polio over the last 70 years 
(Esparza and Van Regenmortel, 2014, Patel et al., 2015). Whilst numerous advancements in 
HIV research have taken place over the past 30 years, no reports of a totally efficacious 
prophylactic or therapeutic vaccine exist (Dangeti, 2013). Currently, it is accepted that an 
efficacious HIV vaccine would consist of an optimised vector and/or immunogen capable of 




2014). An HIV vaccine which elicits both broadly neutralizing antibodies and cell-mediated 
immune responses would be ideal but due to the limited success of previous trials, two 
independent approaches are currently favoured for vaccine development (Mann and 
Ndung’u, 2015). The first is the elicitation of broadly neutralising antibodies (bNAb). This 
approach aims to prevent infection or minimise the chance of infection (Sadanand et al., 
2015). The second approach, which is fundamental to the rationale of this thesis, is the 
development of an effective T cell based vaccine to either prevent initial infection or slow 
disease progression by limiting early viral replication and viral load set point during the acute 
phase of infection (Haynes, 2015).   
  
This chapter will discuss the broad body of clinical and experimental data which currently 
informs the development of a successful T cell based HIV-1 vaccine. Furthermore, this chapter 
will focus on candidate HIV-1 vaccine vectors, particularly highlighting recombinant BCG 
(rBCG) based vaccines developed by HIV-1 Vaccine Development Group based at the 
University of Cape Town (UCT).   
  
1.2 The global diversity of HIV  
Belonging to the genus Lentivirus which lies in the family of Retroviridae, HIV is thought to 
have originated from zoonotic transmission of simian immunodeficiency virus (SIV) from 
nonhuman primates to humans in the early 20th century in West and Central Africa (Faria et 
al., 2014). Since introduction into man, HIV has evolved into several diverse and pathogenic 
strains classified in two lineages (HIV-1 and HIV-2) which have been found to be pathogenically 
and geographically distinctive (Beyrer and Abdool Karim, 2013). These lineages are further 
divided into groups (as shown in Figure 1.1.) of which HIV-1 group M contributes to the 
majority of the global burden of HIV with an estimated 33 million infections (Hemelaar, 2012). 




subtypes. HIV-1 subtype C is dominant in both India and sub-Saharan Africa and is estimated 
to be responsible for 50% of global HIV infections (Neogi et al., 2012).   
 
Figure 1. 1. The global diversity and burden of Human Immunodeficiency Virus (HIV) showing dominant and 
minor subtypes as well as circulating recombinant forms. HIV subtype C (shown in blue) affects the greatest 
number of people with the largest burdens in sub-Saharan Africa and the Indian subcontinent. Taken from 
(Hemelaar, 2012).   
There is immense inter subtype-(17-35%) and intra-subtype genetic diversity (8-17%) 
(Hemelaar, 2012, Hemelaar et al., 2011). Diversity within regions is expected to grow with new 
recombinants entering regions where established subtypes are predominant (reviewed by 
(Vuilleumier and Bonhoeffer, 2015). This, in addition to viral mutation via immune escape 
further renders the development of HIV-1 vaccines exceptionally challenging (Korber et al., 






1.3 The structure and genomic organisation of HIV-1  
HIV is a spherical virus approximately 120nm in diameter with an outer lipid bilayer containing  
HIV envelope (Env) proteins (Figure 1.2) (Engelman and Cherepanov, 2012). Contained within the 
virion is a capsid containing two copies of single stranded positive sense RNA. These 9.8 kilo bases 
(kb) RNA strands are comprised of 9 open reading frames that code for 15 proteins.   
 
Figure 1. 2. Basic genomic and structural representation of HIV-1. (A) The HIV genome is composed of 9 open 
reading frames with a long terminal repeat on both the 5’ and 3’ ends. The 3 structural genes, gag, pol and env, 
are translated into the p53, p160 and gp160 polypeptide precursors respectively. The Gag precursor (p53) is 
cleaved into the matrix (MA, p18), capsid (CA, p24) and nuceloscapsid (NC, p15) proteins. The Pol polypeptide 
precursor (p160) is cleaved to yield Reverse Transcriptase (RT), Protease (PR), Integrase (IN) and Ribonuclease H 
(RNaseH). The Env precursor is cleaved into the extracellular membrane bound gp120 glycoprotein as well as the 
transmembrane gp41 glycoprotein. Taken from (Waheed and Freed, 2010). (B) Extracellular (gp120) and 
transmembrane (gp41) glycoproteins are arranged on the outer lipid layer of the virus. The p17 matrix protein 
assists in proving structural integrity to the virion. The capsid core, comprised of p24 core protein, encases two 








Functionally these 15 proteins are separated into structural, regulatory and accessory 
functions. The structural genes are group specific antigen (Gag) and envelope (Env) and they 
code for proteins that function collectively to promote virion structure and binding to host 
receptors (Shum et al., 2013). The Pol gene codes for 3 enzymes which include reverse 
transcriptase (facilitates the transcription of viral RNA to DNA), integrase (integrates viral DNA 
into the hosts genome) and protease (cleaves the Gag/Pol complex follow expression).  
  
The regulatory genes are regulators of virion expression (Rev) and a trans-activator of 
transcription (Tat) which code for proteins that function to control the transcription of viral 
proteins. Lastly, the accessory proteins include viral protein unknown (Vpu), viral protein 
regulatory (Vpr), viral infectivity factor (Vif), and negative regulatory factor (Nef). In addition, 
the genome of HIV contains 2 long terminal repeats (LTR) which are found on 3’ and 5’ ends 
of the genome. These contain transcription initiation sites as well as transcriptional factor 
binding sites.   
  
1.4 Molecular mechanisms of HIV infection and viral reservoir 
formation  
HIV is a predominantly sexually transmitted pathogen via semen or vaginal mucosa. However, 
non-sexual routes of transmission may occur via contact with other body fluids. Examples of 
these include mother to child transmission, sharing of needles between intravenous drug 
users and exposure to HIV containing blood products (Moir et al., 2011, Patel et al., 2014). 
Once the virus enters the body, fusion of the viral envelope with the cell membrane of target 
host cells (CD4+ T cells and macrophages) occurs via receptor mediated absorption of the 
envelope glycoproteins (Wyatt and Sodroski, 1998). HIV infects CD4+ T cells via the CXCR4 and 
CCR5 chemokine receptors as well as macrophages via the CCR5 co-receptor (Naif, 2013). 
Once infection has occurred, typical or atypical disease progression may occur (discussed in 




transcription factors that are usually excluded from the nuclei of resting cells (such as NF-ĸB, 
NFAT Sp1 and AP-1) (Figure 1.3).   
 
Figure 1. 3. Modulation of T-cell signalling pathways by HIV-1 proteins. Viral proteins both transcription factors 
and cell surface receptors of infected CD4+ T cells that support HIV-1 infection and pathogenesis.HIV-1 proteins 
(gp120, Nef, Tat and Vpr) induce the activation of several keys regulators of cytokine production and cellular 
activation (nuclear factor of activated T cells (NFAT), nuclear factor kappa B (NFκB), activator protein 1 (AP-1) 
and specificity protein 1 (Sp1)). Furthermore, HIV-1 viral proteins enhance the transcription of HIV-1 using host 
inducible promoters thereby promoting viral replication Taken from (Abbas and Herbein, 2013). 
  
This promotes the production of non-specific inflammatory cytokines (such as TNF-α, IL-1, IL6) 
and T cell activation which thereby increases the number of potential target cells for HIV 
infection. This immune activation creates a highly inflammatory microenvironment which 
contributes to the decline of effective T cell immunity through lysis of HIV infected T cells, 






Although anti-retroviral therapy (ART) can lead to the effective restoration of immune 
function and control of HIV replication, persistent viral reservoirs make the clearance and cure 
of HIV infection difficult once established (Picker, 2014). Whilst HIV will preferentially infect, 
replicate and lead to the death of activated CD4+ T cells, HIV gene expression is silenced in 
infected CD4+ T cells that differentiate into central memory T cells (Hermankova et al., 2003). 
This leads to the formation of a transcriptionally inactive but stably integrated provirus which 
can produce viable virus when the T cell is activated by cytokines under the control of the 
inducible transcription factors NFĸB and NFAT (Nabel and Baltimore, 1987). Interestingly, 
these cells remain impervious to the effects of ART (Abbas and Herbein, 2013). Therefore, an 
efficacious T cell based HIV-1 vaccine will have to limit excessive systemic inflammation, 
promote specific lysis of infected cells during early infection and induce a durable effector 
memory response to clear virus that may emerge from potential reservoirs.   
  
1.5. The role of T cells in typical HIV disease progression  
Typical chronic HIV disease progression to AIDS is characterised by a highly suppressed 
immune system, decreased numbers of CD4+ T cells and macrophages, excessive immune 
activation and uncontrolled vireamia (Naif, 2013, Moir et al., 2011). T cells play a central role 
in the immune response to viral, bacterial and parasitic infection by directly mediating the 
death of pathogen infected cells and indirectly by stimulating B cells to produce pathogen 
specific antibodies (Kapsenberg, 2003). Traditionally, CD4+ T cells mediate and assist the two 
major arms of intracellular pathogen elimination, B cell antibody production and cytotoxic 
CD8+ T cell function (CTL) (Masopust and Schenkel, 2013, Sun and Bevan, 2003). Following 
infection, HIV can bind to the CD4 receptor on CD4+ T cells and these cells become the major 
host for exponential HIV viral replication during the first 0-12 weeks. Subsequently, infected 
cells producing virus lyse or are killed by increasing levels of HIV specific cytotoxic CD8+ T cells 
therefore depleting CD4+ T cell levels (Klatzmann et al., 1986). During acute infection, peak 





Figure 1.4. Longitudinal depiction of the typical fluctuation of T cell level and plasma viral load following HIV 
infection. An efficacious T cell based vaccine would aim to minimise viral set point during primary infection by 
promoting greater quantitative and qualitative T cell responses. Taken from Sewell et al., 2000.  
  
This viral set point is important for the rate of disease progression and signals the start of the 
latent stage of HIV infection which can persist for 2-20 years. Whilst cytotoxic CD8+ T cells and 
antibody responses may keep viral load relatively constant during this latent phase, immune 
escape and prolonged immune activation eventually weakens immune efficacy leading to 
increased viral replication and further CD4+ depletion (Saez-Cirion et al., 2014).   
  
This final immune depreciation is the defining characteristic of progressors who often 
succumb to opportunistic infections, the hallmark of HIV related AIDS which is characterised 
by a CD4+ count of <200 cells/mm3. Incapable of mounting effective immune responses to 
pathogens, untreated chronic infection leads to death. Whilst revolutionary advancements in 
anti-retroviral therapy and patient care have been able to reduce disease progression and 






1.6. Atypical disease progression: Protective immune responses inform 
T cell vaccine design   
Atypically, not all HIV infected subject’s progress to AIDS. Understanding how the immune 
systems of these individuals that are able to control HIV and mount effective protection has 
been of massive interest to scientists and may be key to informing vaccine design (Gaardbo et 
al., 2012). Following the discovery of HIV being the causative virus of AIDS, infected patients 
who did not progress to AIDS were identified.   
These patients fall into to three broad groups termed long-term non-progressors (LNTPs), 
viraemic controllers and elite controllers who all exhibit far lower viral loads and lack of CD4+ 
depletion (Gaardbo et al., 2012). Viraemic controllers (<2000 copies/ml) and LNTPs (<10 000 
copies/ml) can be defined as HIV infected individuals that suppress HIV viral load without the 
aid of ARVs. Elite controllers, the group with the most robust infection control, are HIV 
infected individuals who maintain CD4+ counts without treatment and present with 
undetectable viral loads (<50 copies/ml). Lastly, highly exposed seronegative individuals 
(HESN) represent a model to assess natural resistance to HIV-1 (Rowland-Jones and 
McMichael, 1995, Fowke et al., 1996). These individuals include intravenous drug users (Saez 
Cirion et al., 2006), discordant couples (Bégaud et al., 2006), commercial sex workers (Fowke 
et al., 1996) and children born to seropositive mothers.   
  
Understanding host gene regulation patterns that have been associated with protection in 
highly exposed-uninfected individuals (HESN) and HIV controller cohorts can greatly inform 
vaccine design (and interpretation of the effects of candidate vaccine vectors on host gene 
expression). Approximately 40 host genes have been shown to be associated with resistance 
to HIV in these cohorts (reviewed by Lama et al, 2007)(Lama and Planelles, 2007). Whilst 
infected, a major immunological hallmark of HIV-1 controllers is that they longitudinally 
maintain functional CD4+ and CD8+ T cell responses (Radebe et al., 2015, Saez-Cirion et al., 




to CD8+ T cells which then attempt to lyse them, have been shown to correlate with HIV viral 
control (Goulder and Walker, 2012). These individual’s ability to maintain persistent and 
functional T cell immunity represents a clinical model for the type of immunity researchers 
expect an efficacious T cell vaccine would elicit.   
  
In addition to protective MHC molecules, preservation of T cell signalling has also been 
associated with control of HIV-1 vireamia.In a study done by Wu et al, (2011), gene-expression 
profiles in CD4+ and CD8+ T cells derived from LNTP, vireamic untreated and ART-treated 
avireamic patients were compared. They observed an up regulation of the MAPK T cell 
signalling pathway in LNTPs (particularly the JNK, ERK and p38 branches) suggesting that 
activation of these T cell signalling pathways are associated with improved T cell antiviral 
responses and survival (Wu et al., 2011).  
  
HIV further promotes immune dysfunction by increasing the expression of inhibitory 
immunoregulatory markers such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and 
Programmed Death-1 (PD-1) with elevated expression levels of these on T cells reported in 
individuals presenting with progressive infection but not controllers (Day et al., 2006, 
Trautmann et al., 2006). Binding of PD-1 to either of its ligands, PD-L1 or PD-L2 on CD8+ T cells 
leads to decreased proliferative capacity and cytokine secretion. Up regulation of CTLA4 on 
the other hand, is thought to decrease the production of IL-2, a cytokine which promotes 
recruitment of immune effector cells as well as stimulates T cell proliferation (Kaufmann et 
al., 2007, Zaunders et al., 2006). In addition to the above identified protective associations in 
humans, studies of atypical disease progression in NHPs have also lead to the elucidation of 
correlates of T cell mediated protection and these are discussed in conjunction with clinical 




1.6.1 Correlates of HIV/SIV specific T cell immune protection in animal models 
and the clinical setting inform HIV vaccine design   
Traditionally, live attenuated viruses have been the used to prevent infection by viral 
pathogens such as mumps, measles, and smallpox (Nabel, 2013). Once HIV infection is 
established, eradication of the virus becomes exceedingly difficult due to escape mutations 
following immune pressure as well as the establishment of latent viral reservoirs. Therefore, 
an effective T cell vaccine should induce a rapid immune response to clear HIV infected cells 
prior to the establishment of infection (Haynes et al., 2016). T cells are recognised as the 
drivers of immunity towards a range of bacterial and viral pathogens. Several decades of 
investigation into trying to understand how the very cells that HIV targets can still remain 
functionally viable and immunologically competent have yielded interesting protective 
associations in both humans as well as animal models. Discussed below are several readouts 
of T cell function including; breadth and specificity of T cell response, preservation of T cell 
functionality, cytotoxic T cell function and the induction of HIV specific T cell memory.  
  
1.6.1.1 Breadth and specificity of HIV+ T cell responses   
Clinical cohort studies in untreated patients chronically infected with HIV subtype C virus 
indicate that an increased breadth of T cell response, particularly towards Gag epitopes 
correlated with decreased viraemia (Kiepiela et al., 2007a). Furthermore, the preferential 
targeting of certain viral epitopes has been reported to correlate with T cell mediated control 
of infection. Recent multivariate studies comparing the breadth and specificity of T cell 
immune responses in viraemic controllers and non-controllers indicate that Gag-specific CD8+ 
T cell responses are predictive of host control of the viraemia (Tomescu et al., 2014). Similarly 
for the CD4+ T cell response, Ransinghe et al, (2012) assessed the specificity of HIV-specific 
CD4+ T cells in a variety of controller and progressor cohorts (Ranasinghe et al., 2012). They 
were able to distinguish controllers from progressors by assessing the ratio of Gag/Env CD4+ 
T cell responses. A high frequency and magnitude of Gag responses combined with low 





Immune control has also been linked to the breadth of Gag specific T cell response in early 
infection prior to the establishment of viral load set point. (Radebe et al., 2015) recently 
characterised the impact of CD8+ T-cell immunodominance patterns on viral escape and 
mutation during the first year of HIV-1 infection. At 26 weeks post-infection, they reported an 
inverse correlation between the breadth of Gag-specific responses and viral load set point in 
viraemic controllers. The protective associations favouring Gag-specific immune responses are 
not only limited to Gag CD8+ T cell epitopes. These clinical studies collectively demonstrate 
the protective importance of inducing a broad Gag specific T cell response early in infection. 
Consequently, this was one of the justifications for the utilisation of a full length HIV-1 subtype 
C Gag as the immunogen of choice for rBCG vectored vaccines used in this study.  
  
1.6.1.2 The preservation of T cell functionality   
The ability of T cells to produce cytokines is vital to an efficiently functioning immune system. 
HIV specific cytokine production has been widely reported to become diminished as HIV 
disease progresses and the quantification of cytokines in various states of HIV disease 
progression has become a vital marker of T cell protective function. HIV primarily elicits a type 
1 immune response which includes the production of; IFNγ, IL-1, TNFα, IL-2 and IL-6 (primarily 
by T cells and macrophages) (Romagnani et al., 1994, Vandergeeten et al., 2012). Cytokines, 
an amalgamation of the Greek of words for ‘cell’ and ‘movement’, are a broad group of 520kDa 
proteins involved in cellular signalling primarily between cells of the immune system. These 
molecules are so synonymous with the immune response that they are routinely used as basic 
indicators of immune response, in assays such as ELISPOT and ELISA (Ahmed and Gottschalk, 
2009). Two main arms of the cytokine network can be broadly classified into those that 
promote a type 1 (inflammatory) or type 2 (anti-inflammatory) immune responses with a high 
level of regulation between each type of response (Becker, 2004). Studies assessing the 




patients maintain a low activation state whilst simultaneously being able to produce multiple 
cytokines (termed T cell polyfunctionality) (Minton, 2014, Owen et al., 2010, Betts et al., 
2006a). Furthermore, preservation of T cell polyfunctionality is present in elite controllers and 
LNTPs but not chronic progressors indicating that T cell polyfunctionality may be vital for 
immune control of HIV (Baker et al., 2009, Kiepiela et al., 2007b, Betts et al., 2006b). This 
observation is so profound that T cells from untreated elite controllers appear to maintain 
greater T cell polyfunctionality than those from LNTPs undergoing ART (Owen et al., 2010). T 
cell polyfunctionality has been shown to be regulated by the MAPK/ERK pathway which has 
been recently reported to be negatively regulated by the protein Sprouty-2 (SPRY2). Recently, 
Chiu et al, (2014) reported high levels of SPRY2 expression in donor derived HIV-specific T cells. 
They additionally found that they could enhance HIV Gag-specific CTL polyfunctional 
responses by ex vivo inhibition of SPRY2 (Chiu et al., 2014).  
  
Whilst the production of these cytokines has been associated with immune responses to HIV, 
excessive immune activation and production of pro-inflammatory cytokines leads to increased 
viral replication and T cell exhaustion (Vandergeeten et al., 2012, Khaitan and Unutmaz, 2011). 
Therefore, it is vital that any candidate T cell vaccine induces a controlled and HIV specific 
cytokine response. A number of non-human primate and murine studies have indicated that 
HIV vaccines vectored by BCG can induce significant HIV specific T cell cytokine release (Chege 
et al., 2013, Chapman et al., 2012).   
1.6.1.3 The importance of HIV specific CD8+ cytotoxic T cells   
Host mediated lysis of HIV-1 infected cells is vital to stop viral replication. This is largely 
accomplished by the actions of cytotoxic CD8+ T cells. Binding of antigen specific T cell 
receptors to MHC molecules expressing recognizable HIV epitopes elicits a cytokine and 
chemokine cascade that leads to clonal expansion of the CD8+ T cells as well as the production 
of a group of molecules called cytotoxins (Walker and McMichael, 2012). These cytotoxins, 




into the cytoplasm of the infected target cell (Chowdhury and Lieberman, 2008). Here, these 
cytotoxins activate the caspase pathway which leads to programmed cell death, termed 
apoptosis. Chronic progressors have been characterised to have diminished cytotoxic 
functions and this is thought to contribute to unregulated viral replication and progression to 
AIDS (Appay et al., 2000, Goulder et al., 1997). Elite controllers and LNTPs have demonstrated 
that the quality and preservation of cytotoxic T cell function in HIV infection is vital for 
reducing viral load and slower disease progression (Hersperger et al., 2011, Yan et al., 2013).  
Findings from a longitudinal study, which assessed epitope immunodominance in a cohort of 
527 recently infected individuals up until chronic infection, reported that preservation of CTL 
immunodominance patterns from the acute into the chronic phase of infection was 
significantly associated with slower CD4+ T-cell decline (Streeck et al., 2009b). In addition to 
controllers of disease progression, other examples of potent CTL mediated responses have 
been reported in Kenyan seronegative sex workers, who are routinely exposed to HIV (Kaul et 
al., 2004) as well as in uninfected neonates born to HIV+ mothers (Cheynier et al., 1992).   
NHP vaccine studies have been equally as comprehensive in describing the protective role of 
CTLs. Over the past 15 years, researchers have improved CTL inducing vaccines from being 
able to control viraemia to being able to eradicate virus to undetectable levels (Figure 1.5). 
Partial control of viral load using DNA vaccines expressing SIVmac239 Gag and HIV-1 89.6P Env 
was one of the first milestones reached (Barouch et al., 2000). This study demonstrated the 
prevention and progression of AIDS like disease in rhesus macaques challenged with 
SHIV89.6P. Analysis of protective correlates associated low viral load set point with potent CTL 
responses. Whilst early CTL responses can control viraemia, eradication of SIV requires the 
generation of an HIV specific effector memory compartment which can elicit HIV CTL function 
for a prolonged duration following infection. More recently, studies using a rhesus 
cytomegalovirus (RhCMV) vaccine vector have demonstrated immune control and in some 
cases complete eradication of highly pathogenic SIV mac239 strain (Hansen et al., 2009, 
Hansen et al., 2011, Hansen et al., 2013a). They associated the ability of the rhesus 
cytomegalovirus vector (clone 68-1) with the induction of a persistent T cell effector memory 




viral reservoirs (RhCMV vector is discussed further in section 1.8.1). Furthermore whilst this 
clone fails to induce MHC-1a restricted CD8 T cells, MHC class II restricted CD8 T cells were 
present in both protected and non-protected monkeys. This is particularly interesting for BCG 
vaccine development, because in TB patients, M. tuberculosis induces CD8+ T cells, which 
recognize HLA restricted peptides in a CD3/αβ TCR mediated CD8 dependent manner and, 
therefore, BCG is likely to induce similar reponses. Peptide presentation by MHC may reveal 
an additional type of effector cells potentially playing a role in protection against 
M.tuberculosis, SIV and HIV.   Whilst these results are promising, the use of live CMV vectors 
in humans is not safe but inducing similar potent CTL and Tem responses using safer vectors, 
such as BCG, may allow us to translate these observed protective correlates from the animal 
model to the clinical setting.  
  
 
Figure 1.5. Variable control of SIV infected NHPs mediated by CTL stimulating vaccines. Typical disease 
progression in unvaccinated macaques leads to the maintenance of high viral loads following viral load set point 
(None). A partially effective T cell vaccine can lower viral load set point which in turn will lead to lower viral loads 
as disease progresses (partial control). Persistent vaccines, such as the rhesus cytomegalovirus (RhCMV) vaccine 
have been shown to induce persistent CTL responses which not only lower viral set point but continue to elicit a 
sufficient immune response to clear viral reservoirs and eradicate virus (slow eradication). The primary goal for 
a T cell vaccine is the rapid eradication of virus before the establishment of significant infection (rapid 






1.6.1.4 Preservation of T cell memory   
A hallmark of the adaptive immune system is the generation of long-term T cell memory 
following initial exposure to a pathogen (Kaech et al., 2002). Following re-exposure to the 
same pathogen, the immune response is far more rapid and robust than the initial immune 
response. Therefore, T cell vaccines developed to combat intracellular pathogens often focus 
on the generation of long-term antigen specific T cell memory (Kaech et al., 2002). In both 
non-human primates as well as humans, typical SIV and HIV infections are characterised by 
severe depletion of memory CD4+ T cells (Okoye and Picker, 2013). Studies assessing elite 
controllers suggest that in conjunction with the maintenance of T cell polyfunctionality, potent 
antigen specific memory responses are the fundamental mechanism in limitation of viral 
replication and disease progression (Deeks and Walker, 2007, O'Connell et al., 2009). Elite 
controllers have also been reported to maintain more active effector memory CD8+ T cells 
than chronic progressors undergoing successful ART (Lopez et al., 2011).   
  
NHP T cell based SIV vaccine studies using the persistent CMV vector (discussed further in 
section 1.8.1) indicate that protection from highly pathogenic SIV infection can be attributed 
to the high frequency of effector memory T cells (Hansen et al., 2009). However, having a 
persistent vector is no guarantee of eliciting a population of long lived memory phenotype. 
Recent TB studies investigating a safer but similarly persistent vaccine vector, BCG, have 
indicated that persistence of BCG leads to decreased central memory phenotype in the murine 
model (Nandakumar et al., 2014). Supporting this, other studies have reported improved 
central memory responses when BCG has been cleared (Andersen and Smedegaard, 2000, 
Kipnis et al., 2005, Jagannath et al., 2009). This variance indicates that new vaccines vectors, 
such as the ones used in this thesis, need to be understood both independently and in relation 






1.7 A review of HIV vaccine clinical efficacy trials   
During the last 3 decades of HIV research, there have been over 200 HIV vaccine trials with 
only a small fraction showing enough promise to continue to phase 3 efficacy trials (Girard et 
al., Saunders et al., 2012, Esparza, 2013). Whilst these trials have been largely disappointing, 
they highlight the tremendous difficulty associated in developing effective HIV vaccines as well 
as providing vital information to assist pre-clinical development of novel vaccines. Reviewed 
below, are phase 2B and phase 3 HIV vaccine efficacy trials.   
  
1.7.1 The VAX003 and VAX004 trials  
The Vax003 and Vax004 trials by Vaxgen, were the first phase 3 HIV vaccine clinical trials 
conducted (1998-2003). Immunologically, these vaccines aimed to elicit protective Env 
specific antibodies by using a combination of recombinant gp120 proteins and alum adjuvant 
(Flynn et al., 2005). Vax003, containing a clade B and clade E gp120, was used to vaccinate 
5100 men who have sex with men (MSM) as well as 300 high-risk women in Thailand. Vax004 
(2x clade B gp120) was used to vaccinate 2500 high-risk intravenous drug users in North 
America and Europe (Flynn et al., 2005, Pitisuttithum et al., 2006). Whilst both vaccines 
elicited gp120 specific antibodies, neither protective efficacy nor delayed HIV disease 
progression was associated with either vaccine (Flynn et al., 2005, Pitisuttithum et al., 2006).   
  
1.7.2 The HIV Vaccine Trials Network trials (HVTN 0052, 0053, 505)   
Commonly referred to as the STEP and Phambili studies respectively, the HIV Vaccine Trials 
Network (HVTN) 0052 and 0053 trials (Phase 2B) were carried out between 2005 and 2007 by 
Merck in conjunction with HVTN. Unlike the Vaxgen vaccines, these vaccines aimed to 
primarily elicit T cell responses to kill HIV infected cells following infection which was 




replicating adenovirus type 5 (MRKAd5) vector expressing HIV subtype B gag, pol and nef. 
Preclinical rhesus macaque studies, demonstrated that this MRKAd5 vaccine could control 
viral load following SHIV challenge and phase 1 clinical trials confirmed safety and 
immunogenicity (Shiver et al., 2002, Casimiro et al., 2005). This paved the way for phase 2B 
clinical trials and 3000 healthy at risk individuals were enrolled in the Caribbean, Americas and 
Australia (for STEP) and in South Africa (for Phambili). Results from the STEP trial indicated 
that the vaccine was immunogenic with the induction of HIV specific IFNγ release in 77% of 
vaccinated study participants (McElrath et al., 2008). Breadth of the immune response was 
assessed by IFNγ release to Gag, Pol and Nef following ex vivo stimulation. Only a moderate 
62% of vaccinated participants were able to induce a T cell response to 2 or 3 of these proteins. 
Assessment of specificity indicated that HIV specific CD4+ T cell responses were mostly to Gag 
whilst dominant CD8+ T cell responses were mainly Pol specific. The trial was stopped in 2007 
following pre-planned analysis which suggested endpoint study futility (Sekaly, 2008). 
Unfortunately, a higher rate of HIV-1 infection was reported in vaccinated men who were 
uncircumcised who presented with pre-existing anti-vector immunity to adenovirus (McElrath 
et al., 2008). Following this, the Phambili study was also stopped and further analysis indicated 
a 7% greater chance of infection in the vaccinated group as compared to the placebo group 
(Gray et al., 2014).   
  
While these results of the STEP and Phambili trial were disconcerting, an Ad5 vector was again 
utilised during the phase 2B HVTN 505 trial which was terminated in 2013.This trial exclusively 
used male and transgender women who were Ad5 seronegative and circumcised (Hammer et 
al., 2013). Participants were vaccinated with 3 doses of a DNA prime consisting of six plasmids 
individually expressing HIV-1 clade B (Gag, Pol, and Nef) and Env proteins (from clades A, B, 
and C). The rAd5 boost consisted of 4 Ad5 constructs expressing a HIV-1 clade B Gag-Pol fusion 
protein as well as 3 Env glycoproteins (from clades A, B, and C). This trial aimed to elicit both 
cellular and humoral responses. Due to the lack of efficacy, the trial was terminated 28 weeks 
in with more vaccine recipients found to be positive than individuals who received the 




activated CD4+ T cells expressing the HIV-1 co-receptor CCR5. In order to understand the 
effect of anti-vector mechanisms behind the failure in efficacy of these Ad5 vectored vaccine 
trials, the STEP trial was mimicked in Rhesus macaques. They initially infected macaques with 
Ad5 and then vaccinated with replication defective Ad5 SIVmac239 Gag/Pol/Nef vaccine or 
placebo. Finally, groups were exposed to escalating doses of SIVmac 251. Interestingly, even 
at the lowest SIV exposure, vaccination resulted in 2/9 Ad5 seropositive animals becoming 
infected whilst 0/34 in control groups were infected.   
  
These HVTN trials collectively highlight the need for vaccine vectors that do not induce significant 
anti-vector immunity. An example of a vector with a good clinical record of limited anti-vector 
immunity is BCG, utilised in our study (Korioth-Schmitz et al., 2015). Additionally, vaccines need 
to induce a greater breadth of T cell response than that exhibited in the HVTN trials. Whilst the 
immunogens utilised in these trials aimed to elicit responses for multiple HIV proteins (Gag, Pol, 
Nef and Env), recent data suggests that immunodominance towards Gag induces greater control 
(Turk et al., 2013, Radebe et al., 2015, Yang et al., 2015b). Consequently, because of this, and 
other data, we have chosen to use a full length HIV-1 Gag as the immunogen of choice for 
designing our BCG vaccines (Stephenson et al., 2012).  
  
1.7.3 The RV 144 efficacy trial   
Whilst the vaccines used in the Vaxgen and STEP trials aimed to elicit antibody and T cell 
dominated immune responses respectively, the vaccines used in the RV144 trial aimed to do 
both. Beginning in Thailand in 2007, this trial assessed the efficacy of a heterologous prime 
boost regime. The ALVAC canarypox vaccine expressing Gag, Env and Pol was used as a prime 
followed by a recombinant protein boost (VAX003 gp120) (Rerks-Ngarm et al., 2009). Upon 
phase 3 completion, the trial reported a 31.2% infection reduction in subjects who received 
the vaccine as compared to those that received placebo. Coupled with this, high levels of Env 




from study endpoint (McElrath). However, the antibodies associated with reduced risk of 
infection were non-neutralising and were characterised to be V1/V2 binding antibodies 
(Haynes et al., 2012). Additionally, they reported an association between infection and the 
production of Env specific IgA antibodies.   
  
Whilst the vaccine elicited minimal HIV specific CD8+ T cell responses, proliferative CD4+ Env 
responses were reported (Rerks-Ngarm et al., 2009). IFNγ ELISPOT responses on samples 
collected 6 months after immunization showed Gag or Env specific responses in 20% of 
vaccinated group as opposed to 7% of placebo recipients. Comprehensive assessment of T cell 
specificity and functionality were assessed by (de Souza et al., 2012). They reported that the 
RV144 T cell responses were modest as compared to humoral immune responses. 
Additionally, they found that most CD4+ T cell responses were directed to the V2 region of 
Env. Recent studies assessing the impact of the T cell response on breakthrough virus suggests 
that immune pressure was mainly induced by the Env specific humoral response. A follow up 
study to the RV144 trial, The HVTN 097, is currently underway in South Africa.  
 
RV144 therefore represented the first phase 3 clinical trial to show any protective efficacy, 
albeit moderate. Whilst protective correlates indicate that a humoral response was prominent 
for reducing risk of infection, the RV144 trial demonstrates the importance of poxvrial vectors. 
The poxviral SAAVI MVA-C vaccine, (reviewed in section 1.8.2), was incorporated into our 
heterologous prime boost vaccination regime as a boost to the rBCG prime.   
  
1.8 HIV vaccine vectors to induce protective T cell immune responses   
Classically, vaccination against viral and bacterial pathogens has been achieved by the use of 
attenuated or killed pathogen. However, this is not possible with HIV. Therefore, gene delivery 




protective T cell immune responses. Commonly touted vectors can be categorised into; 
replicating viral vectors, attenuated viral vectors, bacterial vectors and plasmid DNA. 
Furthermore, combinations of these vectors in prime-boost regimes have been suggested to 
elicit desired immune responses. As previously discussed both correlates of HIV/SIV specific T 
cell immune protection (section 1.6) as well as previous clinical efficacy trials (section 1.7) 
inform current vector selection and vaccine design. Highlighted below are two prominent 
vectors which have shown novel results in recent studies. Studies assessing cytomegalovirus 
(CMV) as a vaccine vector demonstrate the concept of a persistent vector being able to 
generate persistent CD8+ effector responses leading to eradication of SIV viral reservoirs in 
Rhesus macaques. The second, modified vaccinia Ankara (MVA), which has been a research 
focus of our group, demonstrates the ability of a safe non-replicating viral vector to boost for 
immunodominant Gag specific response.   
  
1.8.1 Cytomegalovirus (CMV) as an HIV vaccine vector  
Belonging to the Herpesviridae family Cytomegalovirus (CMV) has a global prevalence of 
greater than 90% (Manicklal et al., 2013, Lanzieri et al., 2014). Whilst infected individuals are 
often asymptomatic, CMV can be fatal especially to newborns and immunocompromised 
individuals (Manicklal et al., 2013). Whilst these global seroprevalence rates, as well as the 
pathogenicity of CMV in immunocompromised individuals is a concern, CMV is of high interest 
due to its ability to elicit a significantly large persistent T cell response (Barouch and Picker, 
2014). Additionally, CMV can accommodate up to 6 kb of exogenous DNA allowing for multiple 
inserts as well as being able to be highly attenuated whilst not compromising immunogenicity 
(Barouch and Picker, 2014). As an SIV vaccine vector, CMV holds the distinction of being the 
first vaccine that has been able to clear SIV infection in rhesus macaques. A novel study using 
a replicating rhesus CMV vector encoding 6 SIV genes (gag, rev, tat, nef, env and pol) reported 
that 50% of vaccinated rhesus macaques could suppress viral load following repeated high 
dose rectal SIV challenge (Hansen et al., 2009). More recent studies have found this vaccine 




levels of CD8+ T cell effector memory (Hansen et al., 2013a, Hansen et al., 2011). Protection 
was correlated with the magnitude of peak SIV-specific effector memory CTL responses. 
Notably this protection was present in the absence of significant bNAbs response.   
  
There are several challenges associated with translating these results from macaques to 
humans. Whilst live unattentuated CMV vectors are not considered acceptable for humans, 
attenuation of CMV to reduce replication to an optimal amount to longitudinally maintain a 
broad, high frequency effector CTL response is currently being pursued (Picker, 2014). Another 
challenge is that of T cell epitope MHC restriction discrepancies between humans and 
macaques. Protective MHC  restricted CTL responses in macaques vaccinated with RhCMV and 
challenged with SIV mac291 were largely of the MHC class 2 antigen-E type with SIV infected 
cells expressing this MHC-E (Hansen et al., 2013b). This may explain to some degree the robust 
responses observed in these studies and CMV trials expressing human restricted HIV epitopes 
may further inform the translation of these CMV mediated persistent responses from 
macaques to humans. Currently, human trials are planned for attenuated CMV vectors as HIV 
vaccines (Barouch and Picker, 2014). Another option would be to use similarly persistent 
vectors with improved safety profiles such as BCG. Whilst BCG may not induce the massive T 
cell responses seen by CMV, modification of BCG by introducing exogenous 
immunomodulatory genes has been shown to increase the immunogenicity (discussed further 
in section 1.10.1).   
  
1.8.2 Modified vaccinia Ankara (MVA) as an HIV vaccine vector  
Modified vaccinia Ankara (MVA) is a replication deficient pox virus that has exhibited an 
extensive safety profile and immunogenicity as a vaccine vector (Esteban, 2009). One of the 
greatest vaccine intervention successes was the eradication of smallpox using vaccinia virus 
(VACV). However, this vaccine induced a number of side effects and a safer alternative was 




vaccinia virus Ankara (CVA) (Mayr and Munz, 1964). The safety profile of MVA was further 
demonstrated following the vaccination of 120 000 individuals against smallpox in Germany 
in 1979. As opposed to VACV, MVA did not induce any adverse reactions. The most notable 
safety feature of MVA is that it’s unable to replicate past the point of forming immature 
virions. Several phase 2 HIV vaccine clinical trials have demonstrated immunogenicity using 
MVA as a vaccine vector on its own or in a heterologous prime boost strategy. Notably, HVTN 
205 reported more durable antibody responses than RV144 (reviewed in 1.7.3) following a 
DNA/MVA prime boost vaccination regime. Additionally, assessment of T cell responses 
indicated this vaccine regime preferentially targeted Gag (Goepfert et al., 2014). 
Immunodominance of Gag specific T cell responses has been associated with improved clinical 
outcomes (Radebe et al., 2015). Our group, the HIV-1 Vaccine Development Group at UCT, has 
previously focussed on the development of MVA as a vaccine vector in the guise of the SAAVI 
MVA-C vaccine (Ncayiyana, 2009, Shephard et al., 2008). The SAAVI MVA-C immunogen was 
designed to include five HIV-1 subtype C genes to maximize epitope coverage. These included 
gag, reverse transcriptase, tat, and nef expressed as a polyprotein (grttn) as well as truncated 
envelope protein (gp150)(Burgers et al., 2008). This vaccine was utilised in the HVTN 086 
phase 2a trial as part of a DNA-MVA heterologous prime boost regime in combination with a 
HIV-1 subtype C gp140 protein in a MF59 adjuvant (supplied by Novartis).   
  
In animal models, this vaccine has been found to be particularly immunogenic as a boost 
vaccine in a heterologous prime boost regime with DNA, virus like particles and recently with 
Mycobacterium bovis bacillus Calmette–Guérin (BCG) (Chege et al., 2009, Chapman et al., 
Shephard et al., 2008).In this thesis, the use of novel strains of rBCG is investigated as a priming 
vaccine for a SAAVI-MVA-C boost in the murine model. The next section details the use of BCG 
as a vaccine vector and highlights how modification of BCG using modern molecular 





1.9. The use of BCG as a vaccine vector  
Mycobacterium bovis BCG was developed in 1908 at the Pasteur Institute by Léon Charles 
Albert Calmette and Jean-Marie Camille Guérin by repeated subculturing of less virulent 
strains (Hawgood, 2007). Over a 13 year period they developed the first avirulent strain of 
M.bovis BCG by passaging the bacilli 198 times. Since its first use as a vaccine against 
Mycobacterium tuberculosis in 1921, BCG has become the most widely used vaccine in the 
world with an estimated 3 billion doses administered (Zheng et al., 2015). There are currently 
6 major strains of BCG used worldwide due to gene deletions and mutations that have 
occurred or been induced through laboratory propagation. These stains include the original 
Pasteur strain (1173 P2), as well as; Danish (1331), Tokyo (172-1), Russian (BCG-1), Glaxo 1077 
and Moreau (RDJ) (Behr et al., 1999). Differences in the persistence and pathogenicity of these 
strains should be carefully considered when attempting to use BCG as vaccine vector 
(Oettinger et al., 1999, Behr et al., 1999, Gordon et al., 2001). There are several advantages 
as well as limitations to using BCG as a vaccine vector. How these advantages contribute to 
efficacious HIV-1 vaccine design and how modification of BCG can overcome these limitations 
are discussed below.   
  
1.9.1 Numerous advantages of BCG as a vaccine vector  
There are a variety of characteristics that make BCG an attractive vaccine vector.First and 
foremost, BCG has a well-established safety record with a low incidence of vector based 
complications (Hanson et al., 1995). Logistically, BCG does not require a cold chain and is 
relatively cheap and easy to manufacture making it extremely attractive for use in resource 
limited settings (Gheorghiu et al., 1988, Roche et al., 1995). Furthermore, BCG can be 
administered orally or intramuscularly and it can be administered to neonates and the efficacy 
is unaffected by maternal antibodies. Long lived cellular and humoral responses to BCG have 
been well documented with responses to tuberculoproteins reported up to 50 years after 





Due to these advantages, a number of heterologous pathogen and human antigens have been 
expressed in BCG and have resulted in protective immunity in animal models. Notably, 
Langermann et al, (2005) demonstrated that BCG expressing the pneumococcal surface 
protein A (PspA) could protect mice from lethal doses of Streptococcus pneumoniae 
(Langermann et al., 1994). Similarly, BCG expressing a detoxified S1 subunit of pertussis toxin 
was found to completely protect mice against Bordetella pertussis challenge (Nascimento et 
al., 2008, Nascimento et al., 2009). Additionally, in measles studies, Fennelly et al, (1995) 
reported that mice vaccinated with BCG expressing full-length measles virus nucleocapsid 
protein developed substantial measles specific T cell and humoral responses which were 
associated with decreased viral titer following intra-cranial measles infection(Fennelly et al., 
1995). In addition to measles virus, BCG expressing papillomavirus antigens have been shown 
to protect rabbits from cottontail rabbit papillomavirus challenge (Govan et al., 2006, Govan 
and Williamson, 2007). Other notable examples of BCG based vaccines inducing protective 
immunity in animal models include vaccines against; listeria, malaria, leishmaniasis, rotavirus, 
tetanus, human metapneumovirus and Lyme disease (Grode et al., 2005, Matsumoto et al., 
1998, Streit et al., 2000, Stover et al., 1993a, Stover et al., 1993b, Dennehy et al., 2007, 
Mazzantini et al., 2004, Palavecino et al., 2014).  
1.9.2 Strategies to overcome the limitations of BCG as a vaccine vector  
There is currently no perfect vector able to elicit the desired HIV specific protective responses. 
However, modification of vectors and antigen expressions systems can lead to stable, safer 
and more immunogenic vectors. Discussed below, are notable examples of how modern 
molecular techniques have been used to improve BCG to deliver heterologous antigens.  
1.9.2.1 The use of auxotrophic complementation to improve vector stability  
Primarily, instability of episomal vectors, which results in deletion or rearrangement of the 




Bastos et al., 2002). BCG with these deletions usually do not express the recombinant antigen 
and tend to outgrow stable BCG (Medeiros et al., 2002). Studies have shown improvement in 
the stability of episomal vectors by using auxotrophic complementation which utilises 
auxotrophic stains of BCG and includes complementary genes added to the vector (Borsuk et 
al., 2007). Successful use of this method was shown to increase rBCG stability and lead to 
protection against pertussis when using BCG expressing pertussis toxin (Nascimento et al., 
2009).  
  
1.9.2.2 The use of inducible promoters to control antigen expression  
A vital factor for the expression of heterologous antigen in mycobacteria is the rate of 
transcription initiation. This is governed by the strength of the promoter. Whilst a high 
transcription rate may be desirable to maximise the production of antigen, the cost is often 
that high antigen levels lead to toxicity in the mycobacteria (Al Zarouni and Dale, 2002). Such 
is the case with traditional mycobacterial promoters such as the heat shock protein 60 (hsp 
60) and heat shock protein 70 (hsp 70)(Al Zarouni and Dale, 2002, Kumar et al., 1998).   
  
Inducible systems that can be used to down regulate antigen expression in vitro and 
upregulate expression in vivo have been shown to improve stability. A variety of regulated 
expression systems have been tested in mycobacteria (reviewed (Schnappinger and Ehrt, 
2014). Our group has previously demonstrated the successful expression of HIV-1 RT in 
wildtype Pasteur BCG, as well as a pantothenate auxotroph, using a Tet repressor expression 
system (Mbele, 2012).  
  
Another inducible promoter system that can limit toxicity is the mtrA promoter from M. 




effective use of the mtrA promoter, which is up regulated in the macrophage and down 
regulated in vitro, in immunogenic rBCG vaccines expressing HIV antigens in both the murine 
and non-human primate models (Chapman et al., 2012, Chege et al., 2013).   
  
1.9.2.3 Exploiting antigen localization to increase immunogenicity  
Localization of the antigen to the cell membrane or secretion (thereby limiting cytoplasmic 
accumulation of antigen) has also been reported to decrease toxicity in mycobacteria 
(Chapman et al., 2011b, Toussi and Massari, 2014). In addition to toxicity, the location of 
recombinant antigen expression and presentation enhances cell mediated immune responses 
when utilising BCG as a vaccine vector (Grode et al., 2002, Govan et al., 2006, Yu et al., 2007). 
Membrane bound antigens have been shown to be more immunogenic than antigens that are 
expressed in the cytoplasm (Bastos et al., 2002).   
  
Several groups have assessed and compared the effect of antigen localization on immune 
response and protection. Firstly a murine study compared protective efficacy and cell 
mediated immunity in mice vaccinated with 1 of 3 BCG vaccines expressing the 
immunodominant Listeria p60 protein in different bacterial compartments (Grode et al., 
2002). Notably, mice were protected by vaccines expressing cell membrane bound p60 and 
secreted p60 but vaccines that expressed p60 in the bacterial cytoplasm did not confer 
protection.   
  
The M. tuberculosis 19kDa leader sequence in particular has been extensively shown to 
facilitate translocation of expressed antigens to the cell membrane (Stover et al., 1993b, 
Chege et al., 2005, Cayabyab et al., 2009, Im et al., 2007). The action of the 19kDa leader 
sequence is also exceptionally rapid with evidence suggesting export of the protein occurs 




in immunogenicity and protective efficacy of BCG based vaccines, when using the 19kDa 
leader sequence, have also been reported in pneumococcal and SIV studies (Langermann et 
al., 1994, Grode et al., 2002, Someya et al., 2005). Our group has previously demonstrated in 
the murine model that BCG expressing rotavirus VP6 with the 19kDa was more immunogenic 
and protective than when using an α antigen leader sequence (Dennehy et al., 2007). 
Furthermore, our group has demonstrated protective efficacy against cottontail rabbit 
papillomavirus (CRPV) challenge in rabbits vaccinated with rBCG expressing the L1 antigen. 
This was successfully achieved with the antigen fused to a 19kDa leader sequence under the 
control of an mtrA promoter (Govan et al., 2006). Therefore, careful selection of leader 
sequences, promoters and antigen can improve the stability and immunogenicity of BCG as a 
vaccine expressing heterologous antigens.  
  
1.9.2.4 Overcoming the effects of environmental mycobacteria and helminth infections on 
immunity  
The variable efficacy of BCG as a TB vaccine has been well documented (Trunz et al., 2006).  
Factors behind this variable efficacy may affect outcomes when attempting to use BCG as an 
HIV vaccine. Whilst BCG confers protection against disseminated forms of TB following 
administration at birth, protective efficacy against pulmonary TB ranges from 0-80% (Lugosi, 
1992, Brandt et al., 2002a). Decreases in efficacy are most notable in tropical climates with 
factors such as environmental mycobacteria and exposure to extremely high levels of TB being 
postulated to affect vaccine efficacy (Trunz et al., 2006, Fine, 1995, Brandt et al., 2002b).   
  
Studies assessing the antagonistic effects of M. avium on BCG efficacy in the small animal 
model have shown that prior sensitisation with M. aviumdecreases BCG mediatedprotection 
against MTB (de Lisle et al., 2005).  The effects of prior environmental sensitization (M. avium, 
M. vaccae or M. scrofulaceum) on the protective efficacy of rBCG expressing the 




(control BCG not expressing RD-1 was used in parallel) (Demangel et al., 2005). Increased 
protection against TB following sensitization with M. vaccae or M. scrofulaceum was 
observed. Subsequently, they showed that T cell antigens between M. avium and BCG are 
conserved suggesting that antigen cross reactivity may be the driver of the antagonistic effects 
of environmental mycobacteria on BCG efficacy (Demangel et al., 2005).   
  
In addition to environmental mycobacteria, there is considerable evidence that parasitic 
infection may affect the efficacy of BCG (Crampin et al., 2009). The association between 
helminth infection and pulmonary TB has been well documented (Elias et al., 2006, Diniz et 
al., 2001, Tristao-Sa et al., 2002). Murine studies have reported decreased protection against 
TB following BCG vaccination in mice presenting with chronic helminth infection (Elias et al., 
2005). In this case, impaired anti-mycobacterial Th1 responses were reported which are most 
likely attributed to the dominant Th2 responses elicited by helminth infection (Elias et al., 
2005, Elias et al., 2006).   
  
In summary, for the advantages of BCG to be optimally exploited as an HIV vaccine vector, 
modern molecular techniques incorporating optimal expression systems and considerations 
towards overcoming antagonistic environmental effects need to be incorporated.   
  
1.10 Increasing the safety and immunogenicity of BCG as vaccine 
vector  
Whilst BCG has been considered an exceptionally safe vaccine for decades, there has been 
increased risk and incidence of BCG disease reported in immunocompromised individuals in 
the HIV era (Colditz et al., 1994, Trunz et al., 2006). Additionally, BCG may induce immune 
reconstitution inflammatory syndrome (IRIS) in children following ARV therapy (Nuttall et al., 




immunocomprimised individuals. With the increase in prevalence in MDR/XDR TB and the 
advancement of molecular techniques in the 1990s, the need and means to genetically 
enhance BCG has been present (Ottenhoff and Kaufmann, 2012). Modifying BCG strains to 
increase immunogenicity and decrease pathogenicity may be the key to overcoming the 
limitations of BCG and unlocking its full potential as an HIV vaccine vector (Ottenhoff and 
Kaufmann, 2012, Chapman et al., 2011a).   
  
Several pre-clinical and Phase 1 TB vaccine trials involving novel BCG vaccines/vaccination 
regimes have been undertaken in the recent past (Hesseling et al., 2007a, Haile and Kallenius, 
McShane and Hill, 2005, Horwitz et al., 2005, Tullius et al., 2008, Hoft et al., 2008). Various 
successful strategies to further increase the safety and immunogenicity of BCG include the use 
of homologous and heterologous prime boost vaccination regimes (Hawkridge et al., 2008, 
McShane and Hill, 2005, Griffin et al., 2006, Rahman and Fernandez, 2009, Badell et al., 2009, 
Magalhaes et al., 2008b), as well as the use of adjuvants (Haile et al., 2005).  
  
1.10.1 The development of auxotrophic strains to enhance safety and/or 
immunogenicity of BCG as a vaccine vector  
One particularly promising strategy to enhance safety and/or immunogenicity of BCG is the 
development of auxotrophic strains of BCG and MTB (Tullius et al., 2008, McAdam et al., 
1995). Auxotrophic strains contain mutations geared towards preventing the bacteria from 
synthesising essential growth compounds or amino acids. Auxotrophs are unable to grow in 
culture unless the culture is supplemented with the essential compound that the bacteria is 
unable to produce (McAdam et al., 1995, Sampson et al., 2004). Interestingly, these 
auxotrophs have been reported to be safer than wildtype strains of BCG in immune 
compromised mice which is promising in the context of using BCG as an HIV vaccine (Chambers 
et al., 2000, Sampson et al., 2004, Tullius et al., 2008). Several auxotrophs that have been 




leucine auxotrophs, lysine auxotrophs and pantothenate auxotrophs amongst others 
(Sampson et al., 2004, Bange et al., 1996, Hondalus et al., 2000, Sambandamurthy et al., 2002).  
  
The pantothenate auxotroph of BCG Pasteur has been well characterised and studied by our 
group. The ΔpanCD auxotrophs of BCG and Mtb do not synthesise pantothenic acid and thus 
have limited intracellular replication, are safe in SCID mice and protect from challenge with 
M. tuberculosis (Sambandamurthy et al., 2002, Tullius et al., 2008). Mice vaccinated with this 
auxotroph are also characterised by the induction of better T cell responses and decreased 
pathology as compared to corresponding wildtype strains (Chapman et al., 2012). Additionally, 
our group has previously demonstrated that a Pasteur ΔpanCD auxotrophic strain expressing 
HIV-1 Gag is immunogenic when used as a prime followed by a MVA-Gag boost (Chapman et 
al., 2012, Chege et al., 2009, Chege et al., 2013).  
 
1.10.2 The development of recombinant strains to enhance safety and/or 
immunogenicity of BCG as a vaccine vector  
An alternate strategy to increase immunogenicity, and possibly safety, is the addition of 
exogenous genes to BCG to create recombinant BCG strains (Chapman et al., 2011b, Ottenhoff 
and Kaufmann, 2012). One approach, aimed to promote antigen translocation from the 
endosome to the cytoplasm, is the addition of endosome perforating endolysin genes to BCG. 
The use of 2 such endolysins in BCG vaccine studies, listeriolysin (derived from Listeria 
monocytogenes) and perfringolysin-o (derived from Clostridium perfringens), are discussed 
below.   
  
These molecules perforate the phagosomal membrane allowing for the formation of pores 
through which antigen translocation can occur. Antigen released into the cytoplasm elicits 
improved T cell responses (stimulating MHC I antigen presentation) and limits toxicity to the 




promote apoptosis of infected macrophages as well as lysis of the phagosome thereby 
allowing for antigens to move into the cytoplasm (Grode et al., 2005). This group first reported 
that a urease C-deficient BCG strain expressing listeriolysin (Hly) is more protective against 
aerosol MTB challenge in mice as compared to the parental BCG strain (Grode et al., 2005). 
The urease C deficient strain decreases the pH of the phagosome allowing for the optimal 
functionality of listeriolysin (pH 5.5). Furthermore, listeriolysin degrades upon entering the 
cytoplasm which enhances the safety of this strategy. Additionally they demonstrated that Hly 
promoted apoptosis of macrophages infected with BCG leading to cross priming by dendritic 
cells and the induction of stronger T cell responses than the parental BCG strain. This vaccine 
(VPM1002) successfully passed a phase 1 safety trial and a phase IIa neonate trial is currently 
under way (Kaufmann et al., 2014). A similar molecule to listeriolysin is perfringolysin-O (pfo) 
which is derived from Clostridium perfringens (Sun et al., 2009). A representation of the 
mechanism of perfringolysin-O action is shown below in Figure 1.6.   
  
Figure 1.6. The action of perfringolysin on antigen presentation. Following the formation of the mycobacteria 
containing endosome by the macrophage, perfringolysin acts to perforate the endosome allowing for the release 
of apoptosis promoting cathepsins as well as the translocation of antigen through the cytoplasm to the cell 
membrane. Presentation of antigen via the MHC I pathway, allows for cross priming which leads to improved 





Murine and rhesus macaque studies have demonstrated that TB vaccines vectored by a 
perfringolysin knock in, urease C knock out BCG (Aeras 401) elicit enhanced protection and/or 
stronger CD8+ T cell responses to MTB as compared to the wild type strain (Rosario et al., 
2010, Magalhaes et al., 2008b). The perfringolysin gene selected was a mutated gene that was 
picked as it was less toxic to the host cells than the wild type. It has a Gly 137 to Gln mutation 
which decreases the half-life of the protein in the cytosol. Unfortunately, the phase 1 TB 
vaccine safety trial using BCG Danish 1331 expressing pefringolysin O (Aeras-422) was 
terminated due to side effects which included the reactivation of shingles (Kupferschmidt, 
2011, Ottenhoff and Kaufmann, 2012, Hoft et al., 2016). The effects of combining recombinant 
BCG strains containing lysins with auxotrophic strains, such as the pantothenate auxotroph, 
remain undetermined.   
  
1.11. Using animal models to pre-clinically assess immunogenicity of 
rBCG vaccines expressing HIV-1/SIV Gag  
In addition to clinical correlates of protection from elite controllers and LNTPs, studies have 
suggested that a full length HIV-1 Gag may be the most effectively expressed HIV immunogen 
in BCG based vaccines (Cayabyab et al., 2009, Mederle et al., 2002). Small animal and 
nonhuman primate studies using BCG to expresses HIV-1 Gag (exclusively or in conjunction 
with other HIV antigens) are reviewed below.   
  
1.11.1 Small animal model studies suggest that rBCG is most effective as a priming 
vaccine  
Small animal models used in pre-clinical vaccine testing are invaluable for cost effective 
assessment of vaccine immunogenicity. In addition to HIV-1 Gag, the small animal model has 
also been used to pre-clinically test rBCG expressing novel antigens such as Env gp120, Env  V3 





To date, several studies have reported testing rBCG vaccines expressing Gag (exclusively or in 
conjunction with other HIV antigens) in the small animal model. The first reported pre-clinical 
study to show the induction of Gag specific humoral and CTL responses using a BCG vector 
was performed in the early 1990s (Aldovini and Young, 1990, Aldovini and Young, 1991). This 
study, which assessed the induction of HIV specific responses in BALB/c mice following 
vaccination with rBCG expressing HIV-1 Gag, Pol or Env separately, demonstrated the 
induction of Gag specific IFNγ and IL-2 production (Aldovini and Young, 1991). Long lived DTH 
responses to SIV Gag and pure protein derivative (PPD) following intra-dermal vaccination 
with rBCG expressing a full length SIV gag have been reported in the guinea pig model. 
Additionally, they reported the induction of HIV specific humoral responses in the guise of  
IgG2 and IgG1 antibody titres (Kawahara et al., 2006, Kawahara, 2008). Recent reports indicate 
that rBCG expressing HIV-1 CRF01-AE Gag gene (HIV-1gagE) primes BALB/c mice fora matching 
recombinant vaccinia virus boost (Promkhatkaew et al., 2009). They compared a subcutaneous 
BCG prime and intravenous vaccinia boost to a corresponding intradermal prime boost regime. 
Whilst higher Gag specific CTL levels were initially observed following subcutaneous vaccination 
as compared to the intradermal route, similar HIV specific responses were observed at seven 
months post vaccination.   
Im et al, (2007) assessed the induction of HIV specific immune responses in BALB/c mice 
following a rBCG lysine auxotroph prime and rMVA boost (both expressing consensus subtype 
A Gag)(Im et al., 2007). They reported a dose dependent increase in HIV specific CD8+ T cell 
responses. Using a heterologous prime boost vaccination regime, our group have recently 
reported increased immunogenicity and decreased BCG pathology in mice vaccinated with a 
rBCG ΔpanCD /MVA expressing Gag as compared to mice vaccinated with rBCG wildtype /MVA 
expressing Gag (Chapman et al., 2012). Collectively, these small animal studies support the 




auxotrophs, which have been shown to be safer and more immunogenic than wildtype BCG, 
may prime more effectively for heterologous MVA boost.  
  
1.11.2 Non human primate studies suggest that rBCG is most effective as a 
priming vector  
Non-human primates are immunologically and physiologically more similar to humans than 
mice models and therefore represent a better model for the assessment of vaccines. 
Furthermore, the similarity in response to mycobacterial infection between non-human 
primates and humans makes these models more biologically relevant than small animal 
models (Bontrop and Watkins, 2005, Doxiadis et al., 2001, Shinkai and Locksley, 2000). To 
date, several studies have reported testing rBCG vaccines expressing HIV/SIV Gag in the 
nonhuman primate model. Studies using rBCG to express SIV Gag (exclusively or in conjunction 
with other SIV antigens) as part of a homologous prime boost vaccination regime were 
reported to elicit SIV specific responses but not protect from SIV challenge (Yasutomi et al., 
1993, Mederle et al., 2003).  
  
However, when rBCG has been used as a priming vaccine in a heterologous prime boost 
regime, improved immunogenicity and in some cases protective efficacy has been reported 
(Cayabyab et al., 2009, Ami et al., 2005). Using an rBCG prime (expressing SIV Gag, Pol, Env) 
followed by a recombinant adenovirus 5 boost, Cayabyab et al, (2009) reported substantial 
vaccine induced CD8+ T cell polyfunctionality as well as a distinct central memory phenotype 
(Cayabyab et al., 2009). Both of these characteristics are thought to be required for protective 
efficacy of T cell based HIV vaccines (Dangeti, 2013, Barouch and Picker, 2014). Protective 
efficacy against mucosal SHIV challenge induced by an rBCG (SIV gag)/ vaccinia virus (SIV 
gagpol) heterologous prime boost regime has been previously reported (Ami et al., 2005). 
Interestingly, similar protective efficacy was not observed in control animals that received the 




suggesting that rBCG is most effective in preventing infection when used as a prime in a 
heterologous prime boost regime. Our group has previously shown that modified rBCG 
(pantothenate auxotroph) expressing Gag can prime successfully for a Gag virus-like-particle 
boost and that these responses are superior to a single vaccination with either vaccine (Chege 
et al., 2009). Collectively, these non-human primate studies promote the development of 
rBCG expressing HIV-1 Gag as a priming vaccine in a heterologous prime-boost vaccination 
strategy.  
  
1.12 Study Aim and Hypotheses  
Both non-replicating, safe, viral (poxviral) and persistent (RhCMV) vectors have recently be shown to 
induce the best correlates to protective efficacy in HIV/SIV research to date (Pitisuttithum et al., 
2013, Picker, 2014). In the case of the latter, persistent effector memory CTL responses were 
correlated to the eradication of HIV viral reservoirs (Barouch and Picker, 2014). However application 
of CMV to humans is challenging and other persistent vector systems with established safety profiles, 
such as rBCG, represent interesting alternatives to study. Furthermore, the deletion of virulence 
genes as well as the inclusion of exogenous genes to promote improved immunogenicity merits the 
study of the four strains of BCG described in Table 1.1.   
  
This study aimed to assess and compare the safety and immunogenicity profile of four BCG 
based candidate HIV-1 vaccines as priming vaccines in a heterologous prime boost regime. In 
this study recombinant BCG (rBCG) based vaccines expressing codon optimized HIV-1 subtype 
C gag, were constructed by the Anna-Lise Williamson group using varying strains of Danish 
BCG (kindly supplied by AERAS).   
Hypothesis 1: We hypothesized that priming with either rBCG ΔpanCD (gag) or rBCG ΔpanCDpfo 





Hypothesis 2: We hypothesized that priming with either rBCG pfo (gag) or rBCG ΔpanCDpfo 
(gag) and boosting with SAAVI MVA-C would lead to enhanced T cell responses as compared 
to the wild type strain.  
Hypothesis 3: We hypothesized that assessment of murine gene expression following 
vaccination with modified rBCG would explain the molecular origins for vaccine induced 
pathology and immunogenicity.  
 
Table 1. 2. Summary of rBCG vaccines used in this study   
Strain of rBCG  #  Full name  Abbreviated name  
Wild type strain  1  rBCG[pHS501]  rBCG WT (gag)  
2  rBCG[pConepi]  rBCG WT (control)  
Pantothenate auxotrophic 
strain  
3  rBCG ΔpanCD[pHS501]  rBCG ΔpanCD (gag)  
4  rBCG ΔpanCD[pConepi]  rBCG ΔpanCD (control)  
Perfringolysin O 
expressing strain  
5  rBCG pfo[pHS501]  rBCG pfo (gag)  
6  rBCG pfo[pConepi]  rBCG pfo (control)  
Pantothenate auxotrophic  
strain expressing 
perfringolysin O  
7  rBCG ΔpanCDpfo[pHS501]  rBCG ΔpanCDpfo (gag)  
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2.1 Introduction  
There is an urgent need to develop candidate HIV vaccines which are both safe and 
immunogenic (Esparza and Van Regenmortel, 2014). BCG represents a safe and immunogenic 
priming vaccine vector and advances in developing novel strains of BCG have led to the 
opportunity to further assess BCG as an HIV vaccine vector. In order to characterise end point 
immunogenicity conferred by priming with these novel strains of rBCG and boosting with 
SAAVI MVA-C, we first have to understand the safety and immunological properties of each 
rBCG strain. Whilst the Pasteur rBCG ∆panCD has been well characterised by our group 
(Chapman et al., 2012, Chege et al., 2013), this study represents, to our knowledge, the first 
use of Danish ∆panCDpfo to express HIV-1 antigens. The Danish strain of BCG has been 
reported to be superior in safety and TB protective efficacy to the Pasteur strain (reviewed by 
Luca et al, 2013 (Luca and Mihaescu, 2013)). Whilst BCG is a safe vaccine vector in healthy 
individuals, it is virulent enough to cause pathology in immunocompromised individuals 
(Hesseling et al., 2003). Modified BCG vaccine vectors that induce lesser pathology than wild 
type strains would be ideal for use as an HIV vaccine in immunocompromised infants and 
adults.   
  
Independent of heterologous antigen expression, BCG acts as an adjuvant by stimulating Toll-
like receptor (TLR) pathways which lead to the recruitment and maturation of cells at the site 
of disease (Talat Iqbal and Hussain, 2014). Longitudinal assessment of the development of the 
immune response at a major lymphoid site, such as the spleen, would allow us the compare 
ability of different strains of BCG to promote the induction of a Th1 response (Talat Iqbal and 
Hussain, 2014, Hesseling et al., 2007b). Taken in context of the vaccine specific cellular 
(Chapter 3) and molecular (Chapter 4) immunogenicity results, this data would allow us to 
compare how different rBCG strains, with different properties, can influence the immune 





This chapter therefore aims to assess and compare the development of strain specific rBCG 
induced pathology/immune response between groups of mice vaccinated with the 4 strains of 
BCG used in this study. In order to accomplish this, we undertook a longitudinal study in the 
murine model to assess pathology readouts at multiple time points at the organ and cellular levels 
post vaccination. We longitudinally assessed typical markers of BCG infection in the murine model 
including; the enlargement of the spleen due to expansion of immune effector cells, granuloma 
formation in the liver, iNos activity in the liver and disseminated bacterial load in lymph nodes 
(North and Izzo, 1993, Nandakumar et al., 2014, Chapman et al., 2012). To further understand 
the cellular mechanisms of potential adjuvant properties and/or pathology development we 
longitudinally compared levels and activation of splenic T cell, B cells and dendritic cells between 
mice vaccinated with different strains of rBCG.   
  
2.2 Materials and methods  
2.2.1 Design of rBCG shuttle vector and preparation of rBCG vaccines  
The following rBCG recombinants were generated by Dr Ros Chapman. The E.coli/ mycobacterial 
shuttle vector pHS501, expressing a full length BCG codon optimised HIV-1 subtype C gag gene 
was used to transform the four strains of BCG (Figure 2.1) ((Chapman et al., 2013). The 3’ end of 
the gag gene is fused to an immunodominant BALB/C Env cytotoxic T lymphocyte epitope 
(RGPGRAFVTI) from the V3 region of an HIV-1 subtype B Env protein. Additionally, this was fused 
to a paramyxovirus Simian-Virus 5 monoclonal antibody tag (SV5). The 5’ end of the gag gene was 
fused to the M. tuberculosis 19 kDa signal sequence with expression under the control of a M. 
tuberculosis mtrA promoter. An empty vector control not expressing gag (pConepi) was 
additionally created for each of the 4 strains of BCG.   
  
Following transformation, BCG strains were grown on Middlebrook 7H10 agar supplemented 




Middlebrook 7H9 broth supplemented with 10% OADC, 0.2% glycerol and 0.025% tyloxapol 
(7H9) on rollers (4 rpm) at 370C. Kanamycin (10 µg/ml) was included in the media for plasmid 
selection. Media was supplemented with pantothenate (48 µg/ml) for the growth of BCG 




Figure 2.1: Schematic map of E.coli/mycobacterial shuttle vector expressing Gag.   
  
2.2.3 Characteristics of the SAAVI-MVA-C vaccine  
The SAAVI MVA-C vaccine has been designed and well characterised by the HIV Vaccine 
Development Group at UCT (Ncayiyana, 2009, Burgers et al., 2008, Burgers et al., 2009). This 
vaccine expresses an HIV-1 subtype C polyprotein containing Gag, reverse transcriptase, Tat, 
and Nef (Grttn) which is inserted into the del III region of MVA. Additionally, this vaccine 
contains a truncated HIV-1 subtype C Env gp150 which is inserted into the 49/50 region of 
MVA (Figure 2.2). The Grttn is under the control of a 40K promoter whilst the gp150 is under 
the control of the I3 promoter. The same V3 CTL tag is present on this gp150 as in the rBCG 
shuttle vector.   
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2.2.4 Details of mice used in this study  
Female BALB/c mice (age: 4-6 weeks) were purchased from the South Africa Vaccine Producers 
Pty Ltd (Johannesburg, South Africa). Mice were housed at the University of Cape Town Animal 
Unit for 10 days in order to acclimatise prior to vaccination. Vaccination and handling were 
performed by a trained laboratory animal technologist, Mr Rodney Lucas. Ethics approval for 
the experiments was obtained from the University of Cape Town Animal Research Ethics 
Committee (UCT Protocol number: 012/001).  
  
  
Figure 2.2:  Schematic map of SAAVI MVA-C vaccine insert. This rMVA is designed to express a Grttn polyprotein 
under the control of a 40k promoter as well as a truncated gp150 under the control of an I3 promoter (Burgers 
et al., 2008).  
  
2.2.5 Vaccine preparation and vaccination regime  
Stocks of rBCG vaccines and SAAVI MVA-C were stored at -80 °C. Prior to vaccination, vaccines 
were allowed to thaw on ice for an hour. Resuspension buffer (200 μl) (Appendix 1) was used 
to dilute rBCG vaccines to a dose of of 1 x 107 cfu. This was given via intraperitoneal injection 
on Day 0 to 7 groups of 3 mice per rBCG vaccine (8 rBCG vaccines in total). One group of mice 
per each rBCG vaccine was sacrificed at days; 2, 3, 7, 12, 21 and 28 post vaccination (Figure 
2.3). The final group of rBCG vaccinated mice were vaccinated with intramuscular injection 
with 104 pfu of SAAVI MVA-C in 100μl PBS on day 28. This group was sacrificed 12 days after 




lymph nodes were harvested from sacrificed mice at each time point in order to undertake 
comprehensive immunological, histological and pathology characterisation.   
  
 
Figure 2.3. Vaccination schedule and sacrificial time points for longitudinal assessment of the development of 
BCG pathology. Groups of mice (n=3) were vaccinated with 1 of 8 rBCG vaccines (dosage: 107cfu) on day 0. 
Groups were sacrificed at days 2, 3, 7, 12, 21 and 28 post rBCG vaccinations. One group of day 0 BCG vaccinated 
mice (8 groups of 3 mice) were vaccinated on day 28 with SAAVI MVA-C (104 pfu) and sacrificed 12 days after 
this boost on day 40 in concordance with our prime boost vaccination strategy used in chapters 3 and 4.  
  
2.2.6 Preparation of single cell suspension of murine splenocytes following sacrifice  
Spleens from each vaccinated group of 3 mice per time point were pooled in 30 ml of sterile 
Roswell Park Memorial Institute cell culture medium (RPMI) (Life Technologies, Waltham, USA) 
following every sacrifice (1 spleen per/10 ml RPMI). In a bio-safety cabinet, spleens were poured 
onto a steel cell strainer (70 μm pores) placed in a petri dish and homogenised using a 2 ml syringe 
plunger (Sigma Aldrich, St Louis, USA). The homogenate was transferred to a 50 ml Falcon 
centrifuge tube (Becton Dickinson, Franklin Lakes, USA) and the petri dish was washed with 10 ml 
RPMI and this was added to the 50 ml Falcon tube. The homogenate was made up to 50 ml using 
RPMI and this was centrifuged for 5 minutes at relative centrifugal force (RCF) of 230 g (1400 
rpm) in order to pellet the cells. The supernatant was discarded and the pellet was resuspended 
in 50 ml RPMI and washed twice more. A Pasteur pipette was used to remove extracellular fibrin 
clots. Following the final wash, the pellet was resuspended in 1 ml of RPMI. Red blood cells (RBCs) 
were lysed by adding 1 ml of RBC lysis buffer (Sigma,St Louis, USA) to the Falcon tube. This mixture 
was gently agitated for 1 minute exactly and topped up to 50 ml with RPMI. Following 
centrifugation for 5 minutes at 230 g (1400 rpm), the supernatant was discarded and the cells 
were resuspended in 30 ml of R10 complete media (Appendix 1). A Neubauer counting chamber 




in Trypan Blue (Sigma, St Louis, USA). The cell concentration was adjusted to the concentration 
of 1 million/ml for each assay by adjusting the volume of R10 media.   
  
2.2.7 Confirmation of the ΔpanCD deletion and pfo insertion in vaccine stocks  
The deletion of the panCD genes in the rBCG ΔpanCD (gag) and rBCG ΔpanCDpfo (gag) 
vaccines was confirmed by culturing vaccine stocks in the absence of pantothenate (Vitamin 
B5) in 7H9 media. Following a 3 week culture at 37° C, the optical density of the cultures was 
measured at 600nm. Data was plotted using Graphpad Prism Version 5 (Graphpad Software, 
San Diego, USA). PCR was used to assess the presence of the pfo gene in all rBCG vaccine 
stocks. Primers to amplify the perfringolysin gene were synthesised based on the primer 
sequences from (Sun et al., 2009). Primers A (5’- ACGGCTACCGTCTGGACAT- 3’) and B (5’- 
CGATGGCTTCTTCGATGC- 3’) were used to amplify a 2085 base pair segment containing the 
pfo gene. The following PCR conditions were used: 1: A single 95 ̊ C denaturing cycle for 4 min, 
2: 95  ̊C for 30 seconds denaturing, 60  ̊C 1 min annealing followed by a 72  ̊C 2 min for 
extension (30 cycles), 3: 72  ̊C 10 min with one cycle, 4: 4  ̊C storage. All PCR reactions were 
carried out on a GeneAmp PCR machine (Applied Biosystems, Waltham, USA) and PCR 
products were separated on a 0.8% agrose gel.   
  
2.2.8 Histopathology of murine liver using CD3 staining and iNos  
Preparation of histology samples was performed by the Histology Core Facility (Division of 
Immunology, University of Cape Town). Following sacrifice, murine liver lobes from individual 
mice (n=3 per group) were fixed overnight in 4% phosphate buffered formalin. Sections (5 µm) 
were cut from embedded blocks and mounted on glass slides. Sections were incubated 
overnight at 56° C and rehydrated using Zylol and water. These sections were then blocked 
for 15 min in 3% hydrogen peroxide (H2O2) which was then rinsed off with water. Antigen 
retrieval was performed by incubating the slides in 10mM citrate buffer (pH6) in a pressure 
cooker for 2 minutes. These slides were then cooled in water before being blocked for 20 




PBS. Slides were stained with rabbit anti-human CD3 (Dako pab A0452) (1:100) or iNos (K4003) 
(1:100) for 90 minutes at room temperature. Staining with CD11b proved unsuccessful 
because of high background whilst B220 staining enumerated exceptionally few activated B 
cells. Following staining, slides were rinsed in sterile PBS. Slides were stained with anti-rabbit 
Envision secondary antibody (Dako K4003) for 30 minutes which was then rinsed with sterile 
PBS. DAB (1,4-diamino-2-butanone) substrate (Dako K3468) was applied to the slides and 
washed off with sterile PBS after 10 minutes. These sections were then counterstained with 
Mayer's haematoxylin for 4 minutes and washed underwater for 5 minutes. Following this 
rinse, sections were dehydrated by increasing concentrations of Zylol, covered with a cover 
slip and mounted in a synthetic resin based mount, Entellan (Merck, USA). Sections were 
photographed and analysed under the guidance of an experienced pathologist (Dr Irene 
Garcia-Gabay, University of Geneva). Further imaging support was kindly provided by Susan 
Cooper (University of Cape Town). A Zeiss AxioVert200M fluorescence microscope with a Zeiss 
AxioCam High resolution monochrome camera was used to analyse and capture magnified 
photographs of sections.   
2.2.9 Ex vivo growth of rBCG from abdominal lymph nodes of vaccinated mice 
to determine disseminated bacterial burden  
Following sacrifice, 6 abdominal lymph nodes were collected from each group of mice and 
placed in a 2 ml eppendorf tube containing 1 ml of resuspension buffer (Appendix 1). A Qiagen 
homogeniser was used to homogenise the sample into a smooth homogenate with no clumps. 
Two aliquots of 100 µl per sample were stored in sterile Eppendorf tubes. The sample was 
diluted 1 in 10 by adding 900 µl of resuspension buffer to 100 µl of the homogenate. 100 ul of 
sample was plated in duplicate on 7H10 Agar plates. For mice vaccinated with ΔpanCD 
containing strains, 48 μg/ml pantothenate was used to supplement the agar. Resuspension 
buffer alone was plated separately as a negative control. The plates were incubated at 37 °C 
for 21 days. Colonies were then counted using a Stuart Plus touch sensitive colony counter 





2.2.10 Longitudinal assessment via flow cytometry of dendritic cells, T cells and  
B cells in vaccinated murine splenocytes  
Three individual panels of cytometry antibodies were used to longitudinally assess dendritic, 
T and B cell levels and activation status. For T and B cells, optimised antibody cocktails were 
used according to manufacturer’s instructions (Becton Dickinson, Franklin Lakes, USA) (Table 
2.1). For the dendritic cell panel, individual antibodies and isotype controls were sourced 
(Becton Dickinson and Biolegend) and titrated. Following the preparation of single cell 
suspension of splenocytes, 1.5 x 106 splenocytes per group were added to a FACS tube in a 
final volume of 1 ml R10 media. Three tubes per group were used so that separate T, B and 
dendritic cell staining could be done. The supernatant was discarded and 25 μl blocking 
solution (Appendix 1) was added to each tube and mixed gently with a pipette. This was 
incubated on ice for 20 minutes and washed with cold sterile FACS buffer (Appendix 1). 
Cocktails of flourochrome conjugated antibodies were added to the appropriate tubes. These 
tubes were incubated on ice in the dark for 30 minutes and then washed twice with 2 ml sterile 
cold FACS buffer (Appendix 1). Samples were acquired on a BD LSRII flow cytometer. Flow 
cytometry data was analysed using FlowJo Version 7.1 (Treestar) based on the gating 
strategies suggested by the antibody manufacturer (Figure 2.4). We observed that >80% of DC 
subsets were of myeloid origin and focussed on assessing total DC activation (CD11c+ cells). 
Additionally, using the pre-optimised B cell cocktail, we were able to easily identify activated 
B cells as opposed to using the B220 marker in the dendritic cell panel. In order to quantify 
cellular phenotype and activation at the organ level, positively stained cells were adjusted by 
multiplying by the total count per spleen (Calculated by the Neubauer counting chamber 
count done when preparing single cell suspensions of splenocytes for this assay). Longitudinal 
data for these adjusted estimated cell numbers was plotted using GraphPad Prism Version 5 
(GraphPad Software, San Diego, USA). Area under the curve values (AUC) were calculated 






Table 2.1: Antibody panels to assess cellular activation with optimised assay volumes 
    
  
 
Figure 2.4. Gating strategy to determine cellular subset phenotype and activation in rBCG vaccinated mice. (A) In order to 
quantify T cells and T cell activation we first gated on single cells (P1) followed by lymphocytes (P2). CD3+ cells (P3) were used 
as a parent population to enumerate the frequency of activated (CD44+) T cells (P4). (B) In order to quantify B cells and B cell 
activation (P4) we first gated on single cells (P1) followed by a keeper gate (P2) and CD19+ cells (P3). (C) DCs were enumerated 
by defining a population for CD11c+ cells (P3). Activation markers (CD86) (P4) and (CD80) (P5) were assessed.  
 
T cell panel (10 µl)  B cell panel (20 µl)  DC panel  
CD3 APC-Cy7  CD19 APC  CD11c PE-
Cy7(1 µl)  
CD11b PerCP (0.5 µl)  
CD4-PerCP Cy5.5  CD25 PE-Cy7  CD80 PE (0.5 
µl)  
B220 APC-Cy7 (0.5 µl)  
CD44 FITC  CD69 PE  CD86 FITC (0.5 
µl)  






2.3 Results  
2.3.1 Functional confirmation of the ΔpanCD deletion  
In order to confirm the ΔpanCD deletion phenotype in rBCG ∆panCD (gag/control) vaccine 
stocks, we cultured vaccine stocks in 7H9 Middlebrook broth for 21 days in the presence and 
absence of pantothenate (vitamin B5) supplementation (Figure 2.5). Growth was measured 
21 days after culture began using spectrophotometry. Detectable optical density, and hence 
bacterial growth of ∆panCD (gag/control) and ∆panCDpfo (gag/control) from vaccinated mice 
was only observed in the presence of pantothenate supplementation indicating that the 
∆panCD deletion was present in rBCG ∆panCD (gag/control) and rBCG ∆panCDpfo  
(gag/control) vaccines used in this study.   
  
  
Figure 2.5: Functional confirmation of the ΔpanCD deletion in vaccine stocks by 21 day culture with and 
without pantothenate (Vitamin B5) supplementation. Only ΔpanCD containing strains demonstrated no growth 








2.3.2 PCR confirmation of insertion of pfo gene into UreC locus using PCR  
In addition to confirming the deletion of the ΔpanCD deletion in vaccine stocks, we validated 
the presence of the pfo gene in pfo containing rBCG strains (Figure 2.6). Confirmation of the 
insertion of pfo into the UreC locus of BCG was performed using PCR. PCR products were run 
on an agrose gel parallel to a molecular weight marker. Products from rBCG pfo (gag/control) 
and ∆panCDpfo (gag/control) were observed to be larger (approximately 2083 bp) as 
compared to products from ∆panCD and WT strains of rBCG (approximately, 1967 bp). This 
was found to be in line with the validation of the original mutants reported by (Sun et al., 
2009).   
   
  
1: WT (gag)  2: ∆panCD (gag)  3: pfo (gag)  4: ∆panCDpfo (gag)  
5: WT (control) 6: ∆panCD (control) 7: pfo (control) 8: ∆panCDpfo (control)   
  
Figure 2.6:  Confirmation of the presence of the pfo-specific insertion allele. Presence was verified by PCR using 
primer pairs targeted to amplify a 2083bp fragment of the pfo gene in the case of the pfo containing-BCG strains 
(lanes 3,4,7,8) or a 1967bp ureC fragment for the WT and ΔpanCD strains (lanes 1,2,5,6). A no DNA (blank control, 







2.3.3 Longitudinal assessment of disseminated bacterial burden in rBCG vaccinated 
mice  
Following validation of vaccine stocks and vaccination of mice, we aimed to characterise 
bacterial burden at a peripheral site (Figure 2.7). In order to determine the longitudinal 
kinetics of disseminated bacterial load in mice vaccinated with rBCG vaccines, we grew 
colonies of rBCG from the abdominal lymph nodes of sacrificed mice at each time point using 
ex vivo mycobacterial culture. We observed that mice vaccinated with rBCG ∆panCD 
(gag/control) and ∆panCDpfo (gag/control) did not have detectable mycobacteria from 7 days 
post rBCG vaccination. However, detectable and persistent bacterial loads (peaking between 
days 7-12) were observed throughout the time course for mice vaccinated with WT 
(gag/control) and pfo (gag/control). In persistent strains, there was an increase in bacterial 
load following SAAVI MVA-C boost at day 28 suggesting that boosting persistent BCG can 
increase endpoint bacterial load.   
  
 
  vaccinationrBCG SAAVI-MVAboost   vaccinationrBCG SAAVI-MVAboost 
  
  Key:   WT   ΔpanCD    pfo   ΔpanCDpfo   
  
Figure 2.7: Colony counts from homogenized abdominal lymph nodes of mice vaccinated with rBCG (gag) 
vaccines (A) and rBCG (control) vaccines (B) following culture for 21 days on 7H10 agar. Following Day 0 prime 
with rBCG, mice cleared ∆panCD containing strains by day 7. Wildtype and pfo strains were found to persist until 






2.3.4 Longitudinal assessment of murine liver histopathology  
Anti-vector immunity is often detrimental when using vector based antigen delivery systems. 
Developing safer vaccines is a priority whilst simultaneously attempting to maximise 
immunogenicity. Mycobacterial granulomas form in multiple organs as a result of immune 
effector cells surrounding infected cells to limit the dissemination of the pathogen following 
failure to kill the pathogen (Gideon et al., 2015, Ufimtseva, 2015). In order to longitudinally 
assess and compare the pathology associated with each strain of rBCG used in this study, we 
stained liver sections from sacrificed mice with anti-CD3 specific antibody at each time point 
to assess BCG granuloma formation (n=3). Representative figures of positive control staining 
in rBCG vaccinated mouse and negative control CD3+ staining are shown in Figure 2.8. 
Longitudinally, we observed that mice vaccinated with rBCG ∆panCD (gag/control), pfo 
(gag/control) and ∆panCDpfo (gag/control) presented with consistently fewer granulomas 
than the WT strain. We observed peak granuloma counts for most groups at day 21 which 
coincides with peak T cell count. However, peak granuloma counts for groups vaccinated with 
the ∆panCDpfo strain of rBCG (gag/control) were observed on day 12 indicating an earlier T 
cell response. Representative plots for time points 2, 21 and 40 are shown in Figure 2.8 C. 
Additionally, we stained liver sections for the oxidative response marker iNos (peak responses 
shown in Figure 2.9). iNos activity was markedly less intensive in rBCG ∆panCD (gag/control) 
and rBCG ∆panCDpfo (gag/control) strains as compared to mice vaccinated with rBCG WT 
(gag/control) and rBCG pfo (gag/control). To summarise, murine liver histological analysis of 
granulomas associated less pathology to ∆panCD, ∆panCDpfo and to some degree pfo strains 
of rBCG vaccinated mice as compared to Danish WT.  
  
2.3.4 Longitudinal comparison of splenocyte numbers in rBCG vaccinated mice  
Following the vaccination and sacrifice regime described in Figure 2.3, total splenocytes 
numbers were assessed and compared (Figure 2.10). Similar patterns of increasing 
splenocytes count were observed in all vaccinated groups with maximum splenocyte numbers 
peaking on Day 21 post rBCG vaccination. Across the duration of the experimental time 




counts, as determined by the area under the curve value (AUC), as compared to WT (gag). 
Mice vaccinated with the rBCG ∆panCD (gag) and rBCG ∆panCDpfo (gag) strains presented 
with lower splenocytes counts than the WT and pfo strains. Mice vaccinated with rBCG (gag) 
vaccines consistently presented with slightly higher splenocyte counts as compared to mice 




Figure 2.8. Longitudinal assessment of granuloma formation by immunohistochemistry in murine liver following vaccination with rBCG vaccines. Following sacrifice at 
days post vaccination (x-axis), liver sections were stained with anti-CD3 to quantify granulomas in rBCG (Gag) (A) and rBCG (control) (B) vaccinated mice. (C) Representative 
figures showing CD3 staining for rBCG (Gag) vaccines at days 2, 21 and 40 indicate decreased granuloma formation following vaccination with rBCG ΔpanCD (gag), rBCG 
ΔpanCDpfo (gag) and surprisingly rBCG pfo (gag) as compared to rBCG WT (gag).   
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Figure 2. 9: Assessment of iNos production by immunohistochemistry in murine liver 21 days after vaccination with rBCG vaccines. Following sacrifice at 21 days post 





Figure 2.10: Longitudinal splenocytes counts of mice vaccinated with rBCG vaccines. Total splenocyte count for 
rBCG (gag) vaccines (A) and rBCG (control) vaccines (B) were measured at each time point following sacrifice 
(n=3 per group). Indentation of the y-axis represents splenocyte counts of unvaccinated control group.  




2.3.5 Longitudinal comparison of T cell count and activation in rBCG 
vaccinated mice  
A T cell stimulating HIV vaccine vector should be able to deliver antigen and support the 
induction of a specific and controlled immune response. Excessive nonspecific or vector 
specific T cell activation has been shown to increase the chances of infection and has been 
linked to faster HIV disease progression. In order to longitudinally assess and compare the 
effects of vaccination with different strains of rBCG (gag and control) on T cell count and 
activation in the murine model we stained splenocytes of vaccinated mice with an optimised 
antibody cocktail comprising of CD3, CD4 and CD44 as per manufacturers instruction. T cell 
counts in mice vaccinated with recombinant strains of rBCG (gag) and rBCG (control) induced 
similar sigmoid profiles up until peak T cell count at day 21 (Figure 2.11). T cell levels 
decreased for all groups from day 21 to day 28 for all groups. Following a SAAVI MVA-C boost  
 WT ΔpanCD pfo ΔpanCDpfo 
(gag)   5.7 E+09 3.8 E+09   4.8 E+09   3.8 E+09   






on day 28, mice vaccinated at day 40 displayed higher T cell counts than mice sacrificed on 
day 28 that only received rBCG (gag or control) vaccination. Quantification of T cell count 
across the experimental time course (Figure 2.11A, Table 2.3) revealed that mice vaccinated 
with rBCG ∆panCD (gag) (1.65E+08) and rBCG ΔpanCDpfo (gag) (1.64E+08) presented with 
fewer T cells as compared to groups vaccinated with rBCG WT (gag) (2.84E+08) and pfo (gag) 
(2.2E+08). Similar profiles were observed for rBCG (control) groups (Figure 2.11B). Analysis of 
T cell activation across the experimental time course (AUC, table 2.4) revealed that mice 
vaccinated with rBCG ΔpanCD(gag) (5.46E+08) and rBCG ΔpanCDpfo(gag)(5.14E+07) 
activated fewer T cells as compared to rBCG WT (gag) (1.20E+08) and rBCG pfo (gag) 











2.3.5 Longitudinal comparison of dendritic cell (DC) counts and activation  
Dendritic cells are key mediators of early immune response and function to present antigen 
as well as release soluble cytokine and chemokines to attract T cells to the site of infection. In 
order to longitudinally assess and compare the effects of vaccination with different strains of 
rBCG (gag) on dendritic cell count, we stained splenocytes of vaccinated mice with CD11c, 
(Figure 2.12). Area under the curve (AUC) analysis revealed that mice vaccinated with 
WT(gag)(9.89E+07) presented with a greater quantity of splenic DCs over the experimental 
time course as compared to rBCG ∆panCD (gag) (8.12E+07), rBCG pfo (gag) (8.83E+07) and 
rBCG ΔpanCDpfo (gag) (7.91E+07) . Interestingly, AUC values indicated that rBCG (control) 
vaccines recruited more dendritic cells to the spleen as compared to their corresponding rBCG 
(gag) vaccines. Another notable trend was the observed decrease in dendritic cell count from 
the day 28 time point to the day 40 time point in mice vaccinated with the rBCG ∆panCD 
strains (gag and control) of rBCG.   
Antigen presenting cell activation markers, CD80 and CD86 are integral to modulating a T cell 
response during antigen presentation (Sansom et al., 2003). Area under the curve (AUC) 
analysis revealed that mice vaccinated with WT (gag)(2.33E+06) presented with a greater 
quantity of CD80+ DCs over the experimental time course as compared to rBCG ∆panCD (gag) 
(1.82E+06), rBCG pfo (gag) (1.99E+06) and rBCG ∆panCDpfo (gag) (1.69E+06). Similarly, mice 
vaccinated with rBCG WT (gag) (1.75E+06) presented with a greater quantity of CD86+ DCs 
over the experimental time course as compared to rBCG ∆panCD (gag) (1.40E+06), rBCG pfo 
(gag) (1.57E+06) and rBCG ∆panCDpfo (gag) (1.35E+06.). As observed with dendritic cell 
counts, AUC values indicated that rBCG (control) vaccines recruited more activated dendritic 













Figure 2.12:  Longitudinal splenic dendritic cell (DC) count and activation in mice vaccinated with rBCG vaccines. DC count in mice vaccinated with rBCG (gag) (A) and rBCG 
(control) (B) vaccines (n=3 per group). Activation and maturation (C-F) of dendritic cells were rapid and superior following vaccination of WT (gag/control) as compared to 
modified strains. Indentation of the y-axis represents T cell count/activation of unvaccinated control group. 
 WT  ΔpanCD  pfo  ΔpanCDpfo  
(gag)  9.89E+07  8.12E+07  8.83E+07  7.91E+07  
(control)  1.06E+08  8.41E+07  9.24E+07  8.58E+07  
 WT  ΔpanCD  pfo  ΔpanCDpfo  
(gag)  1.75E+06  1.40E+06  1.57E+06  1.35E+06  
(control)  1.89E+06  1.52E+06  1.66E+06  1.46E+06  
 
 
2.3.5 B cell counts and activation levels  
Whilst our vaccines did not contain B cell specific epitopes, activation of B cells and the 
function of B cells as antigen presenting cells are vital for broad based effective T cell 
responses. Following the infiltration of BCG into organs, B cells, together with dendritic cells 
are key in orchestrating the presentation of antigen to stimulate the development and 
expansion of a T cell response. Notably, the B cells activation is most dominant 1-4 days after 
infection. In order to longitudinally assess and compare the effects of vaccination with 
different strains of rBCG (gag and control) on B cell count and activation status we stained 
splenocytes of vaccinated mice with an optimised antibody cocktail comprising of CD19, CD25 
and CD69. Total B cell numbers were observed to increase to peak levels at 12 days post rBCG 
vaccination. Quantification of B cell count across the experimental time course (Figure 2.13A, 
Table 2.8) revealed that mice vaccinated with rBCG pfo (gag) (2.0E+09) presented with more 
B cells as compared to groups vaccinated with rBCG WT (gag) (1.87E+09), rBCG ∆panCD (gag)  
(1.72E+09) and rBCG ΔpanCDpfo (gag) (1.66E+09). Similar profiles were observed for rBCG 
(control) groups (Figure 2.13B).   
Analysis of B cell activation across the experimental time course (Figure 2.13 C, Table 2.9) 
revealed that mice vaccinated with rBCG pfo (gag) (2.15E+07) presented with more activated 
B cells as compared to groups vaccinated with rBCG WT (gag) (1.697E+07), rBCG ∆panCD 
(gag) (1.66E+07) and rBCG ∆panCDpfo (gag) (1.83E+07). Similar profiles were observed for 
rBCG (control) groups (Figure 2.13D). rBCG (gag) vaccines appeared to induce greater 
activated B cell frequencies in the spleens as compared to their respective controls. 



















Figure 2.13. Longitudinal splenic B cell count and activation in mice vaccinated with rBCG vaccines. B cell count in mice vaccinated with rBCG (gag) (A) and rBCG 
(control) (B) vaccines (n=3 per group). B cell activation peaked on day 2 in spleens of rBCG (gag) (C) and rBCG (control) (D) vaccinated mice. Indentation of the y-axis 
represents B cell count/activation of unvaccinated control grou
  WT   ∆panCD   pfo    ∆panCDpfo   
rBCG (gag)  1.69E+07  1.66E+07  2.15E+07  1.83E+07  
rBCG (control)  1.32E+07  1.58E+07  1.72E+07  1.61E+07  
 WT   ∆panCD   pfo    ∆panCDpfo   
rBCG (gag)  1.87E+09  1.72E+09  2.0E+09  1.66E+09  
rBCG 
(control)  
1.75E+09  1.59E+09  1.85E+09  1.52E+09  
Figure 2.8. Area under the curve (AUC) values for B cell count 






2.4 Discussion   
The data in this chapter provides a comprehensive longitudinal characterisation of the 
immune response to 4 rBCG vectored HIV-1 vaccines in the murine model. Additionally, this 
data highlights the differences that genetic modifications in the mycobacterial vector genome 
can have on pathology and immune response at the systemic, organ and cellular levels.   
Following successful validation of vaccine strain phenotype, we longitudinally compared 
disseminated bacterial load in the abdominal lymph nodes, in order to assess systemic 
persistence of BCG in vaccinated mice. Mice vaccinated with ΔpanCD well as ΔpanCDpfo 
(gag/control) were able to clear the mycobacteria by Day 7 post-infection. This clearance 
could have been due to immune function or the inability of the mycobacteria to survive in an 
environment limited in pantothenate. Studies of other attenuated mycobacterial auxotrophs, 
such as the lysine auxotroph, indicate that this clearance is not due to immune function, but 
rather the inability of the BCG to survive in the absence of essential factors. Pavelka et al, 
(2003) demonstrated this by assessing clearance of the M. tuberculosis lysine auxotroph, 
following vaccination with 106 CFU in normal immunocompetent C57BL/6 and 
immunocompromised SCID mice (Pavelka et al., 2003). Immunocompetent mice were found 
to clear the auxotroph at the same rate as SCID mice indicating that clearance was due to the 
inability of the auxotroph to survive (Pavelka et al., 2003).   
Whilst an HIV vaccine vector which is attenuated to such a degree is desired in a landscape 
where anti-vector immunity has been associated with the failure of clinical trials, current T 
cell HIV vaccine paradigms indicate that persistent vectors can induce prolonged CD8+ T cell 
effector memory responses. However, there is considerable debate particularly with BCG as 
a vaccine vector with some reports indicating improved memory responses upon clearing of 
BCG and others reporting that persistent BCG bacilli perpetuate CD4+ T effector memory 
(Nandakumar et al., 2014). The finding of a dominant yet synergistic effect of ΔpanCD in 
combination with pfo, notably demonstrates a mechanism to improve the safety of rBCG pfo 




where despite impressive preclinical immunogenicity results, a pfo containing vaccine was 
deemed clinically unsafe (Sun et al., 2009, Yang et al., 2015a, da Costa et al., 2014).   
In addition to clearance, mice vaccinated with ΔpanCD well as ΔpanCDpfo (gag/control) 
present with significantly fewer (as measured by CD3+ staining) and less active (as measured 
by iNos) liver granulomas as compared to mice WT and pfo strains. The formation and 
maintenance of granulomas is indicative of the inability of the immune system to clear 
infection. Whilst these findings for the Danish ΔpanCD containing strains are consistent with 
our groups previous study into Pasteur rBCG ΔpanCD (gag) (day 21 peak granuloma formation 
approximately 100 per lobe), these results represents the first indication, from an 
immunological readout, that rBCG pfo may be a less pathogenic strain than WT (Chapman et 
al., 2012). This data demonstrates the superiority of these modified strains of rBCG in inducing 
less pathology than the WT Danish strain.   
In addition to granuloma number, iNos activity has been widely reported to control 
mycobacterial growth (Bekker et al., 2001). Our results indicated greater iNos activity in rBCG 
WT (gag/control) and to some degree rBCG pfo (gag) control as compared to ΔpanCD 
containing strains. Specific mycobacterial components, termed mannose-capped 
lipoarabinomannan (ManLAM) have been shown to induce a significant proportion of iNos in 
macrophages in response to mycobacteria (Afonso-Barroso et al., 2013). Deletion of the panC 
and panD genes has been reported to decrease mycobacteria resistance to oxidative stress 
which suggests that this attenuation of BCG may responsible for the decreased iNos activity 
observed in mice vaccinated with rBCG ΔpanCD (gag/control) Importantly in the context of 
an HIV vaccine, iNos has been shown to enhance HIV viral replication in primary macrophages 
so an excessive iNos response to BCG vectors is not desirable (Blond et al., 2000).   
Following the assessment of rBCG induced pathology at the organ level we compared cellular 
phenotypes and activation in the spleens of vaccinated mice. Firstly, the longitudinal pattern 
of immune response to all strains of BCG was found to be in concordance with classical studies 
into dynamics to BCG (Khalil et al., 1975, Kaufmann et al., 1995). Namely, an increase in 




This was followed by the slow accumulation of T cells in lymphoid organs (the spleen) to a 
peak activated T cell response 21 days post infection which then decreased progressively, 
until a SAAVI MVA-C boost. Optimally, an effective T cell priming vaccine would have to 
initiate a T cell specific immune response whilst moderating T cell recruitment and activation 
at the site of disease in order to limit potential target cells for HIV infection (Haynes, 2015). 
We firstly assessed levels of total splenocytes in mice vaccinated with each regime. Similarly 
to the liver histology, rBCG WT (gag/control) had the most profound effect 
recruiting/expanding 1.5x more cells in the spleen than ΔpanCD and ΔpanCDpfo strains 
further supporting ΔpanCD strains as being less inflammatory than WT. The activation and 
proliferation of DCs and T cells following mycobacterial infection is the major driver of 
inflammation and therefore anti-vector immunity but can additionally be vital to the 
establishment of a vaccine specific memory response (Cooper, 2009). Arama et al, (2012) 
showed that mice vaccinated with the immunogenic BCG-CS (BCG expressing Plasmodium 
falciparum circumsporozoite protein) up regulated CD80 and CD86 on DCs with the priming 
of circumsporozoite-specific memory cells (Arama et al., 2012). Our data indicated that rBCG 
WT (gag/control) conferred greater activation of DCs and T cells than modified strains of rBCG 
which may at a cellular level explain why we observe less inflammation in modified strains.   
HIV vaccines need to be safe and immunogenic. Whilst the data in this chapter suggests the 
superiority of rBCG ΔpanCD, rBCG ΔpanCDpfo and to some degree BCG pfo in creating less 
inflammation and pathology than rBCG, next chapter of this thesis compares endpoint recall 
HIV specific T cell immune responses generated following vaccination with either of these 
strains as part of rBCG/SAAVI MVA-C regime. Chapter 4 primarily investigates the genetic 
differences associated with the characterised endpoint immunogenicity but additionally 
addresses the potential host genetic mechanisms involved in the differences in systemic 
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3.0. Introduction   
Following the characterisation of vector induced pathology and immune response (Chapter 
2) for rBCG Danish WT (gag/control), rBCG ∆panCD (gag/control), rBCG pfo (gag/control) and 
rBCG ∆panCDpfo (gag/control), we assessed the ability of these newly characterised 
candidate HIV-1 vaccines to prime the murine immune system for a heterologous boost with 
the established poxviral SAAVI MVA-C vaccine. Modified strains of rBCG used in this study 
have shown impressive results in terms of limiting pathology. Readouts on the magnitude and 
quality of the HIV specific T cell response would inform on the suitability of these strains as 
candidate HIV-1 vaccine vectors.   
  
Both persistent vectors (RhCMV) as well as non-replicating poxviral vectors (RV144 
canarypox) have recently been shown to be associated with protective HIV/SIV specific 
responses (Hansen et al., 2013a, Pitisuttithum et al., 2013) (reviewed in section 1.8). 
Historically, the UCT group has focused on the development of both persistent as well poxviral 
vectors in the guise of rBCG and SAAVI MVA-C respectively. Due to BCG being the imperfect 
standard of vaccination against TB, constant efforts have been made to improve the safety 
and immunogenicity of BCG by the genetic modification (da Costa et al., 2014). An additional 
benefit of this research is that these modified rBCG strains can be used to express 
heterologous antigen to maximise the potential of BCG as a vaccine vector for other diseases 
(Chapman et al., 2011b). A more comprehensive review detailing the advantages of BCG as a 
vaccine vector can be found in Chapter 1.   
  
In this study, we hypothesized that combining antigen translocation enhancing lysins, such as 
perfringolysin O, with a ΔpanCD knockout would increase the immunogenicity of Danish 
rBCG. We further hypothesised that combining the Danish perfringolysin O knock in with the 




generating CTL response to kill HIV infected cells during early infection in line with current 
HIV T cell vaccination models(McMichael and Koff, 2014).   
  
The process for evaluating the immunogenicity of candidate HIV vaccines designed to induce 
T cell responses in the murine model are well established and desirable endpoint readouts 
are informed by both clinical correlates of protection (as seen in controllers, discussed in 
section 1.6) as well as non-human primate studies (Mann and Ndung’u, 2015, Barouch and 
Picker, 2014, Dangeti, 2013). Once HIV infection is established, eradication of the virus 
becomes exceedingly difficult due to escape mutations following immune pressure as well as 
the establishment of latent viral reservoirs (Picker, 2014). Therefore, an effective T cell 
vaccine should induce a rapid CD8+ CTL immune response assisted by CD4+ T cells to clear 
HIV infected cells prior to the establishment of infection (Figure 3.1). Additionally, the 
generation of persistent antigen specific T cell memory compartments, which would continue 
to lyse infected cells following acute infection, has been shown to clear SIV infection to 
undetectable levels in the NHP model (Hansen et al., 2011).   
  
Assays that measure the quality and magnitude of vaccine induced HIV specific T cell immune 
responses, following ex vivo stimulation with HIV-specific CD4+ and CD8+ peptides, can be 
used to compare immunogenicity between candidate vaccines and regimes. Ex vivo 
quantification of IFNγ production by T cells, in response to HIV specific peptide stimulation, 
represents the most basic and cost effective preliminary comparison of the magnitude of 
vaccine induced T cell responses (Streeck et al., 2009a). The secretion of IFNγ (a Th1 cytokine) 
has been associated with the control of HIV/SIV viral replication (Roff et al., 2013). The IFNγ 
ELISPOT assay is routinely used in HIV vaccine research (Streeck et al., 2009a) to measure the 
quantity of CD4+ and CD8+ T cells producing IFNγ which are visualised as spot forming units 







Figure 3. 1. The role of the T cell immune response in recognising antigen and lysing HIV infected cells. 
Presentation of antigen bound to MHC receptors trigger the adaptive immune response (1) Viral epitopes are 
presented by MHC I molecules on infected cells to T cells expressing the CD8+ T cell receptor (CD8+ TCR). (2) 
Viral epitopes are additionally presented by MHC II molecules on antigen presenting cells to T cells expressing 
the CD4+ T cell receptor (CD4+ TCR). (3) CD4 T cells mature into Th1 cells which produce the Th1 cytokines IL-2, 
IFNγ, and TNF-α which promotes the activation and maturation of effector CD8+ T cells (4). Effector CTL 
responses lyse infected cells and can thereby inhibit early viral replication. (Taken from Immunodeficiency (Winni 
De Haes, 2012).   
  
The desired immune response for an HIV stimulating T cell vaccine is coordinated by a 
complex regulated network of Th1 and Th2 cytokines (as discussed in section 1.6). The soluble 
cytokine milieu induced by a vaccine has notable implications for protective efficacy and 
potentially for disease pathogenesis (Stacey et al., 2009). The desired immune response for 
an HIV vaccine designed to induce T cell responses would be coordinated by a complex 
regulated network of Th1 and Th2 cytokines (as discussed in section 1.6). Bead based 
quantification arrays, can detect the levels (pg/ml) of multiple soluble cytokines from single 









and compared the induction of Th1 cytokines (IFNγ, TNFα, IL-2) as well as Th2 cytokines (IL10, 
IL-4 and IL-6)(Chen et al., 1999).  
 
In addition to the induced cytokine milieu, the quality of the immune response at the single 
cell level merits investigation. Depending on the markers expressed as well as maturation 
phenotype, T cells can plastically change function depending on the immune environment 
(Kolber, 2004). Central memory T cells (TCM) serve as a persistent reservoir to generate rapid 
effector memory T cell (TEM) populations which mature into effector T cells (Dutton et al., 
1998). From a T cell vaccine perspective, the induction of (TCM) and (TEM) phenotypes are 
important in order to provide a prolonged immune control of viral replication (Hansen et al., 
2011).   
  
The simultaneous production of multiple cytokines by T cells, particularly IFNγ, IL-2, and TNFα 
(discussed in section 1.6) has been reported to be associated with delayed disease 
progression and control of viral replication (Minton, 2014, Owen et al., 2010). Flow 
cytometery allows the separation and quantification of specific cellular phenotypes based on 
physical size, granularity and staining with panels of flourochrome conjugated antibodies. The 
flow cytomtery based intracellular cytokine staining assay (ICS), uses the action of Golgi 
inhibitors to stain CD4+ and CD8+ T cells for multiple cytokines (such as IFNγ, IL-2, and TNF- 
α) following ex vivo stimulation with peptide (Trigona et al., 2003). The addition of memory 
and activation markers, (such as CD62L and CDD44) (Gerberick et al., 1997, Kipnis et al., 2005) 
to this cytometry panel, can allow for the simultaneous quantification of vaccine induced T 
cell memory phenotypes. A Th1 dominant cytokine response is associated with the generation 
of long term vaccine specific memory T cell phenotypes. This chapter therefore aimed to 
assess the quality and magnitude of vaccine induced CD4+ and CD8+ T cell responses, in ex 
vivo stimulated splenocytes, from rBCG/SAAVI MVA-C vaccinated mice using the IFNγ ELISPOT 
assay, cytokine bead array (CBA) and multi-parameter flow cytometry to generate 





3.1 Materials and methods  
3.1.1 Mice and Vaccination Strategy  
Details of mice used in this study as well as preparation of rBCG vaccines is described in 
Chapter 2. rBCG vaccines were given via intraperitoneal injection on Day 0 to Groups of 3-5 
BALB/c per rBCG vaccine (8 rBCG vaccines in total) (Table 3.1). All mice were boosted with 104 
pfu of SAAVI MVA-C in 100μl PBS on day 28 by intramuscular injection. Protocol design, 
experimental procedures and data interpretation were conducted under the advice of an 
experienced murine immunologists, Professor Enid Shephard. Both the full length HIV-1 gag 
in the rBCG vaccines as well as the gp150 in SAAVI MVA-C were tagged with a 
immunodominant HIV-1 class I (H-2Dd)-restricted gp120 peptide (RGPGRAFVTI)(V3CTL 
peptide, also know if some publications as ‘peptide H’) for the detection of immune responses 
in BALB/c mice as used in pre-clinical testing of several rBCG vaccination regimes (Cayabyab 
et al., 2006, Chapman et al., 2012, Saubi et al., 2011). Mice were sacrificed by cervical 
dislocation 12 days after the day 28 boost. Spleens were harvested from sacrificed mice in 
order to evaluate vaccine induced T cell responses. Experiments were repeated 3-5 times.  
Table 3.1: Summary of rBCG vaccines used in this study  
Strain of rBCG  #  Full name  Abbreviated name  
Wild type strain  1  rBCG[pHS501]  rBCG WT (gag)  
2  rBCG[pConepi]  rBCG WT (control)  
Pantothenate auxotrophic 
strain  
3  rBCG ΔpanCD[pHS501]  rBCG ΔpanCD (gag)  
4  rBCG ΔpanCD[pConepi]  rBCG ΔpanCD (control)  
Perfringolysin O 
expressing strain  
5  rBCG pfo[pHS501]  rBCG pfo (gag)  
6  rBCG pfo[pConepi]  rBCG pfo (control)  
Pantothenate auxotrophic  
strain expressing 
perfringolysin O  
7  rBCG ΔpanCDpfo[pHS501]  rBCG ΔpanCDpfo (gag)  






3.1.2 Detection of HIV specific IFNγ secretion using the ELISpot 
assay  
Single cell suspension of suspension of splenocytes were prepared as described in Chapter 2, 
section 2.2.6 and utilised in the below assays. The Enzyme-Linked ImmunoSpot (ELISPOT) 
assay was used to determine the frequency of IFNγ producing CD4+ and CD8+ T cells in 
response to stimulation with individual HIV peptides which have been shown to be specific 
for HIV CD4+ and CD8+ responses (Table 3.2). Whilst overlapping peptides are routinely used 
in human studies to assess HIV specific immune response, only a limited number of peptides 
are recognised in the murine model.  The BD Biosciences IFNγ mouse ELISpot kit (Becton 
Dickinson, Franklin Lakes, and USA) was used as per manufacturer’s instructions. When dry, 
plates were analysed using an ImmunoSpot Analyzer (Series 3B) and automatically 
enumerated using Immunospot Image Analyzer running ImmunoSpot Version 3.2 software 
(Cellular Technology Ltd, Shaker Heights, USA). For each condition, the mean spot forming 
unit triplicate and standard deviation was adjusted to spot forming units (SFU/106 
splenocytes). Background responses were determined by irrelevant peptide and responses 
were considered positive if they were greater than twice background response. Data was 
plotted using GraphPad prism Version 5 (GraphPad, San Diego, USA).  
Table 3.2: Stimulation peptides used in this study  
Peptide  Final Concentration  MHC class of H-2Kd binding peptides  Sequence  
VC3CTL   2 µg/ml  MHC I restricted   RGPGRAFVTI  
Gag CD8+  2 µg/ml  MHC I restricted   AMQMLKETI  
Gag CD4+ (13)  2 µg/ml  MHC class II-restricted   NPPIPVGDIYKRWIILGLNK  
Gag CD4+ (17)  2 µg/ml  MHC class II-restricted  FRDYVDRFFKTLRAEQATQE  
Irrelevant (NC)  2 µg/ml  (negative control)  TYSTVASSL  







3.1.3 Cytokine bead array  
The mouse Th1/Th2 Cytokine Bead Array (CBA) kit (Becton Dickinson, Franklin Lakes, and USA) 
was used to quantify HIV–specific secreted IFNγ, TNF-α, IL-2, IL-4, IL-6, and IL-10. Following 
the isolation of single cell suspension of splenocytes from vaccinated mice, 1.5 x 106 cells were 
incubated for 48 hours in the presence of the immunodominant V3CTL CD8+ peptide or 
pooled HIV-1 specific CD4+ and CD8+ peptides (Table 3.2) in a 96 well plate. Following 
stimulation, the plates were centrifuged at 230 g (1400 rpm) for 5 min to pellet the cells. 
Supernatant was removed using a pipette and stored at -80°C in sterile Eppendorf tubes until 
all samples were collected. Samples were thawed slowly on ice on the day of the assay.   
  
The assay was carried out as per manufacturer’s instructions. Fluorescence was measured by 
flow cytometry using a FACS calibur cytometer (Beckton Dickinson, USA) with the assistance of 
an experienced technician, Desiree Bowers. The determined cut off for positivity was 8 pg/ml 
following subtraction of background responses from HIV specific responses. Data was plotted 
using GraphPad prism (Version 5, GraphPad, San Diego). The Students t test was used to 
assess significant differences between cytokine levels in mice under different vaccine 
regimes.   
  
3.1.4 Intracellular cytokine staining (ICS)  
In order to determine intracellular cytokine production and hence T cell polyfunctional 
profiles, we used the ICS assay. Following the procedure of splenocyte preparation (described 
in section 2.2.6) one and a half million splenocytes per condition were stimulated in a FACS 
tube, in triplicate, with either pooled HIV peptides (V3CTL CD8, Gag CD8, Gag CD4 (13 &17)) 
(Table 3.2), an irrelevant peptide negative control or Con A as a positive control. In order to 
prevent secretion of cytokine following stimulation, 0.02μg/μl brefaldin A (BFA; SigmaAldrich, 




Cells were washed in 1 ml of wash buffer (Appendix 1) and blocked in 50μl blocking solution  
(Appendix 1) for 15 minutes at 4˚C. Cells were stained in 99.75μl stain buffer (BD Biosciences,  
USA) with 0.05μg of each fluorochrome-conjugated surface antibody (CD4-V500, CD8-
PerCPCy5.5, CD3-Alexa 700, CD62L-APC and CD44-FITC). An APC isotype control only stain 
was used to ensure optimal separation of CD62L. Excess unbound antibodies were removed 
by a washing with 1 ml of wash buffer (Appendix 1).   
Following 20 minute incubation at 4°C, cells were washed with 1 ml FACS wash buffer. 
Cytofix/Cytoperm (Becton Dickinson, Franklin Lakes, USA) (100 µl) was used to stain cells with 
IFN-γ-PE-Cy7 (0.1 μg), IL-2-PE (0.1 μg) and TNF-α-V450 (0.2 μg) for 20 minutes at 4°C. Cells 
were washed with FACS buffer, fixed with 4% paraformaldehyde (Merck, Frankfurt, Germany) 
and data was acquired on BD Fortessa cytometer. Data was analysed using FlowJo (Treestar) 
and GraphPad Prism Version 5.0 (Version 5, GraphPad, San Diego). Representative gating 
strategy is shown in Figure 3.2.  
  
Figure 3.2. Gating strategy for flow cytometry analysis of HIV specific T cell functionality and memory 
phenotype. A singlet gate (P1), was used to exclude double events. A lymphocytes gate (P2) was used as a parent 
population for a CD3+ gate (P3) to identify T cells. CD3+ cells were further separated by CD4+/CD8+ gating (P4 
and P5). Separate cytokine gating was performed for CD4+ and CD8+ subsets and Boolean gating was used to 
measure the production of IFNγ, IL-2 and TNFα. HIV specific CD4+ and CD8+ cytokine positive cells were then 
phenotyped using CD44+ and CD62L+ separation to identify central memory (TCM),effector memory (TEM) 






3.2 Results  
3.2.1 Induction HIV-1 specific IFNγ release by rBCG (gag)/SAAVI MVA-C 
prime-boost vaccination regime  
  
We assessed four different strains of rBCG to prime groups of mice for HIV specific CD4+ and  
CD8+ T cell IFNγ release following a rBCG/SAAVI MVA-C prime boost regime. (Figure 3.3) 
(mean SFU±SD values shown in Table 3.3). All rBCG vaccines expressing V3CTL tagged Gag 
primed for a significant boost of the immunodominant V3CTL CD8+ peptide (p<0.01) (Figure 
3.3A) (max SFU: rBCG pfo (gag) 773±19). This was not observed for the Gag (CD8+) peptide 
(Figure. 3.3B). Both rBCG pfo (gag) and rBCG ΔpanCDpfo (gag) significantly primed for a boost 
for the CD4+ (13) peptide (p<0.01) (Figure 3.3C) (max SFU: rBCG ΔpanCDpfo (gag) 654±39). 
Only the rBCG ΔpanCD (gag) (p<0.01) and the rBCG ΔpanCDpfo (gag) (p<0.001) vaccine 
primed for a boost of the Gag CD4+ (17) peptide (Figure 3.3D) (max SFU: rBCG ΔpanCDpfo 
(gag) 537±25).   
  
We next compared the magnitude of response between groups primed with rBCG vaccines 
expressing Gag. We found that priming with rBCG ΔpanCD (gag) vaccine induced a greater  
IFNγ response to Gag CD8+ (p<0.01) as compared to priming with rBCG ΔpanCDpfo (gag)  
(Figure 3.3. B). Additionally, the rBCG pfo (gag) (p<0.01) and the rBCG ΔpanCDpfo (gag) 
(p<0.01) vaccines induced a greater IFNγ response to Gag CD4+ (13) peptide as compared to 
the WT (gag) (Figure 3.3 C). The rBCG ΔpanCDpfo (gag) vaccine also induced significantly 
higher Gag CD4+ (17) responses than rBCG WT (gag) (p<0.05) and rBCG pfo (gag) (p<0.001).  
Summarily, modified rBCG vaccines generally induced improved induction of IFNγ as 
compared to rBCG WT (gag).   
 
 
rBCG  1: WT  2: WT  3: ∆panCD  4: ∆panCD  5: pfo  6: pfo  7: ∆panCDpfo  8: ∆panCDpfo  
  (gag)  (control)  (gag)  (control)  (gag)  (control)  (gag)  (control)  
V3CTL  688±41  259±21  449±25  158±14  451±19  293±18  561±56  173±17  
Gag CD8  256±20  215±50  413±25  239±38  313±13  171±17  113±11  56±12  
Gag CD4 (13)  180±23  62±29  270±16  141±11  684±25  252±25  654±39  201±5  
Gag CD4 (17)  107±12  87±8  174±10  82±12  57±9  62±8  537±25  156±32  
Figure 3. 3. Induction of CD4+ and CD8+ HIV specific T cell responses in rBCG/SAAVI-MVA-C prime boost vaccinated mice. Following vaccination and sacrifice, splenocytes 
IFNγ production was assessed following ex vivo stimulation with V3CTL CD8+ (A), Gag CD8+ (B), Gag CD4+ (13)(C) or Gag CD4+ (17) (D) peptides. (Responses were determined 
following subtraction of background responses which were consistently < 20 SFU/106 splenocytes. Students unpaired t test was used to compare means between groups, 
***p≤0.001, **p≤0.01,*p≤0.05. Data is representative of 4 experiments with 5 mice per vaccine group.  
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7:  rBCG ∆panCDpfo (gag)  
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3.2.2 Induction HIV-1 specific Th1 and Th2 cytokine release by rBCG (gag)/  
SAAVI MVA-C prime-boost vaccination regime  
As discussed in section 3.0, the systemic cytokine profile induced following vaccination has 
significant implications for the establishment of an effective persisting T cell response. In 
order to determine the cytokine milieu induced by rBCG/SAAVI MVA-C vaccination regimes, 
we measured cytokine secretion following splenocyte stimulation with either the V3CTL 
immundominant peptide or Gag (pooled CD4+/CD8+) peptides. Preliminary experiments 
indicated that individual Gag responses were not as robust as V3CTL responses following a 48 
hour stimulation so we chose to pool Gag antigens. Splenocytes from vaccinated mice were 
found to produce detectable levels of IFNγ, TNFα and IL-6 (IL-2, IL-4 and IL-10 were 
undetectable) (Figure 3.4, pg/ml±SD values are shown in Table 3.4).   
  
Following stimulation with the V3CTL peptides, all rBCG vaccines expressing Gag appeared to 
prime for the induction of significant IFNγ boost responses as compared to the strain specific 
empty vector controls (p<0.01-p<0.001) (Figure 3.4A)(max value rBCG ΔpanCDpfo (gag): 
1289±32). All rBCG vaccines expressing Gag (apart from rBCG WT) appeared to prime for 
significant boost responses when TNFα was measured as compared to the strain specific 
controls (p<0.01-p<0.001) (Figure 3.4B) (max value rBCG ΔpanCDpfo (gag) : 355±35 pg/ml). 
Only the rBCG ΔpanCD (gag) (p<0.01) and rBCG ΔpanCDpfo (gag) (p<0.01) strains primed for 
significant boost responses when IL-6 was measured (Figure 3.3 C) (max value: pfo (gag) 
402±33).  
  
In addition to V3CTL CD8+, we measured IFNγ and IL-6 for pooled Gag peptides (CD4+/CD8+). 
Only rBCG ΔpanCDpfo (gag) appeared to prime for significant boost responses when IFNγ was 
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Figure 3.4 Induction of CD4+ and CD8+ HIV specific cytokine secretion. Production of IFNγ (A), TNFα (B) and IL-6 (C) were observed following V3CTL CD8+ stimulation. 
Production of IFNγ (D) and IL-6 (E) was observed following stimulation with pooled Gag CD4+ and CD8+ peptides. (Following subtraction of non-specific background, a cytokine 
level of 8pg/ml was considered as a cut off for a positive response. Students unpaired t test was used to compare means between groups ***p≤0.001, **p≤0.01,* p≤0.05). 
Data is representative of 5 experiments with 3-5 mice per vaccine group.  
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1:   rBCG WT (gag)  
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3:   rBCG ∆panCD (gag)  
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A  299±76  40±8  1027±73  42±16  706±51  65±10  1289±32  36±17  
B  29±7  18±4  77±8  22±3  76±5  32±3  86±6  20±3  
C  17±11  25±12  355±35  54±10  402±33  166±108  264±28  35±16  
D  265±56  23±8  517±62  152±27  366±45  145±50  319±73  32±16  













Both rBCG ΔpanCD (gag) and rBCG pfo (gag) appeared to prime for significant boost 
responses when IL-6 was measured as compared to the strain specific controls (p<0.05) 
(Figure 3.4E) (max value: rBCG (gag) ΔpanCDpfo (gag) 704±85 pg/ml).   
We next compared the magnitude of response between groups primed with rBCG (Gag) 
vaccines. Following V3CTL CD8+ stimulation, groups primed with rBCG ΔpanCD (gag) (p<0.01), 
rBCG pfo (gag) (p<0.01) and rBCG ΔpanCDpfo (gag) (p<0.001) produced more soluble TNFα 
than WT (gag) (Figure 3.4B.) This was also observed for IL-6 (rBCG ΔpanCD (gag) (p<0.001), 
rBCG pfo (gag) (p<0.001) and rBCG ΔpanCDpfo (gag) (p<0.001)) and (Figure 3.4C). Following 
stimulation only with pooled Gag peptides mice vaccinated with rBCG ΔpanCD (gag) (p<0.01) 
produced more soluble IFNγ than rBCG WT (gag) (Figure 3.4D) and the rBCG pfo (gag) 
(p<0.05), group produced more soluble IL-6 than rBCG WT (gag) (Figure 3.4E).   
  
3.3.3 Induction of multifunctional HIV specific CD4+ and CD8+ T cells 
following rBCG/SAAVI MVA-C prime boost vaccination  
  
Clinical studies focussing on elite controllers have cited the preservation of multi-functional T 
cells as a correlate of protection (Owen et al., 2010). We aimed to compare the induction of 
CD4+ and CD8+ specific T cell functionality following the described heterologous prime boost 
regime.  rBCG ΔpanCD (gag) and rBCG ΔpanCDpfo (gag) induced a greater percentage of tri-
functional cytokine producing cells (IFNγ, TNFα, IL-2) than rBCG WT (gag) (p< 0.05) (Figure 
3.5A) (max % of CD4 cells: rBCG ΔpanCD (gag) 0.23±0.08). Furthermore rBCG pfo (gag) and 
rBCG ΔpanCDpfo (gag) induced a greater percentage of TNFα+IL-2+ cells than rBCG WT (gag) 
(p< 0.01) (Figure 3.5A) (max % of CD4 cells: pfo (gag) 0.61±0.17). We found that rBCG 
ΔpanCDpfo (gag) induced a greater percentage of IFNγ mono-functional cells than rBCG WT 




























Figure 3.5 Assessment of vaccine induced HIV specific CD4+ T cell functionality following ex vivo stimulation with pooled HIV-1 peptides. (A) Cytokine production in 
splenocytes of mice primed with rBCG (gag) and boosted with SAAVI MVA-C boosted (B) Cytokine production in splenocytes of mice primed with rBCG (control) vaccines and 
boosted with SAAVI MVA-C. Percentage cytokine producing cells for each cytokine combination are shown. Data is representative of 4 independent experiments containing 
3 groups of 3-5 mice per vaccine. A cut-off criterion for positivity of cytokine response was 2x unstimulated background + minimum of 0.05% response + minimum of 20 cells 
for positivity. Negative control/unstimulated values have been subtracted and unpaired students t tests were used for statistical analysis. (***p≤0.001,**p≤0.01,*p≤0.05).  
  IFNγ+ 
TNFα+IL-2  
IFNγ+ TNFα  IFNγ+IL-2  TNFa+IL-2  IFNγ  TNFα  IL-2  
WT  0.05±0.04  0.17±0.04  0.22±0.05  0.3±0.07  0.43±0.06  0.43±0.15  0.42±0.09  
ΔpanCD  
  
0.23±0.08  0.25±0.07  0.2±0.07  0.45±0.13  0.72±0.09  0.75±0.14  0.78±0.09  
pfo  
  
0.18±0.04  0.37±0.080  0.18±0.03  0.61±0.17  0.62±0.13  0.57±0.17  0.39±0.21  









Table 3.5: Percentage of HIV - Specific cytokine producing CD4+ T cells (mean %±SD)   
rBCG WT    
rBCG Δ panCD pfo   
rBCG Δ panCD   
  rBCG  pfo   




Lastly, rBCG ΔpanCD (gag) induced a greater percentage of IL-2 mono-functional cells than 
rBCG WT (gag) (p<0.01) and rBCG pfo (gag) (p<0.01). We next assessed HIV specific CD8+ T 
cell functionality (Figure 3.6).  The rBCG ΔpanCDpfo (gag) vaccine induced a greater 
percentage of cells simultaneously producing three cytokines (0.32±0.11) but this was not 
significantly different from other groups. The rBCG ΔpanCDpfo (gag) vaccine induced a 
greater percentage of IFNy+ TNFα+ double positive cells than rBCG pfo (gag) (p<0.05) (max % 
of CD8+ cells: rBCG ΔpanCDpfo (gag) 0.83±0.11). Additionally, the rBCG ΔpanCDpfo (gag) 
vaccine induced greater levels of IFNγ (max %: 2.01±0.21) than rBCG WT (gag) and rBCG pfo 
(gag). No significant differences were observed when comparing groups primed with any of 
the rBCG (control) vaccines.   
3.3.4 Induction of HIV specific effector (TEM) and central memory (TCM) T 
cells following rBCG/SAAVI-MVA C prime boost vaccination  
Recent RhCMV vectored SIV vaccine studies have associated prolonged control of SIV with 
persistent effector memory T cells (Hansen et al., 2011). The establishment of vaccine specific 
T cell memory phenotypes is a key protective correlate that T cell vaccines aim to elicit. By 
measuring the expression of CD62L and CD44, we identified and compared levels of effector 
memory (TEM CD62L-, CD44high) and central memory (TCM CD62L+, CD44+high) T cells 
between vaccine groups. For CD4+ cells, rBCG ΔpanCD (gag) (p< 0.01) and rBCG ΔpanCDpfo 
(gag) (p< 0.01) induced a greater percentage of TEM than rBCG WT (gag) (Figure 3.7A) (max: 
rBCG ΔpanCD (gag) 1.28±0.2). Additionally, rBCG ΔpanCD (gag) (p<0.05) induced a greater 
percentage of TEM than rBCG pfo (gag). No significant differences were observed between TCM 
levels for CD4+ cytokine producing cells (max value: rBCG pfo (gag) 0.65±0.26.) For CD8+ cells, 
rBCG ΔpanCD (gag) (p< 0.05), rBCG pfo (gag) (p<0.01) and rBCG ΔpanCDpfo (gag) (p<0.001) 
induced a greater percentage of TEM than WT (gag) (Figure 3.7B) (max value: max value: pfo 
(gag) 2.06±0.16). No significant differences were observed between TCM levels for CD8+ 
































Figure 3. 6 Assessment of vaccine induced HIV specific CD8+ T cell functionality following ex vivo stimulation with pooled HIV-1 peptides. (A) Cytokine production in 
splenocytes of mice primed with rBCG (gag) and boosted with SAAVI MVA-C boosted (B) Cytokine production in splenocytes of mice primed with rBCG (control) vaccines and 
boosted with SAAVI MVA-C. Percentage cytokine producing cells for each cytokine combination are shown. Data is representative of 4 independent experiments containing 3 
groups of 3-5 mice per vaccine. A cut-off criterion for positivity of cytokine response was 2x unstimulated background + minimum of 0.05% response + minimum of 20 cells 
for positivity. Negative control/unstimulated values have been subtracted and unpaired students t tests were used for statistical analysis. (***p≤0.001,**p≤0.01,*p≤0.05).  
 IFNγ+ TNFα+IL-2  IFNγ+ TNFα  IFNγ+IL-2  TNFα+IL-2  IFNγ  TNFα  IL-2  
WT  0±0  0.59±0.23  0.29±0.1  0.13±0.06  1.12±0.16  0.62±0.18  0.31±0.1  
ΔpanCD  
  
0.22±0.04  0.6±0.14  0.17±0.04  0.13±0.03  1.73±0.35  1.06±0.22  0.17±0.02  
pfo  
  
0.186±0.04  0.453±0.15  0.18±0.03  0.24±0.17  1.58±0.13  1.24±0.17  0.22±0.05  














Table 3.6: Percentage of HIV 
- 
Specific cytokine producing CD8+ T cells (mean %±SD) 
  







Figure 3. 7 Memory phenotype of HIV-1 specific CD4+ and CD8+ T cells. Effector memory (TEM CD62L-, CD44high) 
and central memory (TCM CD62L+, CD44high) HIV-1 specific CD4 (A) and CD8 (B) T cells were assessed by flow 
cytometry. Data is representative of 4 independent experiments containing 3 groups of 3-5 mice per vaccine. A 
cut-off criterion for positivity of cytokine response was 2x unstimulated background + minimum of 0.05% 
response + minimum of 20 cells for positivity. Unpaired students t tests were used for statistical analysis. 
(***p≤0.001,**p≤0.01,*p≤0.05).  
Table 3.7: Percentage of HIV
 
-specific CD4+ memory T cells    Table 3.8: Percentage of HIV-specific CD8+ memory T cells 
(mean %±SD) 
    
  
3. 4 Discussion  
Heterologous prime-boost regimens attempt to enhance and broaden immune responses by 
combining different vaccine strategies (Woodland, 2004). Notably, the only HIV vaccine 
clinical trial to demonstrate partial protective efficacy (RV144, reviewed in section 1.7.3) 
incorporated a heterologous prime-boost regimen consisting of an ALVAC canarypox prime 
with a protein boost. rBCG expressing HIV-1 Gag has been shown to prime the murine immune 
system for T cell specific responses as part of heterologous prime boost vaccination strategies 
with poxviral vectors (Chapman et al., 2011a). The UCT group has worked extensively with 
rBCG Pasteur as an HIV-1 vaccine vector in combination with heterologous boost (SAAVI MVA-
C and others) and have optimised vector stability, vaccination regimes and dosage using these 
vaccines (Chapman et al., 2012, Chapman et al., 2013, Chege et al., 2013). This study 
  1: WT   3: ΔpanCD   5: pfo   7: ΔpanCDpfo   
TEM  1.02 ±0.2  1.61±0.27  2.06±0.16  1.94±0.23  
TCM  0.57±0.35  0.65±0.14  0.92±0.26  0.79±0.12  
 1: WT   3:ΔpanCD   5: pfo  7:ΔpanCDpfo   
TEM  0.50±0.19  1.28±0.2  0.44±0.27  1.08±0.16  




represents the first use of rBCG Danish as an HIV-1 vaccine vector. The Danish strain of BCG 
has been reported to be superior in safety and protective efficacy to the Pasteur strain 
(reviewed by Luca et al, 2013 (Luca and Mihaescu, 2013)).  
  
Furthermore, modification of BCG through the individual use of the panCD deletion and 
perfringolysin O knock in has been shown to improve safety and immunogenicity in MTB and 
HIV-1 murine model systems (Sambandamurthy et al., 2002, Sun et al., 2009). We 
hypothesised that combining the Danish rBCG with ΔpanCD and pfo modifications could 
enhance the safety and immunogenicity of rBCG as a candidate HIV-1 vaccine vector. Here, 
we assessed the ability of modified strains of Danish rBCG ΔpanCD (gag), rBCG pfo (gag) as 
well as the combination rBCG ΔpanCDpfo (gag) to prime for a SAAVI MVA-C boost as 
compared to WT Danish rBCG (gag).   
  
Discussed below are comparative interpretations of our results in relation to clinical and 
experimental correlates of HIV-1 protection, suggested mechanisms of rBCG Danish strain 
specific vector effects on heterologous prime boost regime as well as suggested future work 
to build on the findings and address the short comings of this initial pre-clinical vaccine 
assessment.   
  
3.4.1 Summary of comparative immunogenicity data  
The above results of comparative readouts following ex vivo stimulation of splenocytes from 
vaccinated mice represent the basic tests to inform candidate vaccine development. However, 
in this model system both inter- and intra- assay variation and discrepancies in findings exist 
and this section summarises all results in a concise and comparative manner to extract 




We summarised data from assays measuring peptide specific CD4+ and CD8+ responses (Table 
3.9). For CD4+ T cells, we found that rBCG ΔpanCDpfo (gag) primed for the greatest cumulative 
induction of IFNγ (following stimulation with Gag CD4 (13) and (17) peptides) (1191 SFU) as 
well priming for the greatest cumulative induction of multi- and bi-functional cells (1.56%).   
  






   WT  ΔpanCD  pfo  ΔpanCDpfo  
IFNγ SFU/106 splenocytes   287±35  444±26  741±34  1191±47  
Multi/Bi-functional CD4+ T cells  0.74%±0.05  1.13%±0.08  1.34%±0.08  1.56%±0.11  
CD4+TEM  0.50±0.19  1.28±0.2  0.44±0.27  1.08±0.16  




IFNγ SFU 106 splenocytes   944±61  862±198  764±33  674±39  
Multi/Bi-functional CD8+ T cells  1.01%±0.08  1.12%±0.07  1.05%±0.11  1.51%±0.09  
CD8+TEM  1.02 ±0.2  1.61±0.27  2.06±0.16  1.94±0.23  
CD8+TCM  0.57±0.35  0.65±0.14  0.92±0.26  0.79±0.12  
  
Additionally, the rBCG ΔpanCD (gag) vaccine primed for the greatest antigen specific CD4+ 
effector memory responses (1.28%). Conversely, comparison of vaccine specific CD8+ T cell 
induction indicated that rBCG pfo (gag) primed for the greatest IFNγ production (following 
stimulation with V3CTL and Gag CD8+ peptides) (764 SFU/106). Furthermore priming with 
rBCG pfo (gag) induced the greatest levels of HIV specific effector (2.06%) as well as central 
(0.92%) memory T cells. The variance within the ELISPOT was greater than expected with a 
number of factors possibly responsible for this (Smith et al., 2009). Nonetheless, the ICS assay 
confirmed antigen specific T cell induction. Priming with rBCG ΔpanCDpfo (gag) induced the 
highest percentage of multi- and bi-functional vaccine specific CD8+ T cells (1.51%). 




modifications can synergistically act to improve both HIV specific CD4+ and CD8+ responses. 
Lastly, mice primed with rBCG pfo (gag) and rBCG ∆panCDpfo (gag) induced greater CD8+ TEM 
and TCM responses as compare to mice primed with rBCG WT (gag) and rBCG ∆panCD (gag).  
  
3.4.1 Induction of vaccine specific IFNγ producing CD4+ and CD8+ T cells   
The generation and maintenance of HIV specific CD4+ and CD8+ T cell response has been 
associated with control of HIV vireamia in the clinical setting (Radebe et al., 2015, Ranasinghe 
et al., 2012)(Discussed in section 1.6.1.2). In this study, we assessed the induction of HIV 
specific CD4+ and CD8+ T cells following the described vaccination regime by firstly measuring 
IFNγ secretion in splenocytes following stimulation with HIV-1 specific peptides (Table 3.2). In 
order to facilitate detection of prime boost responses in the murine model, we utilised an 
immunodominant gp120 peptide, V3CTL (also known in some studies as ‘peptide’ H) 
(Cayabyab et al., 2006, Chapman et al., 2012, Saubi et al., 2011). This peptide was fused to the 
full length Gag immunogen in the rBCG vaccines and the gp150 sequence expressed by the 
SAAVI MVA-C boost.   
  
All rBCG (gag) vaccines were able to prime for significant vaccine specific boost responses of 
the immunodominant V3CTL CD8+ epitope. Priming with the combination rBCG ΔpanCDpfo 
(gag) vaccine significantly priming for boost of 3 vaccine specific epitopes (V3CTL, CD4+ (13) 
and CD4+ (17)). Notable differences were observed in the ability to different strains of rBCG 
to prime for a CD4+ Gag response. Whilst rBCG pfo (gag) and rBCG ΔpanCD (gag) primed for 
either significant CD4+ (13) and CD4+ (17) boost responses respectively, rBCG ΔpanCDpfo 
primed for a SAAVI MVA-C boost of both CD4+ epitopes. This suggests that priming with rBCG 
combining the panCD deletion and pfo insertion may synergistically improve CD4+ T cell 
responses following heterologous boost, possibly through differences in antigen presentation 





3.4.2 Priming with rBCG ΔpanCDpfo (gag) is associated with dominant Gag 
CD4+ responses  
We also noted that mice primed with rBCG ΔpanCDpfo (gag) induced Gag dominant CD4+ (14 
and 17) responses as compared to V3CTL. This is an interesting result as dominance and 
preservation of Gag specific responses in chronically infected HIV-1 individuals has been 
associated with slower disease progression (Mann and Ndung’u, 2015, Ranasinghe et al., 
2012). Gag has extensively been suggested as the preferred immunogen for T cell inducing 
HIV-1 vaccines (Williamson and Rybicki, 2015).   
  
These results were comparable, and in some cases improved when compared to other studies 
that primed with rBCG expressing HIV-1 antigens as part of heterologous boost regimes 
(Hopkins et al., Chapman et al., 2013, Saubi et al., 2011). However, since these studies utilised 
different vector systems, HIV antigens and vaccine doses, we cannot empirically compare the 
magnitude of responses.   
  
3.4.3 Effect of rBCG on SAAVI MVA-C boost responses  
Previous studies done by the UCT group (Chapman et al., 2013), as well as preliminary 
experiments done in this study (data not shown) suggest that BCG prime did not affect SAAVI 
MVA-C responses. This indicated that differences in responses observed following rBCG 
(gag)/SAAVI MVA-C vaccination were due to the immunogenicity of the priming vaccine rather 
than differential suppression of the SAAVI MVA-C response. Furthermore, with this being the 
first study done by the UCT group using rBCG Danish, we noted that whilst this strain of rBCG 
is safer than Pasteur, it did not reduce immunogenicity and the ability to prime for a 





3.4.4 Combining panCD and pfo modifications can increase vaccine specific T cell 
functionality   
In addition to investigating the success of the prime boost regime and quantifying the 
induction of antigen specific T cells, we aimed to assess the induction of polyfunctional CD4+ 
and CD8+ T cells responses following rBCG/SAAVI MVA-C vaccination regimes. Robust HIV 
specific CD4+ T cell responses have been associated with control of vireamia in elite controllers 
(Porichis and Kaufmann, 2011) and an efficacious vaccine would assist in the generation of 
such responses to assist cytotoxic T cell effector function (Figure 3.1). Antigen specific CD4+ T 
cells have previously been shown to assist in generating functional CD8+ T cell memory 
(Shedlock and Shen, 2003). In our study, mice primed with rBCG ΔpanCD (gag) and rBCG 
ΔpanCDpfo (gag) 4.4-4.6 fold increase in triple cytokine producing CD4+ T cells than WT (gag). 
Collective analysis of CD4+ T cell functionality (Table 3.9) indicate that the rBCG modifications 
can work synergistically to induce the greatest collective HIV specific bi- and multi- functional 
CD4+ when combined as in rBCG ΔpanCDpfo (gag).   
  
Multifunctional CD8+ T cells have also been shown to be associated with control of HIV 
vireamia in elite controllers (Betts et al., 2006b) and candidate HIV T cell vaccines should aim 
to elicit such responses. Assessment of CD8+ T cell polyfunctionality revealed that priming 
with modified strains of BCG induced triple cytokine producing CD8+ T (0.18-0.32%) cells 
whilst priming with rBCG WT (gag) did not (0%). Collective analysis of CD8+ T cell functionality 
(Table 3.10) indicates that priming with rBCG ΔpanCDpfo (gag) induces the greatest collective 
bi- and multi-functional CD8+ T cells as compared to the other 3 rBCG priming vaccines used 
in this study. This suggests that priming with rBCG combining the panCD deletion and pfo 
insertion may synergistically increase the CD8+ T cell polyfunctionality following heterologous 





3.4.5 Effect or rBCG modifications on the induction of vaccine specific T cell 
memory  
In addition to the magnitude and quality of the vaccine induced antigen specific T cell 
response, we were interested in the induction of HIV specific central (TCM) and effector (TEM) 
memory T cells in vaccinated mice. Both CD4+ and CD8+ TEM cells have been shown to be 
associated with control of vireamia in clinical cohorts as well as in SIV challenge models that 
have demonstrated vaccine induced protection (Picker, 2014). Importantly, the induction of 
CD4+ and CD8+ TEM responses have been shown to be the most promising cellular correlate 
of vaccine induced protection in SIV infected macaques (Picker, 2014). Hansen et al, (2011) 
vaccinated macaques with RhCMV (clone 68-1) vaccines expressing SIV antigens and 
challenged these macaques with highly pathogenic SIV239 (Hansen et al., 2011). They 
attributed early control of SIV viral replication as well as long term clearance of viral reservoirs 
to vaccine induced CD4+ and CD8+ TEM responses.  
  
3.4.6 The effects of bacilli clearance and antigen processing on immunogenicity   
In our study individual modifications of rBCG Danish appear to synergistically support the 
induction of significant HIV specific CD4+ and CD8+ TEM as compared to rBCG WT. Some reports 
have indicated that improved memory responses are associated with clearing of BCG whilst 
others show that persisting BCG bacilli perpetuate CD4+ T effector memory  
(Nandakumar et al., 2014). In this study, we show that rBCG ∆panCD (gag) and rBCG 
∆panCDpfo (gag) can be cleared from peripheral sites after 7 days post infection, induce less 
pathology than WT rBCG (gag) whilst still priming for significant heterologous boost responses 
associated with improved CD4+ and CD8+ TEM. Mechanistically, the panCD deletion (in rBCG 
∆panCD (gag) and rBCG ∆panCDpfo (gag)) has been associated with decreased inflammation 
by rendering the bacilli more susceptible to oxidative stress as well as decreasing polyketide 





The induction of HIV specific CD4+ and CD8+ T cell responses following priming with modified 
rBCG expressing Gag indicates that both MHC class I and II presentation of the vaccine antigen 
occurs. Alternatively, rBCG expressing perfringolysin O (found in rBCG pfo (gag) and rBCG 
∆panCDpfo (gag) has been shown to lead to the induction of improved CD8+ T cell responses 
as compared to rBCG WT by enhancing antigen translocation into the cytoplasm and 
stimulating MHC I antigen presentation (Sun et al., 2009).   
NHP studies assessing the persistence of rBCG ∆panCDpfo (gag) vectored TEM responses as 
well as possible in vivo challenge would provide an improved model system as compared to 
mice to assess immunogenicity of this vaccine in particular. Our study did not assess CTL 
cytotoxity or measure levels of cytolytic markers which would allow us to compare the 
potency and longevity of the CTL response (Koup and Douek, 2011) although we do look at 
the expression of genes involved in the CTL response in the next chapter.   
  
3.4.7 The deletion of panCD can attenuate rBCG pfo without reducing 
immunogenicity   
Whilst TB vaccine trials in NHP models of rBCG pfo (AERAS 401) indicated that this vaccine is 
highly immunogenic, a clinical trial (AERAS-422) was terminated due to side effects which 
included the reactivation of shingles (Kupferschmidt, 2011, Ottenhoff and Kaufmann, 2012). 
The contribution of the perfringolysin O in mediating these adverse effects is undetermined, 
but our results indicate that modification by deletion of panCD can improve the safety and 
immunogenicity of Danish rBCG pfo as an HIV-1 vaccine vector.   
  
To further understand the molecular mechanisms that are associated with the improved 
vectored responses as well as to understand how these modifications to rBCG vectors 
contribute to the decreased pathology observed in chapter 2, we next assessed gene 




Chapter 4: The effects of priming with different rBCG  
(gag) vaccines on host gene expression following 
SAAVI MVA-C boost  
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4.0. Introduction   
Modified Danish rBCG (gag) vaccines have been shown to induce less pathology (Chapter 2) 
and be more immunogenic (Chapter 3) as compared to rBCG WT (gag) when used as a priming 
vaccine for a SAAVI MVA-C boost. Notably, rBCG ΔpanCDpfo (gag) has been shown to 
collectively prime for improved vaccine specific T cell responses following a SAAVI MVA-C 
boost as compared to priming with rBCG ΔpanCD (gag) and rBCG pfo (gag).  In this chapter, 
we comparatively assessed host Th1/Th2 gene expression profiles in the splenocytes of 
rBCG/SAAVI MVA-C vaccinated mice to characterise biomarkers associated with the described 
improved safety and immunogenicity in modified strains. This chapter introduction highlights 
the developing field of systems vaccinology, notable examples of gene expression profiling 
used in vaccine development, as well as discussing beneficial host gene networks regulated 
by rBCG as a vaccine vector.   
  
4.0.1 Gene expression profiling informs vaccine development  
The major aim of a vaccine is to establish protective immunity and/or immunological memory 
against the pathogen. The induction of an efficacious vaccine specific T cell immune response 
may affect the expression and activation of a number of host factors including; Th1 
transcription factors, cytokines, chemokines, T cell regulatory markers and cell surface 
receptors.  The advent of assays that measure a broad spectrum of host gene expression has 
led to the development of the field of systems vaccinology. Systems vaccinology aims to better 
understand host gene expressions (using ‘omics’ based technologies) that are associated with 
protective and non-protective responses in order to create safer and more immunogenic 





A number of technologies are available to assess post-vaccination gene expression in both 
animal models as well as humans. These include; high-throughput DNA and RNA sequencing 
(Han, 2008), microarrays, CyTOF mass cytometry (O'Gorman et al., 2014), RNAi screening as 
well as Real Time PCR based arrays (Suschak et al., 2016). Whilst these assays allow us to 
perceive the immune response at a greater depth than ever before, there are several 
considerations to be taken into account when interpreting this data. Firstly, gene expression 
profiling provides a measurement of gene expression at a particular time point. With the 
relatively short half-life of many RNAs, positive and negative feedback regulation as well as 
post translational modification, the timing of when to assess gene expression after 
vaccination/ex vivo stimulation is crucial (Nakaya and Pulendran, 2012). Secondly, these large 
data sets can generate many significant gene expression changes. In order to correctly make 
valid biological conclusions, data needs to be assessed in conjunction with conventional 
immunological assays such as pathology assays, ELISPOT and FACS (Sekaly and Pulendran, 
2012, Poland et al., 2013).   
  
Discussed below are several examples of how gene expression profiling has contributed to 
vaccine development against a variety of diseases as well as the implications and challenges 
in using these methods in HIV vaccine development.   
  
4.0.1.1 Notable examples of informative gene profiling in human vaccine initiatives  
The first validation of the systems vaccinology method was reported by studies assessing the 
yellow fever vaccine YF-17D (Querec et al., 2009a). This vaccine represents one of the most 
effective live attenuated vaccines with more than 600 million doses administered globally. 
Immunologically, this vaccine induces both cell-mediated and humoral responses and is 





In a study performed by Querec et al, (2009) gene expression in PBMCs of vaccinated 
individuals were assessed at 1 week post vaccination. Early unique gene signatures (including 
B cell growth factor TNFRS17) could be used to predict the magnitude of neutralizing antibody 
responses with up to 100% accuracy several weeks later (Querec et al., 2009b). Independently, 
Gaucher et al, (2008) used whole genome transcriptional profiling as well as flow cytometry 
to assess genes associated with the induction of protective polyfunctional T cell responses 
(Gaucher et al., 2008). Both of these studies concluded that early gene expression signatures 
of type I interferon, complement genes, as well inflammasome related genes could predict 
protective efficacy of the vaccine. These independent proof of concept studies clearly 
demonstrate the benefits of incorporating systems based approaches to predict vaccine 
immunogenicity.   
  
Another prominent example of a successful systems vaccinology approaches to predict human 
vaccine immunogenicity is that of the seasonal trivalent inactivated influenza virus (TIV) which 
induces predominantly antibody responses.  In contrast to the yellow fever vaccine, 
individuals vaccinated with TIV have usually previously been exposed to either seasonal 
influenza or received previous TIV vaccination. A study done by Nakaya et al, (2011) therefore 
aimed to test if systems vaccinology based approaches could be used to predict recall 
response immunogenicity (Nakaya et al., 2011). Using individuals from 3 different influenza 
seasons, they reported that expression of the kinase CaMKIV at day 3 inversely correlated with 
antibody titres measured later on in the study. They were also able to stratify 90% of study 
participants as high responders (a >4 fold titre increase 30 days post vaccination) and low 
responders (< 4 fold antibody titre increase 30 days post vaccination) based on the patterns 
of gene expression suggesting that systems vaccinology based approaches can be used to 






4.0.2.1 The use of gene profiling in HIV vaccine development  
Collectively, the above studies using systems vaccinology based approaches to predict 
immunogenicity suggest that systems vaccinology may represent a key methodology in the 
process to assess new HIV vaccines. The modestly successful RV144 trial (reviewed in Chapter 
1) showed a protective efficacy of 31.2% against the acquisition of HIV with analysis revealing 
that IgG antibodies against the V1V2 regions of HIV-1 envelope 26 weeks post-vaccination was 
inversely correlated to infection (Pitisuttithum et al., 2013). Several reports have suggested 
that in cases where the correlates of protection remain unclear, retrospective analysis of gene 
signatures following vaccination/challenge may predict the quality of endpoint 
immunogenicity (Nakaya et al., 2011, Derrick et al., 2014). Therefore it is suggested, for 
vaccine development in the absence of clear correlates of protection (such as the rBCG based 
HIV-1 vaccine vectors used in our study), systems vaccinology based approaches incorporating 
gene expression profiling be used in the development phase in animal models as well as early 
stage human trials (Zak and Aderem, 2012, Andersen-Nissen et al., 2012).   
  
Gene expression itself does not guarantee translation of encoded proteins because a variety 
of regulatory processes following gene expression could prevent or modify levels of protein 
translation. These processes include amongst others; methylation of mRNA (Fu et al., 2014), 
decreased translation due to micro RNA (Cai et al., 2009) as well as post-translational protein 
modification (Filtz et al., 2014). The assessment of relative gene expression in animal and 
human vaccine studies provides a snap shot of the inherent effects of vaccination on the host 
immune system as well as the host immune response to encountering antigen again (recall 







4.0.3 The molecular mechanisms of BCG adjuvant activity  
With a well-established safety profile, induction of both adaptive and humoral immune 
responses and well documented adjuvant activity, BCG represents a well characterised 
vaccine vector (Chapman et al., 2011a). The inherent effects of rBCG on mammalian host gene 
expression have been well documented and its adjuvant activity has been shown to have 
therapeutic effects against a range of diseases including disseminated forms of TB, leprosy 
and cancer (Talat Iqbal and Hussain, 2014). A comprehensive review of the advantages and 
recent improvements of rBCG as a vaccine vector is provided in Chapter 1.   
  
Once of the main reasons cited for BCG displaying such broad nonspecific protection is that 
BCG activates antigen presenting cells (APCs) through the interaction of BCG 
pathogenassociated molecular patterns (PAMPs) with Toll-Like receptors (TLRs) 2, 4 and 8. 
This initiates inflammatory pathways which recruit dendritic cells, neutrophils and 
macrophages to the site of infection (Talat Iqbal and Hussain, 2014). Activation of these TLRs 
additionally leads to the downstream activation of the transcription factor NFκB which in turn 
induces proinflammatory cytokines such as IL-12 and TNFα (Kumar et al., 2014).   
  
In addition to activating the innate arm, internalisation of BCG by APCs leads to the activation 
of T helper cells which are thought to assist in the formation of antigen specific memory 
phenotypes (Talat Iqbal and Hussain, 2014). The predominant Th1 cytokines secreted by these 
BCG induced CD4+ T cells include IFNγ, IL-2 and TNFα (Li et al., 2011). The preservation of T 
cells that simultaneously produce these cytokines has been shown to correlate with 
longitudinal control of HIV viral load in controller cohorts (Porichis and Kaufmann, 2011, Owen 
et al., 2010). BCG has also been found to counterbalance inflammation (a concept pertinent 
in the context of HIV-1 vaccination) by inducing BCG activated T regulatory cells (Tregs) which 




are BCG induced gene signatures that have been associated with protection in Tuberculosis 
vaccine trials as well as BCG induced gene signatures associated with protection in vaccine 
trials where rBCG has been used to express heterologous antigen.   
  
4.0.3.1 rBCG induced gene expression in TB vaccine studies  
As discussed in Chapter 1, the relative success and need for improvement of rBCG as a TB 
vaccine has unwittingly led to improvements of rBCG as a vaccine vector for other pathogens. 
The field of TB vaccine research therefore provides insight into protective genes regulated by 
BCG that are associated with protective immune responses. Discussed below are several TB 
vaccine studies that highlight vaccine induction of protective host pathways. In conjunction 
with knowledge of protective HIV immune networks (discussed in in Chapter 1), these studies 
assisted us in developing specific research questions about rBCG regulated protective gene 
networks involved in the immune response to rBCG vectored HIV-1 vaccines.   
  
Several studies have used real-time PCR based arrays to assess protective gene associations 
following vaccination with BCG in the murine model. Lim et al, (2009) evaluated pulmonary 
cytokine and chemokine responses in the lungs of mice immunized with  BCG or a ΔsecA2 
mutant of Mycobacterium tuberculosis (Lim et al., 2009). They found that that these vaccines 
induced comparable levels of vaccine specific cellular responses in the lung 10 days after 
vaccination and these protective responses were associated with the differential regulation of 
12 genes. This included IFNγ, IL-21, IL-27, IL-17f, CXCL9, CXCL10, and CXCL11 as compared to 
naïve unvaccinated mice. In addition to correlates of protection, systems vaccinology 
approaches have also been used to characterise protective responses associated with varying 
routes of vaccination. In a recent study,  gene expression related to BCG induced protective 
anti-TB responses were assessed using real time PCR arrays (Derrick et al., 2014). Mice were 
vaccinated with 5 × 105 CFU of BCG Pasteur either via the intranasal or subcutaneous route. 




compared to subcutaneous vaccination. They also reported significantly elevated expression 
levels of Th1 and T- helper genes IFNγ, interleukin-9 (IL-9), IL-11, and IL21 up to 8 months after 
vaccination in mice receiving intranasal BCG immunization as compared to naïve mice.   
  
A microarray based study aimed to identify biomarkers that could predict the success of BCG 
mediated protection against virulent M.bovis infection (Aranday Cortes et al., 2010).  Mice 
were vaccinated with Danish BCG via intradermal injection (2x105 cfu) and then intranasally 
infected with 600 cfu M. bovis 6 weeks later. Mice were sacrificed at days 3 and 14 post 
infection and microarray was used to assess the transcriptome profile in the lungs and spleen. 
Data was normalised to naive uninfected mice. In addition to the presence of IFNγ related 
genes, they also found the induction of Th17 genes to be associated with BCG protection. The 
T helper cell Th17 gene network functions to assist in the establishment and regulation of 
effective anti-microbial Th1 functions.  
  
In addition to murine models, the systems vaccinology approach to understanding how BCG 
mediates protection by regulating host genes has also recently been studied in the human 
model of BCG (Matsumiya et al., 2015). Using samples from a  phase 1 BCG clinical trial in the 
United Kingdom  (clinical trials registration: NCT01194180) (Harris et al., 2014), in which BCG 
vaccinated or BCG naïve individuals were challenged with BCG,  Matsumiya et al, (2015) 
correlated intradermal BCG growth following BCG challenge to gene expression (DNA 
microarray) and T cell function (flow cytometry) at 2 weeks post challenge (Matsumiya et al., 
2015). They found that the IFNγ and IL-17 pathways are strongly induced in BCG vaccinated 
individuals and expression of these gene subsets was found to correlate to reduced 
mycobacterial growth. They furthermore observed a negative correlation between BCG 





The above studies collectively demonstrate the host gene expression mechanisms associated 
with BCG mediated protection as a TB vaccine. In the context of our study, we were interested 
in how modifying BCG (through deletion of the panCD genes, insertion of perfringolysin (pfo) 
or combining these two modifications) leads to the improved safety and immunogenicity of 
rBCG as a priming vaccine for HIV specific responses following a SAAVI MVA-C boost.  
  
4.1 Study Aims   
The immunotherapeutic characteristics of BCG, as well as the reported induction of tightly 
regulated protective gene networks by BCG contribute to the body of evidence which 
indicates that rBCG represents a potentially safe and immunogenic HIV-1 vaccine vector. 
Based on both the identified protective gene/immunology associations in HIV studies as well 
as the protective associations linked to BCG mediated protection against mycobacterium, in 
this study we were primarily interested in addressing the following 2 aims with provided 
rationale.   
  
1) We aimed to assess the induction of Th1 genes following priming with different rBCG 
(gag) vaccines and boosting with SAAVI MVA-C: Key markers of the Th1 immune 
response includes; IFNγ inducible genes (Taborda-Vanegas et al., 2011),  T-helper 
related genes which assist in the downstream generation of vaccine specific 
multifunctional T cell phenotypes/T cell memory and genes related to cytotoxic T cell 
activity. In order to further understand the pathology and immunogenicity data of this 
study, we aimed to characterise Th1 gene networks and pathways differentially 
regulated in murine splenocytes following rBCG/SAAVI MVA-C prime boost regimes 





2) We aimed to assess the regulation of the Th1 immune response following priming with 
different rBCG (gag) vaccines and boosting with SAAVI MVA-C: Whilst the induction of 
potent T cell responses and inflammatory cytokines is vital for anti-viral immune 
function, excessive inflammation can lead to increased BCG pathology and HIV viral 
replication (Hesseling et al., 2009, Appay et al., 2014). As HIV vaccines have to be 
immunogenic as well as safe, we aimed to compare the relative expression levels of 
Th1 regulatory genes following vaccination and ex vivo stimulation with HIV peptides 
following the proposed vaccination regime.   
  
4.2.1 Experimental design to assess inherent and recall gene 
expression   
Gene expression was assessed in the unstimulated splenocytes of mice primed with rBCG 
(gag) compared to the corresponding rBCG (control) at 12 days after the SAAVI MVA-C boost 
(Vaccinated unstimulated group-VU). The following combinations of vaccinated unstimulated 
(VU) groups were included: rBCG (gag) prime/SAAVI MVA-C boost, rBCG (control) 
prime/SAAVI MVA-C boost and a control group receiving SAAVI MVA-C alone. We additionally 
aimed to characterise recall gene expression induced by rBCG/SAAVI MVA-C vaccination by 
assessing gene regulation in the splenocytes of vaccinated mice that were stimulated ex vivo 
for 6 hours with HIV-1 peptides (Vaccinated stimulated group-VS). The following combinations 
of vaccinated stimulated (VS) groups were included: rBCG (gag) prime/SAAVI MVA-C boost 
and rBCG (control) prime/SAAVI MVA-C boost. Since gene expression is most commonly 
assessed in relation to the baseline responses of unvaccinated mice, we included a group of 
unstimulated splenocytes from unvaccinated mice (Unstimulated unvaccinated – 








Comparison Summary  
Research Question  Comparison  
Which genes (common and variable) are induced in mice primed 
with rBCG (gag) compared to the corresponding rBCG (control) at 12 
days after the SAAVI MVA-C boost?  
  
Unstimulated (VU): rBCG 
(gag) compared to rBCG  
controls   
Which genes (common and variable) are induced 6 hours after ex 
vivo stimulation with HIV-1 peptides in mice primed with rBCG (gag) 
compared to the corresponding rBCG (control)?  
Stimulated  (VS):  
Comparison of rBCG (gag) to 
rBCG control  
  
4.2 Materials and methods  
As demonstrated in the TB vaccine studies discussed above, real-time PCR provides a 
standardised method for profiling gene expression in BCG vaccine models.  The mouse 
Th1/Th2 RT² Profiler™ PCR Array (Qiagen, Hilden, Germany), provided a platform to 
simultaneously assess the relative expression of 86 immunologically pertinent genes involved 
in the Th1/Th2 immune response. Additional to the standardised array provided by 
SABiosciences, it was possible to add 4 genes to this array that were not present in the defined 
array. The genes we chose to additionally include coded for IL-21, programmed death-1 (PD1), 
granzyme B (Gzmb) and perforin (Prf1). The TB vaccine studies discussed above demonstrated 
the protective association of IL-21 in BCG mediated protection in the murine model. HIV 
pathogenesis studies have showed PD-1 to play a role in limiting HIV T cell responses and be 
associated with immune exhaustion (Porichis and Kaufmann, 2012). Lastly, both granzyme and 
perforin are cytolytic degranulation markers and are an essential part of CTL effector function 
(Voskoboinik et al., 2015). All genes contained in this array are shown in Table 4.1. Genes were 
grouped into several gene network categories based on their consensus function as part of 





Table 4.1: List of genes and functional groupings for RT2-Th1/Th2 PCR array  
Gene Symbol  Official Full Name  Gene 
Symbol  
Official Full Name  
1. 1. Th1 a 
Ifng  
ssociated cytokine, transcription factors and 
associated genes Interferon gamma  
3. T-hel per associated genes and innate functions  
Il17a  Interleukin 17A  
Il23a  Interleukin 23, alpha subunit p19  Il15  Interleukin 15  
Nfkb1  Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells 1, p105  
Il2  Interleukin 2  
Il12b  Interleukin 12B  Il7    Interleukin 7  
Il12rb2  Interleukin 12 receptor, beta 2  Il9  Interleukin 9  
Stat1  Signal transducer and activator of transcription 1  Il2ra  Interleukin 2 receptor, alpha chain  
Stat4  Signal transducer and activator of transcription 4  Il5  Interleukin 5  
Tbx21  T-box 21  Tmed1  Transmembrane emp24 domain containing 1  
Il18bp  Interleukin 18 binding protein  Tlr4  Toll-like receptor 4  
Il18r1  Interleukin 18 receptor 1  Tlr6  Toll-like receptor 6  
Nfatc1  Nuclear factor of activated T-cells  Il21  Interleukin 21  
Nfatc2  Nuclear factor of activated T-cells  4. T cell antig en presentation and co-stimulation  
Nfatc2ip  Nuclear factor of activated T-cells  Cd80  CD80 antigen  
Il1r1  Interleukin 1 receptor, type I  Cd86  CD86 antigen  
Tnf  Tumor necrosis factor  Cd28  CD28 antigen  
Tnfrsf8  Tumor necrosis factor receptor superfamily, member 8  Cd4  CD4 antigen  
Tnfrsf4  Tumor necrosis factor (ligand) superfamily, member 4  Cd40  CD40 antigen  
Spp1  Secreted phosphoprotein 1  Cd27  CD27 antigen  
Il27  Interleukin 27  Pdcd1  Programmed cell death 1  
Il27ra  Interleukin 27 receptor, alpha  Icos  Inducible T-cell co-stimulator  
Il6  Interleukin 6  Ctla4  Cytotoxic T-lymphocyte-associated protein 4  
2. Cytolyti c degranulation markers  Cd40lg  CD40 ligand  
Prf1    Perforin 1 (pore forming protein)  Ccr5  Chemokine (C-C motif) receptor 5  
Gzmb  Granzyme B  Igsf6  Immunoglobulin superfamily, member 6  





5. Chemokines and chemokine receptors for mucosal/tissue migration 
and T cell recruitment  
7. JAK-STAT signal transduction  
Ccl11  Chemokine (C-C motif) ligand 11  Irf1  Interferon regulatory factor 1  
Ccl5  Chemokine (C-C motif) ligand 5  Irf4  Interferon regulatory factor 4  
Ccl7  Chemokine (C-C motif) ligand 7  Jak1  Janus kinase 1  
Ccr2  Chemokine (C-C motif) receptor 2  Jak2  Janus kinase 2  
Ccr3  Chemokine (C-C motif) receptor 3  Jak3  Janus kinase 3  
Ccr4  Chemokine (C-C motif) receptor 4  Junb  Jun-B oncogene  
Ccr10  Chemokine (C-C motif) receptor 10  Tyk2  Tyrosine kinase 2  
Cxcr3  Chemokine (C-X-C motif) receptor 3  Mapk9  Mitogen-activated protein kinase 9  
6. Th2 Respons e   Socs1  Suppressor of cytokine signaling 1  
Gata3  GATA binding protein 3  Socs3  Suppressor of cytokine signaling 3  
Gfi1  Growth factor independent 1  Socs5  Suppressor of cytokine signaling 5  
Il10  Interleukin 10  House keeping genes and controls  
Bcl6  B-cell leukaemia/lymphoma 6  Actb  Actin, beta  
Maf  Avian musculoaponeurotic fibrosarcoma  RTC  Reverse transcription control  
Inha  Inhibin alpha  Hsp90ab1  Heat shock protein 90 alpha b1  
Tcfcp2  Transcription factor CP2  Gapdh  Glyceraldehyde-3-phosphate dehydrogenase  
Il13ra1    Interleukin 13 receptor, alpha 1      
Cebpb  CCAAT/enhancer binding protein (C/EBP), beta      
Crebbp  CREB binding protein      






4.2.2 Animals used and vaccine strategy  
Similarly to other experiments in this study, female BALB/c mice (age: 4-6 weeks) were 
purchased from the South Africa Vaccine Producers Pty Ltd (Johannesburg, South Africa). 
Mice were housed at the University of Cape Town Animal Unit for 10 days in order to 
acclimatise prior to vaccination. Vaccination and handling were performed by a trained 
laboratory animal technologist, Mr Rodney Lucas. rBCG Vaccines (Table 3.1) were prepared 
before vaccination as described in Chapter 2. Mice were vaccinated on day 0 via 
intraperitoneal injection with 1 x 107cfu/200 μl of rBCG and boosted on day 28 with an 
intramuscular injection of 104 pfu SAAVI MVA-C.   
  
Ethics approval for the experiments was obtained from the University of Cape Town Animal 
Research Ethics Committee (UCT Protocol number: 012/001). Protocol design and 
experimental procedures were conducted under the advice of experienced murine 
immunologist, Professor Enid Shephard. Mice were sacrificed by cervical dislocation 12 days 
after the day 28 boost. Spleens were harvested from sacrificed mice in order to evaluate 
vaccine induced gene expression. Experiments were repeated 3 times with 5 mice per group.   
  
4.2.3 Preparation of splenocytes and stimulation  
Single cell suspension of splenocytes was prepared as described in Chapter 2. Unstimulated 
splenocytes (1.5 million in 1 ml R10) for each vaccinated group were centrifuged at 1400 rpm 
(using an 18-place Cryovial rotor, Eppendorf, Hamburg, Germany) for 5 minutes in Eppendorf 
tubes and the supernatant discarded. The cell pellet was resuspended in 2 ml RNA later 
(Sigma, USA) and stored at -80°C.  For HIV-1 stimulation, pooled peptides (Chapter 3, Table 
3.2) were used to stimulate 1.5 million splenocytes per vaccine group and incubated for 6 




5 minutes. Cell pellets were resuspended in 2 ml RNA later (Sigma, St Louis, USA) and samples 
were stored at -80°C.  
  
4.2.4 RNA extraction  
The RNeasy kit from Qiagen was used to extract RNA from slowly thawed splenocytes stored 
in RNA later (Sigma). Samples were centrifuged at 10 000 rpm (using an 18-place Cryovial 
rotor, Eppendorf, Germany) for 5 minutes to pellet RNA cells. The pellet was suspended in 
350μl RLT buffer. This solution was transferred to a Qiashredder homogenising spin column 
(Qiagen). These columns were centrifuged at 10 000rpm (Cryovial rotor, Eppendorf) for 2 
minutes. One volume of 70% ethanol was added to the lysate and gently mixed with a pipette. 
The sample was transferred to an RNeasy spin column placed in 2 ml collection tube. This was 
centrifuged at 10000rpm for 15 seconds. The flow through was discarded and 700μl of RW1 
buffer was added to the RNeasy spin column. Tubes were centrifuged at 10000rpm for 15 
seconds. The flow through was discarded and 500μl of RPE buffer was added to the RNeasy 
spin column. Tubes were centrifuged at 10000rpm for 15 seconds. The flow through was 
discarded and a further 500μl of RPE buffer was added to the RNeasy spin column. Tubes 
were centrifuged at 10000rpm for 2 minutes. The collection tube was discarded and the 
RNeasy spin tube placed in a new sterile collection tube. RNA was eluted by adding 50μl RNase 
free water to the RNeasy tube and centrifuging at 10000 rpm for 1 minute. An aliquot of 2μl 
was stored in a PCR tube for assessment of the RNA quality and concentration. The remaining 
48μl of RNA was stored at -80°C to be used in real time PCR array.  
  
4.2.5 RNA quality assessment  
RNA quality and concentration was assessed using a bioanalyzer (Agilent, SA). Quality was 
assessed independently by experienced technicians at the Centre for Proteonomic and 




number ≥ 7 and a concentration higher than 5ng/μl was suitable to be used in RT-PCR arrays 
according to manufacturer’s instructions.   
  
  
4.2.6 cDNA synthesis  
Synthesis of cDNA was performed in a PCR sterile room using the RT2 First Strand Kit (Qiagen).  
All reagents supplied in the kit were vortexed briefly for 30 seconds. In a sterile PCR tube,  
100ng of RNA was added to 2 µl of 5x genomic elimination buffer and made up to 10 µl using 
RNase free water. Following mixing with a sterile pipette, the genomic elimination mixture 
was incubated at 42°C for 5 minutes. The reaction was stopped by chilling the samples on ice.  
The reverse transcription cocktail was prepared whilst the first strand mixture was on ice. To 
constitute this; 16 µl of BC3 RT buffer, 4 µl of P2 primer control, 8 µl of RT enzyme mix  and 
12 µl of RNase free water was added to a sterile PCR tube and gently mixed using a pipette. A 
volume of 10µl of the first strand mix was added to the RT cocktail to render a final volume 
of 50µl and this was mixed gently. The sample was then incubated for 15 minutes at 42°C and 
the reaction immediately stopped by heating for 5 minutes at 95°C. To stop the reaction and 
dilute the cDNA, 91 µl of RNase free water was added to the synthesised cDNA. These 
products were stored on ice and the RT2-PCR array was set up immediately.   
  
4.2.7 RT-PCR array  
In order to make the master mix required for each sample, 550 µl of 2x RT2 qPCR Master Mix 
was added to 448 µl RNase free water and 102 µl of diluted cDNA. This created a master mix 
of volume 1100 µl which was stored on ice.  Four samples per 384 well RT2-PCR array 




of master mix added to each sample well containing optimised printed primers pairs. Once all 
master mix samples were added, the plate was sealed using the supplied adhesive cellophane 
cover and centrifuged for 5 minutes at 230g. Plates were run on an ABI 7900HT PCR machine 
(Applied Biosytems, Foster City, USA) by staff at the Centre for Proteomic and Genomic 
Research (CPGR, Mowbray, Cape Town). The manufacture’s recommended PCR cycle for the 
7900HT PCR machine was used.   
  
4.2.8 Data Analysis  
Data was analysed using the Sabiosciences RT2-PCR array software with support from Dr 
Judith Hornby from CPGR and Whitehead scientific. A list of genes assessed by this assay is 
shown in Table 4.1.  Cut-off for significance was p≤0.05 and a fold change >2.0 when using 
2ΔΔCt Method (Livak and Schmittgen, 2001). Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) was used as the housekeeping gene and all PCR array plates passed manufacturers 
as well as PCR machine quality control. Radial plots were generated using Microsoft Excel. A 
combination of pathway analysis tools (http://www.pathwaycommons.org/about/) and 
analysis resources provided by Qiagen (http://www.sabiosciences.com/rt_pcr_product/) 
were used to infer gene network groupings and pathway activity presented in the discussion 
of this chapter.  
4.3 Results  
We compared the differential host gene expression in splenocytes of BALB/c mice induced by 
priming with either 4 strains of rBCG (gag) (or empty vector control) and boosting with SAAVI 
MVA-C. Using RNA with RNA integrity number (RIN) >7, all RT-PCR array plate runs passed 
assay and RT-PCR machine quality controls.  Data was normalised to naïve unstimulated 
unvaccinated murine splenocytes (UU) and is presented as normalised mean relative fold 
change ± standard deviation in tables as well as the range being provided in text. In order to 




and corresponding non-significant differential fold changes across compared groups whilst 
significant fold changes are highlighted in the accompanying data tables. For each of the two 
comparisons we do (endpoint gene expression (VU) and gene expression during the recall 
response(VS)), we discuss; adjuvant activity of rBCG, the effect of priming with different rBCG 
strains on host gene expression, genes regulated by the SAAVI MVA-C vaccine and lastly, the 







4.3.1 The impact of priming with different rBCG strains following SAAVI  
MVA-C boost on endpoint gene expression   
In order to determine the effects of priming with rBCG (gag) vaccines on Th1/Th2 gene 
expression, we firstly normalised gene expression profiles from all rBCG (gag) vaccinated 
unstimulated samples (VU) to naive (UU) mice (Table 4.2 and Figure 4.1).   
4.3.1.1 Genes associated to the adjuvant activity of rBCG  
In order to identify genes associated to the adjuvant activity of each rBCG, we first looked at 
genes that were significantly regulated and common to all groups receiving an rBCG prime.   
Toll-like receptor 6 (TLR6), an innate receptor for microbial antigen, was found to be 
consistently down regulated in the splenocytes of all rBCG primed mice (-2.14 to -9.18). 
Similar results for the Th1 chemokine receptor CXCR3 were observed (-2.81 to -11.11). CXCR3 
has been found to have multiple functional associations depending on the T cell that it is 
expressed on (reviewed by Groom and Luster, 2011)(Groom and Luster, 2011). In TB animal 
models, CXCR3 has been associated with T regulatory cells (Tregs) which infiltrate peripheral 
organs to limit inflammation.  
  
Assessing gene expression in mice primed with rBCG (control) and boosted with SAAVI MVAC 
would suggest more genes associated to the strain specific adjuvant functions of rBCG. We 
found 2 genes to be down regulated in all mice primed with rBCG (control) but not in the  
SAAVI MVA-C alone group. This included signal transducer and activator of transcription 4 
(STAT4), which functions as a transcription factor aiding the development of CD4 T cells (-6.18 
to -19.52), as well as CCR10 (-3.35 to -13.68) which has been reported to be involved in the 
chemotaxis of T cells between peripheral sites and central lymphoid organs.   
 
 
Table 4.2: Vaccinated unstimulated (VU) normalised to unvaccinated unstimulated (UU) for all groups     
 











WT (control)  ΔpanCD  
(control)  








Il27ra  3.22± 0.47  3.03±0.51  2.43±0.06  2.32±0.36  -0.81±0.1  -0.60±0.01  -0.44±0.11  -0.53±0.03  3.22±0.45  
Il1r1  -7.14± 0.16  -6.25±0.71  -9.09±0.35  -8.52±0.72  -0.22±0.05  -0.47±0.01  -0.64±0.17  -0.30±0.01  -0.51±0.20  
Ccl5  -4.16± 0.87  -5.26±0.74  -5.04±0.14  -3.24±0.27  -1.02±0.03  -0.96±0.06  -1.09±0.01  -1.17±0.33  -0.83±0.1  
Il18r1  -1.04±0.21  -1.54±0.30  -3.71±0.46  -5.36±0.28  -0.29±0.01  -0.34±0.01  -0.91±0.02  -0.48±0.36  0.42±0.01  
Il18  1.34± 0.23  -0.54±0.61  -2.44±0.28  -0.78±0.40  -0.32±0.12   -1.15±0.37  -1.08±0.04  2.17±0.17  
Stat4  0.26±0.01  0.87±0.17  1.06±0.21  0.47±0.19  -12.34±1.06  
 
-6.18±0.23  -16.13±0.74  -0.21±0.01  
3  Tlr6  -3.57±0.63  -6.62±0.76  -3.41±0.31  -3.12±0.24  -4.53±0.31  
 
-2.14±0.29  -6.82±0.13  0.84±0.26  
Il17a  -4.29±0.34  -10.04±0.97  4.34±0.64  4.16±0.35  -1.25±0.25   -1.09±0.34  -1.48±0.04  0.92±0.05  
4  Cd28  -3.70±0.86  -3.13±0.62  -3.84±0.49  -3.22±0.48  -2.17±0.23  -1.41±0.31  -4.47±0.45  -0.74±0.31  0.35±0.12  
Cd4  -3.70±0.09  -6.25±0.31  -3.57±0.36  -3.73±0.15  -1.67±0.15  -1.84±0.01  -1.27±0.63  -1.06±0.17  -0.59±0.02  
5  Cxcr3  -7.69±0.80  -11.11±1.07  -5.56±0.02  -5.26±0.74  -2.81±0.16  -6.41±0.51  -3.78±0.37  -5.56±0.42  0.40±0.06  
CCR2  -1.19±0.23  -0.92±0.14  -0.31±0.01  -1.54±0.04  0.84±0.05  0.79±0.2  1.01±27  1.67±0.24  2.23±0.13  
CCR10  -1.36±0.05  -1.40±0.43  -0.84±0.03  -1.07±0.01  -4.76±0.34  -7.62±0.20  -3.35±0.73  -13.68±0.27  0.95±0.47  
7  Jak 2  -3.37±0.45  -5.35±0.12  -4.00±0.54  -3.17±0.08  0.97±0.01  1.34±0.13  0.21±0.01  1.06±0.17  0.08±0.01  
JunB  -0.57±0.20  -0.64±0.04  -0.21±0.06  -0.69±0.04  -1.18±0.47  -0.36±0.1  -1.05±0.2  -1.41±0.01  3.78±0.30  
SOCS1    -0.24±0.01  -0.93±0.11  -1.43±0.18  -0.87±0.14  -3.48±0.27  -2.01±0.13  -3.71±0.34  -2.51±0.24  2.87±0.18  
MAPK8  -0.66±0.01  -0.35±0.04  -0.16±0.07  -0.49±0.01  -0.09±0.03  -0.87±0.31  -0.92±  -1.11±  2.43±0.07  
 
*Data is representative of 3 separate experiments (n=5 mice 
per experiment). Cut-off for significance fold change ≥ 2, p≤ 
0.05 using  
 
Significant fold change up regulation ±SD 
Significant fold change down regulation ± SD 















Figure 4.1 Expression pattern of genes from unstimulated splenocytes of rBCG (gag)/SAAVI-MVA-C vaccinated mice assessed using real-time PCR. Relative gene expression 
in unstimulated splenocytes of rBCG (gag) and rBCG (control) vaccinated mice (VU) is shown. All samples were normalized to naive (unvaccinated mice). Data is representative 
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 We also observed the down regulation of suppressor of cytokine signalling 1 (SOCS1) (-2.01 
to -3.71) in all groups primed with rBCG (control) as compared to naïve mice. SOCS1 was 
however up regulated in mice receiving SAAVI MVA-C alone (fold change: 2.87). SOCS1 
functions in the JAK-STAT signal transduction pathway and has been reported to compete 
with STATs for binding of Th1 cytokine receptors and thereby assist in the regulation of the 
Th1 response (Linossi and Nicholson, 2015). Lastly, CD28, which is a co stimulatory marker 
involved in T cells binding to antigen presenting cells,  was down regulated in mice primed 
with rBCG WT (control) and rBCG pfo (control) but not in mice primed with rBCG ∆panCD 
(control) and rBCG ∆panCDpfo (control).   
  
4.3.1.2 Effect of rBCG modification on gene expression following rBCG (gag)/SAAVI 
MVA-C prime boost regime  
Next, to assess the effect of rBCG modification on priming with rBCG (gag) and boosting with 
SAAVI MVA-C,  we compared gene expression in groups primed with the 4 rBCG (gag) 
vaccines. We found 5 genes to be commonly down regulated across all four groups. This 
includes; Interleukin 1 receptor 1 (IL-1R1), Chemokine (C-C motif) ligand 5 (CCL5), CD28, CD4 
and Janus kinase 2 (Jak 2). IL-27 receptor alpha subunit (IL-27Ra), which functions both to 
promote IFNγ release as well as reduce excessive pathology in established infection (Liu et al., 
2014), was found to be consistently up regulated (2.32 to 3.22) in all groups primed with rBCG 
(gag) vaccines but also the SAAVI MVA-C alone group suggesting that this up regulation is due 
to the HIV specific boost response.   
  
Next we investigated differentially regulated genes across these same rBCG (gag) primed 
groups. Notably interleukin 17 (IL-17A), which has been associated with the establishment of 
rBCG induced memory T cell populations, was down regulated in mince primed with rBCG WT 
(gag)( -4.29) and rBCG ∆panCD (gag)( -10.04) and up regulated in mice primed with rBCG pfo  




only in mice primed with rBCG pfo (gag) (-2.44) whilst its receptor IL-18R1 was down regulated 
in mice primed with rBCG pfo (gag) (-3.7) and rBCG ΔpanCDpfo (gag) (-5.36).   
  
4.3.1.3 Gene regulations associated to the SAAVI MVA-C boost  
Understanding genes induced by the SAAVI MVA-C is important because regardless of the 
improvements in immunogenicity through modification, priming rBCG is best used in 
conjunction with a more immunogenic heterologous boost. In this study, groups of mice given 
SAAVI MVA-C only presented with up regulated Th1 cytokines including IL-18 (3.22) and IL27a 
(2.17)(also up regulated in rBCG (gag) primed mice). Additionally, chemokine (C-C Motif) 
receptor type 2 (CCR2) (2.23) as well as Junb (3.78) and Mapk8 (2.43) were up regulated.  
Lastly, whilst SOCS1 was down regulated in all rBCG (control) primed groups, it was up 
regulated in mice primed with SAAVI MVA-C (2.87).  Up regulation of SOCS-1 is associated 
with shutting down Th-1 responses but since gene array data provides a single time point of 
gene expression data we cannot correlate this with the Th1 responses observed in Chapter 3. 
A reason for this could possibly be that Th1 gene expression peaked earlier than the measured 
time point.  
4.3.1.4 Gene regulations changes associated to rBCG modification when priming for 
a Gag specific response  
To assess the influence of different rBCG modifications on host gene expression following 
priming with rBCG containing Gag, we compared significant gene regulation changes between 
groups primed with rBCG (gag) vaccines and the matching strain specific rBCG (control) 
groups. Since this comparison overlaps with the above results on rBCG adjuvant activity we 
presented these rBCG (gag)/rBCG (control) comparisons as Venn diagrams to delineate genes 
that are  involved in the response to Gag and are associated with modified rBCG strains.   
 
 
rBCG WT(gag and control) rBCG ΔpanCD (gag and control) 
   
Figure 4.2 Venn diagrams showing the overlap between the differentially regulated genes induced by priming with rBCG (gag) or rBCG (control). For each diagram, the 
circles represent the number of differently expressed genes induced for rBCG (gag) (blue) and corresponding rBCG (control) (yellow). The intersections of each circle 
represents the number of genes commonly expressed by both rBCG (gag) and rBCG (control).  
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4.3.2 The impact of priming with different rBCG strains on the recall response 
following SAAVI MVA-C boost  
To assess and compare gene regulation changes associated with the recall response following 
rBCG/SAAVI MVA-C prime boost regimens, gene expression data from splenocytes that were 
stimulated ex vivo with HIV-1 peptides, normalised to data from unvaccinated mice (naïve) 
(UU) and compared (Table 4.3 and Figure 4.3).    
  
4.3.2.1 Common genes associated with the adjuvant activity of rBCG regardless of 
modification  
To identify genes associated to the adjuvant activity of each rBCG in relation to the recall 
response, we looked at genes that were significantly regulated and common to all groups 
receiving an rBCG prime.  We found 6 common gene down regulations in these groups. These 
genes were; the pro-inflammatory cytokine Interleukin 18 (IL-18) (-5.34 to -31.47), the 
proinflammatory cytokine receptor Interleukin 1 receptor 1 (IL1R1) (-3.12 to -13.75), the T cell 
receptor CD4 (-5.26 to -11.35), the T cell co-stimulatory marker CD28 (-3.25 to -6.23), the 
chemokine receptor CXCR3 (-4.17 to -10.39) and the chemokine (C-C motif) receptor 4 CCR4 
(-2.03 to -8.73). Assessing gene expression in mice primed with rBCG (control) and boosted 
with SAAVI MVA-C would further suggest genes associated to the adjuvant activity of rBCG 
that influence the recall response. We found 7 genes to be down regulated in all mice primed 
with rBCG (control) but not in the SAAVI MVA-C alone group. This included; the 
proinflammatory cytokine receptors IL-27Ra (-4.16 to -9.21) and IL-18R1 (-3.12 to -6.16), the 
proinflammatory chemokine/cytokine CCL5 (-4.17 to -5.63), the innate toll like receptors TLR4 
(3.22 to-3.8) and TLR6 (-2.32 to -3.33) and lastly 2 chemokines CCR2 (-2.13 to -7.14) and CCR3 
(-2.11 to -8.33). 
 
 
Table 4.3: Table of relative gene expression:  Vaccinated stimulated (VS) normalised to unvaccinated (UU) 
#  Gene Symbol  WT (gag)  ΔpanCD (gag)  pfo (gag)  ΔpanCDpfo  
(gag)   
WT (control)  ΔpanCD  
(control)  
pfo  (control)  ΔpanCDpfo  
(control)   









NFkB1  0.98±0.06  1.71±0.21  2.71±0.08  3.31±0.37  -1.56±0.26  -0.98±0.10  -4.16±0.44  -2.88± 0.02  0.26±0.13  
IFNγ  1.32±0.18  1.14±0.54  2.82±0.13  3.02±0.19  0.21±0.03  0.39±0.15  0.46±0.14  1.10±0.01  3.61±0.02  
IL12B  5.5±0.45  3.86±0.14  2.41±0.12  1.96±0.08  1.32±0.36  1.85±0.13  1.21±0.03  1.40±0.17  1.17±0.37  
IL6  1.26±0.06  1.05±0.04  1.39±0.09  1.45±0.12  4.6±0.11  4.57±0.27  4.66±0.25  3.24±0.07  4.66±0.14  
IL-9  1.07±0.01  0.63±0.2  0.15±0.02  1.26±0.03  -1.39±0.02  -1.04±0.31  -4.00 ±0.38  -0.65±0.19  1.82±0.03  
IL27Ra  0.86±0.21  0.31±0.07  0.44±0.13  0.29±0.11  -4.81±0.74  -9.21±0.37  -4.34±0.29  -4.16±0.22  0.48±0.05  
SPP1  -1.43±0.38  -4.47±0.22  -1.85±0.41  -3.41±0.13  1.87±0.07  7.76±0.21  3.6± 0.16  4.61± 0.52  3.15±0.31  
IL18  -11.21±0.87  -5.34±0.31  -31.47±1.08  -13.13±0.31  -7.14±0.46  -6.25±0.13  -9.12±0.87  -9.18±0.14  -3.02±0.04  
IL18R1  1.12±0.04  1.31±0.01  1.25±0.01  1.64±0.03  -3.97±0.31  -6.16±0.20  -3.12±0.34  -3.26±0.13  0.65±0.16  
STAT4  -16.6±0.86  -42.49±1.26  -6.67±0.15  -2.7±0.11  1.24±0.03  1.62±0.11  1.33±0.37  1.02±0.01  1.00±0.02  
IL1R1  -13.75±0.17  -5.41±0.51  -12.14±0.28  -4.21±0.71  -3.97±0.31  -6.47±0.23  -3.12±0.34  -3.26±0.13  0.34±0.05  
TBX21  -3.18±0.35  -3.23±0.15  -2.82±0.64  -6.51±0.37  1.37±0.04  1.66±0.19  1.79±0.05  1.20±0.01  0.75±0.19  
TNFRSF8  -7.29±0.12  -3.74±0.52  -3.98±0.31  -5.31±0.04  1.16±0.01  1.05±0.14  1.38±0.01  1.09±0.22  0.27±0.01  
IL12RB2  -2.56±0.44  -2.15±0.07  -2.92±0.10  -4.11±0.15  0.79±0.16  1.49±0.36  1.69±0.01  1.77±0.50  9.62±0.01  
CCL5  1.87±0.21  1.50±0.17  1.35±0.13  1.04±0.09  -4.17± 0.23  -5.06 ±0.53  -5.63 ±0.07  -5.16 ±0.31  1.14±0.14  
3  TLR 4  0.36±0.40  0.98±0.13  0.74±0.18  0.57±0.01  -3.72±0.33  -3.76±0.15  -3.8±0.19  -3.22±0.04  1.29±0.01  
TLR6  0.94±0.24  1.27±0.08  0.19±0.26  1.36±0.24  -3.33±0.46  -2.43±0.08 -2.32±0.17  -2.39±0.09  0.63±0.20  
  
4  
CD4  -8.2±0.11  -9.29±0.47  -11.35±0.23  -8.64±0.48  -7.69±1.02  -11.11±0.96 -5.26±0.40  -5.37±0.43  0.24±0.06  
CD28  -4.55±0.74  -4.11±0.37  -6.06±0.48  -3.85±0.33  -3.57±0.15  -3.25±0.29  -6.23±0.06  -3.71±0.20  1.08±0.017  
CD80  0.29±0.01  0.31±0.01  0.86±0.22  0.94±0.02  -0.49±0.013  -0.78±0.30  -3.32± 0.03  -0.21±0.04  1.31±0.01  
5  CXCR3  -7.37±0.23  -6.89±0.22  -10.39±0.65  -6.94±0.26  -4.17±0.20  -9.09±.0.41  -6.25±0.23  -5.55±0.15  0.15±0.01  
CCR2  1.16±0.01  1.24±0.01  1.40±0.01  1.27±0.12  -6.25 ±0.49  -7.14 ±0.12  -6.12 ±0.18  -2.13 ±0.01  1.96±0.1  
CCR3  0.80±0.05  0.76±0.12  1.17±0.02   1.03±0.17  -8.33 ± 0.24  -6.81 ± 0.26  -5.41± 0.41  -2.11±0.06  0.34±0.03  
CCR4  -8.73±0.29  -7.14±0.24  -8.45±0.21  -5.26±0.39  -5.26± 0.18  -4.55± 0.23  -5.58 ± 0.18  -2.03±0.64  0.62±0.21  






SOCS1  4.51±0.31  3.53±0.37  4.26±0.87  1.21±0.31  0.30±0.13  1.17±0.01  1.62±0.17  1.74±0.25  1.37±0.04  
IRF4  1.51±0.22  0.72±0.05  2.5±0.31  2.56±0.55  1.47±0.01  1.08±0.01  1.15±0.11  1.60±0.16  4.76±0.06  
JUNB  -4.76±0.20  -8.33±0.17  -7.14±0.16  -16.67±0.37  1.63±0.14  0.64±0.03  0.31±0.16  1.18±0.18  1.36±0.17  
JAK1  -4.55±0.47  -5.00±0.32  -5.56±0.07  -4.15±0.64  1.58±0.02  0.93±0.04  0.11±0.09  0.64±0.023  1.16±0.12  
JAK 2  -2.33±0.16  -3.23±0.64  -3.70±0.39  -2.56±0.20  1.19±0.07  1.01±0.13  0.62±0.08  0.14±0.01  0.36±0.16  
SOCS5  -4.15±42  -4.17±0.07  -6.25±0.19  -4.01±23  0.35±0.06  0.27±0.06  1.05±0.02  0.47±0.04  0.87±0.13  




 Figure 4.3 Expression pattern of genes from ex vivo stimulated splenocytes of rBCG (gag)/SAAVI-MVA-C vaccinated mice assessed using real-time PCR. Relative gene 
expression in stimulated splenocytes of vaccinated mice (VS) is shown. All samples were normalized to naive (unvaccinated mice). Data is representative of 3 individual 
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4.3.2.2 Variable gene regulations associated with strain specific adjuvant activity of 
rBCG associated with recall response  
In order to determine strain specific rBCG adjuvant activity, we looked at genes that were 
differentially regulated in mice prime with rBCG (control) and boosted with SAAVI MVA-C but 
not significantly regulated in the SAAVI MVA-C alone groups. We observed that he Th1 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (Nfκb1) was 
down regulated in mice primed with rBCG pfo (control) (-4.16) and rBCG ΔpanCDpfo (control)( 
-2.88). In mice primed with rBCG pfo (gag), we additionally observed a down regulation of the 
cytokine interleukin 9 (IL-9) (-4.00) (which has been described to promote cell proliferation 
and limit apoptosis) as well as the T cell co-stimulatory molecule CD80 (-3.32). Lastly, the C-C 
chemokine receptor type 10 (CCR10) was found to be uniquely down regulated in mice primed 
with rBCG ΔpanCD (control) (-21.22) and rBCG ΔpanCDpfo (control) (-23.32) suggesting this 
gene regulation is associated to the ΔpanCD modification.   
4.3.2.3 Common gene regulations associated with the recall response following 
rBCG (gag)/SAAVI MVA-C prime boost regime  
Next, to assess the effect of rBCG modification on the recall response following priming with 
rBCG (gag) and boosting with SAAVI MVA-C, we compared gene expression in groups primed 
with the 4 rBCG (gag) vaccines. We found 8 genes to be commonly down regulated across all 
four groups primed with rBCG (gag) vaccines. These included 4 Th1 related genes which were; 
the transcription factors TBX-21 (-2.82 to -6.51) and STAT4 (-2.7- to -42.49), the cytokine and 
cytokine receptor subunit IL12RB2 (-2.15 to -4.11) and the TNF receptor TNFRSF8 (-3.74 to 
7.29). Additionally, 4 genes that are part of the JAK-STAT pathway were down regulated 
including JUNB (-4.76 to -16.6), JAK 1(-4.15 to -5.56), JAK 2(-2.33 to-3.70) and SOCS5 (-4.01 
to-6.25).   
4.3.2.4 Variable gene regulations associated with rBCG modification specific effects 
on recall response  
In order to assess the effect of rBCG modifications on the recall response to HIV antigens after 




(gag) primed groups. Unlike in groups primed with rBCG pfo (control) and rBCG ΔpanCDpfo 
(control) (discussed above), mice primed with rBCG pfo (gag) and rBCG ΔpanCDpfo (gag) we 
found to have Nfkb1 up regulated (2.71 to 3.31). This was insignificant in groups primed with 
rBCG WT (gag) and rBCG ∆panCD (gag). Similarly the potent Th1 cytokine interferon-gamma 
(IFNγ) was up regulated only in groups primed with rBCG pfo (gag) (2.82) and rBCG ΔpanCDpfo 
(gag) (3.02). So was the interferon regulatory factor 4 which belongs to a group of 
transcription factors that regulate interferon expression (2.5 to 2.56). Interleukin 12 beta 
subunit (IL12B) and suppression of cytokine secretion 1 (SOCS1) were up regulated in mice 
primed with rBCG (gag), rBCG ∆panCD (gag), rBCG pfo (gag)  but not in mice primed with 
rBCG ΔpanCDpfo (gag). Lastly, 2 genes were only significantly down regulated in mice primed 
with rBCG ∆panCD (gag) and rBCG ΔpanCDpfo (gag). These were secreted phosphoprotein 1 
(SPP1) (-3.41 to -4.47), which has been reported to promote cell survival by regulating 
apoptosis and Map Kinase 8 (MAPK8) (-4.85 to-5.32).   
4.3.2.5 Gene regulations associated with SAAVI MVA-C  
In the group receiving only the SAAVI MVA-C vaccination, we observed up regulation of the 
inflammatory cytokines IFNγ (3.61) and IL-6 (4.66). We additionally found SPP1 to be up 
regulated (3.15). These results suggest peak Th1 response at 12 days after SAAVI MVA-C 
vaccination confirming the timing of boost and sacrifice times for the prime boost regimes. 
Lastly, IL-18 was down regulated in mice receiving SAAVI MVA-C alone (-3.02).  
4.2.3.6 Gene regulations changes associated to rBCG modification when priming for 
a Gag specific response  
To assess the influence of different rBCG modifications on host gene expression following 
priming with rBCG containing Gag and recall response, we compared significant gene 
regulation changes between groups primed with rBCG (gag) vaccines and the matching strain 
specific rBCG (control) groups. Common genes associated to the effect of rBCG strains 
(regardless of gag/control insert) suggest pathways involved in rBCG adjuvant activity.  
 
 
 Figure 4.4 Venn diagrams showing the overlap between the differentially regulated genes induced by ex vivo stimulation after rBCG/SAAVI MVA-C prime boost 
regimen. For each diagram, the circles represent the number of differently expressed genes induced for rBCG (gag)(blue) and corresponding rBCG (control)(yellow) . The 




4.4. Discussion   
We have shown in preceding chapters that modified rBCG (expressing HIV-1 Gag) induces less 
pathology (Chapter 2) and improved antigen specific CD4+ and CD8+ T cell responses (Chapter 
3) as compared to rBCG WT (gag)(as part of a heterologous boost). In this chapter, we 
compared the expression of 86 immunologically pertinent Th1 and Th2 genes in the spleens 
of mice primed with either rBCG WT (gag), rBCG ∆panCD (gag), rBCG pfo (gag) or rBCG would 
elucidate the molecular mechanisms of reduced pathology and improved HIV specific T cell 
responses (induced by modified rBCG as compared to priming with WT Danish). Whilst a 
number of genes were consistently regulated across all groups as part of the immune 
response to vaccination ex vivo peptide stimulation, we analysed the unique gene 
associations to find associations with the pathology and immunogenicity data.   
  
4.4.1 Effect of priming with different rBCG (gag) vaccines on host gene 
expression following SAAVI MVA-C boost  
In order to determine molecular signatures associated with rBCG induced 
pathology/immunogenicity, we assessed gene expression in unstimulated splenocytes from 
groups of mice primed with rBCG (gag) vaccines and boosted with SAAVI MVA-C (28 days post 
rBCG vaccination). We noted that down regulation of genes involved in the IL-18 pathway, 
was associated with priming with rBCG pfo (gag) and rBCG ∆panCDpfo (gag). An up regulation 
of IL-17A, which is produced mostly by T helper cells was also associated with rBCG vaccines 
expressing perfringolysin. Inherent activation and regulation of the IL-17/IL-18 pathway 
(Figure 4.5), has varying implications for both BCG induced protection as well as HIV 






Figure 4. 5 Priming with rBCG expressing perfringolysin and HIV-1 Gag leads to induction of the IL-17/IL-18 
pathway. IL-18/IL18R1 interaction can lead to the expression of anti-viral and anti-bacterial gene products IFN 
and NOS2 but also the HIV-1 co-receptor CCR5.  
  
 A TB vaccine study assessing gene expression in BCG vaccinated humans, reported that the 
IL-17 pathways are strongly induced in BCG vaccinated individuals and expression of these 
gene subsets was found to correlate to reduced mycobacterial growth (Matsumiya et al., 
2015). They furthermore observed a negative correlation between BCG growth and the 
frequencies of IL-17 multi-functional T cells.  Lastly, IL-17 production has been associated with 
protection against MTB in mice vaccinated with the recombinant rBCG ΔureC hly which 
expresses an endolysin similar to perfringolysin called listeriolysin (Desel et al., 2011). As 
compared to the WT strain this rBCG ΔureC hly, induced improved protective responses that 
were highly characterised by IL-17 production. This, together with our data, led us to believe 
that endolysins can increase the production of rBCG specific IL-17 following vaccination. IL-17 




SIV. A NHP study reported that IL-17 producing CD4 T cells are infected at a greater rate in 
vivo than other T cells in macaques infected with SIV mac251 (Cecchinato et al., 2008). They 
also demonstrated that in highly vireamic animals, Th1 responses dominated over Th17 
responses suggesting that the Th1/Th17 balance is important for protection. Human HIV 
studies have suggested that preferential infection of IL-17 CD4+ T cell subsets is irreversible 
and may lead to the lack of immune control of HIV pathogenesis (Mavigner et al., 2012).   
4.4.2 Gene expression associations involved in the recall response to HIV-1 
peptides   
A major aim of T cell based HIV-1 vaccine approaches is to induce vaccine specific Th1 cytokine 
release, multi-functional T cells as well as vaccine specific memory T cells (Mann and Ndung’u, 
2015). Whilst all 3 of the modified rBCG (gag) vaccines were deemed to induce improved T 
cell responses than rBCG WT (gag) when used in combination with a SAAVI MVA-C boost, we 
attempted to determine if we find gene regulations associated with differences in 
immunogenicity. To compare gene regulation changes associated with the recall response 
following rBCG/SAAVI MVA-C prime boost regimens, gene expression data from splenocytes 
that were stimulated ex vivo with HIV-1 peptides was normalised to data from unvaccinated 
mice (naïve). The recall response in mice primed with rBCG pfo (gag) and rBCG ΔpanCDpfo 
(gag) was associated with up regulation of the major inflammatory cytokine and transcription 





Figure 4.6: The recall response following ex vivo stimulation in mice primed with rBCG expressing 
perfringolysin and HIV-1 Gag. NFKB1, IFNγ and IRF4 commonly regulate Mucin 1, cell surface associated protein 
(MUC1). MUC1 is associated to reduced apoptosis as well as binding cytoplasmic antigen.  
 
These differences indicate that the early aspects of Th1 gene induction (NFkB and IFNγ) persist 
even after 6 hours of ex vivo stimulation is associated with mice primed with rBCG expressing 
perfringolysin (rBCG pfo (gag) and rBCG ΔpanCDpfo (gag). Whilst the induction of NFkB and 
IFNγ are essential for the establishment of effector T cell responses to HIV, consistent up 
regulation of these inflammatory transcription factors and cytokines have been associated 
with increase viral replication. Persistence of effector T cell function has been associated to 
highly inflammatory vaccine vectors such as CMV. We postulate that this persistent up 
regulation of inflammatory markers is additionally associated with the generation of 
improved TEM responses in mice primed with rBCG pfo (gag) and rBCG ΔpanCDpfo (gag) as 
seen in Chapter 3. In addition to the mechanisms of how perfringolysin influences the HIV-1 
recall response, we were interested in the effects of the panCD deletion on the recall 
response. Uniquely, the recall response of mice primed with rBCG ΔpanCD (gag) was 
associated with a 42 fold down regulation in STAT4 which acts to promotes CD4+ T cell 
development and IFNγ production following IL-12 stimulation. The 42 fold down regulation of 
STAT4 in mice primed with rBCG ΔpanCD (gag), indicates a decrease in the activity of the JAK-
STAT signal transduction pathway. STAT 4 is a vital Th1 transcription factor for the expression 
of IL-2 and IFNy (Figure 4.7) which promotes the clonal expansion of antigen specific cells and 











inflammation induced by the rBCG ΔpanCD (gag) of rBCG.  Whilst HIV specific IL-2 was found 
to be produced by splenocytes following ex vivo peptide stimulation in Chapter 3, gene 
expression data contradicted this with no IL-2 up regulation observed. This is probably due to 
cytokine secretion kinetics and assay sensitivity.  
 
Figure 4.7 : Down regulation of STAT4 is associated with the less pathogenic rBCG ΔpanCD(gag) vaccine. A 
large down regulation in the Th1 transcription factor STAT4 would lead to decreased IL2 and IFNγ production. 
Physiologically, this would present as decreased clonal expansion of T cells, decreased inflammation and 
therefore decreased pathology   
  
In addition to STAT4, we observed chemokine and chemokine receptors (CCR2, CCR3, CCR4, 
and CXCR3) to be down regulated in rBCG (control) primed mice. Notably, CCR10, which is 
involved in tracking of cells to areas of inflammation, was highly down regulated in mice 
primed with rBCG ΔpanCD (control) and rBCG ΔpanCDpfo (control). Pathway analysis (Figure 
4.8) of these chemokine/receptor interactions suggests that G protein-coupled receptor 
kinase 6 (GRK6) controls the expression of these cytokines (not included on the RT-PCR array). 
Decreased expression of chemokines and chemokine receptors following ex vivo stimulation 
in rBCG ΔpanCD (control) and rBCG ΔpanCDpfo (control) could explain decreased splenic 
inflammation in the spleens of these mice as compared to rBCG WT (control) and rBCG pfo 












In the next Chapter, we propose dynamic models for each priming vaccine which 
mechanistically link these observed host gene expression differences to the improved safety 
and immunogenicity associated with modified rBCG as compared to WT Danish.   
  
  
Figure 4.8 Down regulation of chemotactic function is associated with priming with rBCG with the ΔpanCD 
deletion. By the process of phosphorylation, GRK6 can deactivate the expression of a number of chemokines 
and chemokine receptors including CCR10 which was highly down regulated in mice primed with rBCG ΔpanCD 













Chapter 5: Final Conclusions  
 
5.1 Introduction  
The UCT group has a long history of developing both persistent HIV-1 vectors (in the guise of 
rBCG) as well as HIV-1 poxviral vectors (such as MVA-Gag, SAAVI MVA-C). The development 
of improved modified strains of rBCG as candidate TB vaccines has furthered the potential of 
rBCG as a vaccine vector for heterologous antigens such as HIV-1 (da Costa et al., 2014, 
Chapman et al., 2011a, Chege et al., 2013, Hopkins et al., 2011). In this study, we assessed the 
safety and immunogenicity of 3 modified strains of Danish rBCG expressing HIV-1 Gag, (as well 
as a WT control) as priming vectors for a SAAVI MVA-C boost in the murine model. We have 
shown in preceding chapters that modified rBCG (expressing HIV-1 Gag) induces less 
pathology (Chapter 2) and improved antigen specific CD4+ and CD8+ T cell responses (Chapter 
3) as compared to rBCG WT (gag)(as part of a heterologous boost). In Chapter 4, we compared 
the expression of 86 immunologically pertinent Th1 and Th2 genes in the spleens of mice 
primed with either rBCG WT (gag), rBCG ∆panCD (gag) rBCG pfo (gag) or rBCG ∆panCDpfo 
(gag) and boosted with SAAVI MVA-C. We hypothesised that identification of host gene 
expression changes in unstimulated splenocytes (VU) and stimulated splenocytes (VS) would 
elucidate the molecular mechanisms of reduced pathology and improved HIV specific T cell 
responses (induced by modified rBCG as compared to priming with WT Danish).The 
assessment of relative gene expression in the murine spleen provides a snap shot of the 
effects of vaccination on the host immune system (VU) as well as the host immune response 
to antigen (VS) (recall response upon stimulation). It should be noted that gene expression 
itself does not guarantee translation of encoded proteins. Therefore, a systems vaccinology 
based approach dictates that we interpret our relative gene expression data in relation to the 





5.1.1 Improved bacilli clearance and decreased pathology associated with priming with 
rBCG containing the panCD deletion  
The attenuation of rBCG through deletion of the panCD genes has been shown to be a 
promising strategy to improve the safety of rBCG as a vaccine vector and has been shown to 
be associated to limited survival of the bacteria and hence pathology in mice 
(Sambandamurthy et al., 2002, Sampson et al., 2004, Chapman et al., 2012). The first of the 3 
modified rBCG priming vaccines discussed is rBCG ∆panCD (gag) (Figure 5.1).   
 We observed fewer rBCG granulomas and CD3+ T cell levels in the livers of mice vaccinated 
with rBCG ∆panCD (gag) as compared to the other 3 strains. This decreased T cell tracking to 
the site of infection, which we hypothesise is in part caused by the reduced virulence and is 
favourable for an efficacious HIV vaccine that aims to limit the spread of infected T cells 
(Esparza and Van Regenmortel, 2014, McMichael and Haynes). Decreased T cell tracking to 
central organs could also be the result of the attenuated rBCG ∆panCD (gag) and rBCG 
∆panCDpfo (gag) being cleared earlier (shown in Chapter 2 in the abdominal lymph nodes).    
Both clearance of BCG and conversely persistence of the bacilli have been reported to be 
associated with improved memory T cell responses. In this study, we show that mice primed 
with rBCG ∆panCD (gag)  (strains that are cleared from the periphery at day 7 post 
vaccination) present with improved CD4+ T cell effector memory following ex vivo stimulation 
with HIV peptide (as compared to rBCG WT (gag) and rBCG pfo (gag)).  
Persistence of BCG has also been associated with impaired T cell responses. In a recent study 
by Nandkumar et al, (2014), waning murine BCG responses 78 weeks post infection were 
characterised by reduced T cell functionality and up regulation of the T-cell inhibitory 
receptors CTLA 4 and killer cell lectin-like receptor subfamily G member 1 (KLRG-1) (>97% of 
CTLA-4+ or KLRG-1+ T-cell subsets did not produce IFN-γ, IL-2 or TNF-α). In this study, we 
demonstrate that priming with an attenuated Danish rBCG with limited persistence (rBCG 




rBCG WT (gag) and rBCG pfo (gag). Multifunctional CD4+ and CD8+ T cells have been 
associated with control of HIV vireamia in non-progressors and rBCG HIV-1 vaccine vectors 
should support the generation of such T cell functionality (Baker et al., 2009). In terms of 
clearance of the bacillus, a recent study by Gideon et al, (2015) indicated that a balanced 
Th1/Th2 response is more favourable for sterilisation of tuberculosis granulomas and this 












Figure 5.1: Systemic, cellular and genomic characteristics of priming with rBCG ∆panCD (gag). At the systemic level, mice primed with this vaccine cleared rBCG by day 7 post-
vaccination in abdominal lymph nodes. CD3 staining of liver sections revealed less T cell infiltration, granuloma formation and a more rapid granuloma dissociation than rBCG WT 
(gag). Phenotyping of splenocytes revealed lower levels of T cell activation and T cell numbers than mice primed with rBCG WT (gag). At the cellular level we assessed, the induction 
of HIV-1 specific T cells following SAAVI MVA-C boost and subsequent ex vivo peptide stimulation. rBCG ∆panCD (gag) primed significantly for a boost of T cell responses and was 
associated with improved CD4+ T cell memory and T cell functionality as compared to groups primed with rBCG WT (gag). Regulation of MAPK8 as well as SPP1 indicated that the 




   
Regardless of the anti-inflammatory response, the induction of improved CD4+ and CD8+ T 
cell responses, as compared to WT (gag), indicate that Danish rBCG ∆panCD (gag) can be far 
less inflammatory whilst priming effectively for HIV specific T cell responses in combination 
with a SAAVI MVA-C boost.   
A hallmark of the recall response in rBCG ∆panCD (gag) primed mice was the 42 fold down 
regulation of STAT4, a potent Th1 transcription factor. Additionally, down regulation of 
MAPK8 and SPP1 indicates potentially decreased rates of apoptosis in these mice.  
Preclinically, for both adjuvant activity and influencing the recall response, Danish rBCG 
ΔpanCD (gag) appears to be a safe and immunogenic priming vaccines for a heterologous 
poxviral boost.   
5.1.2 Prolonged inflammation following recall response and improved TEM frequency 
associated with priming with rBCG expressing perfringolysin (pfo)   
  
We next investigated host biomarkers associated with priming with rBCG pfo (gag), a 
persistent BCG vector. Concurrent analysis of systemic, cellular and genomic data in this study 
revealed a great deal about the impact of priming with rBCG pfo (gag) on the murine model 
system (Figure 5.2). Following priming with rBCG pfo (gag), we observed persistence of 
bacteria in secondary lymphoid organs such as the abdominal lymph nodes until experimental 
endpoint unlike in mice primed with rBCG ∆panCD (gag).  However, rBCG pfo (gag) was also 
able to prime for comparable boost responses to priming with rBCG ∆panCD (gag).  A hallmark 
of rBCG pfo (gag) induced immunogenicity as part of a SAAVI MVA-C boost was the induction 
of improved CD8+ T cell effector memory responses. Clearance of SIV in macaques vaccinated 
with RhCMV vectored SIV vaccines has been associated with persistent CD8+ TEM responses 
(Hansen et al., 2013a) and induction of such responses are favoured as an endpoint when 
testing T cell inducing HIV vaccines.   
Gene expression analysis revealed a number of Th1 (inflammatory) genes were up regulated 
(IFNy, NFkB). Whilst a Th1 dominant response favours anti-viral function, uncontrolled and 




Murine and rhesus macaque studies have demonstrated that TB vaccines vectored by 
perfringolysin knock in/urease C knock out BCG (Aeras 401) elicit enhanced protection and/or 
stronger CD8+ T cell responses to MTB as compared to the wild type strain (Sun et al., 2009, 
Rosario et al., 2010, Magalhaes et al., 2008a). Unfortunately during the duration of this study, 
the phase 1 TB vaccine safety trial using BCG Danish 1331 expressing pefringolysin O 
(Aeras422) was terminated due to side effects which included the reactivation of shingles 
(Kupferschmidt, 2011, Ottenhoff and Kaufmann, 2012).  We hypothesised that the lysis of 
endosomes induced by perfringolysin in conjunction with increased apoptosis and a 
persistent vector could lead to an intracellular environment with a high level of non-specific 
inflammation and immune activation.   
Whilst perfringolysin has been attenuated by the Gly 137 to Gln mutation which decreases 
the half-life of the protein in the cytosol, it still remains a toxin and antigen to rBCG as well as 
the host. Since an efficacious HIV-1 vaccine should be safe as well as immunogenic, our 
results, as well that of the AERAS 422 suggest that rBCG pfo (gag) should not be used 
exclusively as an HIV-1 vaccine. However, the perfringolysin molecule has enormous 
biological potential as an immunotherapeutic to induce translocation from the endosome and 
promote CD8+ T cell responses. Recent advances include the production of anti-perfringolysin 
antibodies which may assist with improving the safety of these therapies by limiting the 
longevity of pfo expression and function (Yang et al., 2015a).  Conversely, it can be argued 
that the non-specific inflammation induced by lysing the endosome is too unregulated in the 
context of an HIV vaccine which has to tightly influence the immune response to the specific 






Figure 5.2: Systemic, cellular and genomic characteristics of priming with rBCG pfo (gag). At the systemic level, mice primed with this vaccine showed persistent rBCG in lymph nodes at 
experimental endpoint. At the cellular level we assessed, the induction of HIV-1 specific T cells following SAAVI MVA-C boost and subsequent ex vivo peptide stimulation. Phenotyping of 
splenocytes revealed greater dendritic cell activation as compared to rBCG WT (gag). We hypothesised this to be due to cross priming initiated by the pore forming action of pfo on the 
endosome. rBCG pfo (gag) primed significantly for a boost of T cell responses and was associated with improved CD8+ T cell effector memory with rBCG WT (gag) and rBCG ∆panCD (gag).  




5.1.3 Synergistic action of panCD deletion and pfo to increase safety and immunogenicity 
of rBCG Danish   
  
Individually, rBCG ∆panCD (gag) and rBCG pfo (gag) have been shown to induce improved 
CD4+ and CD8+ T cell responses as compared to rBCG WT (gag). One of the major aims of this 
study was to assess the immunological characteristics of priming with a combination of the 
two modifications in the guise of rBCG ∆panCDpfo (gag) (Figure 5.3). Concurrent analysis of 
systemic, cellular and genomic data for mice primed with this vaccine and boosted with SAAVI 
MVA-C showed host immunological characteristics to be in part a combination of that 
observed in mice primed with either rBCG ∆panCD (gag) or rBCG pfo (gag).   
In terms of the development of liver pathology and peripheral bacterial clearance, mice 
primed with rBCG ∆panCDpfo (gag) were more similar to those primed with rBCG ∆panCD 
(gag) (reduced granuloma formation and clearance of bacterial load from abdominal lymph 
nodes by day 7). However, this did not diminish the induction of HIV specific CD8+ T cell 
effector memory function suggesting that whilst the panCD deletion confers improved safety, 
it does not abrogate the benefit of pfo mediated immunogenicity enhancement.   
Preservation of similar anti-apoptotic pathways as seen in mice primed with rBCG ∆panCD 
(gag) was observed (MAPK8, SPP1) suggesting that less pfo driven apoptosis may occur. Taken 
together this study demonstrates unique safety and protective correlates that rBCG Danish 
can elicit as a HIV-1 vaccine vector when modified. Additionally, we demonstrate that 
combining the ∆panCD modification with pfo can synergistically improve the immunogenicity 





Figure 5.3: Systemic, cellular and genomic characteristics of priming with rBCG ∆panCDpfo (gag). At the systemic level, mice primed with this vaccine showed persistent rBCG in lymph 
nodes at experimental endpoint. CD3 staining of liver sections revealed moderately less T cell infiltration and granuloma formation than rBCG WT (gag).  At the cellular level we assessed, 
the induction of HIV-1 specific T cells following SAAVI MVA-C boost and subsequent ex vivo peptide stimulation. rBCG ∆panCDpfo (gag) primed significantly for a boost of T cell responses 
and was associated with improved CD4+ and CD8+ T cell effector memory compared to rBCG WT (gag). At the genomic level, persistent up regulation of inflammatory mediators NFkB and 




Appendix 1  
 
Formulations of rBCG buffering and growth solutions   
  
1. BCG resuspension buffer:   
8.5% w/v NaCl, 10%glycerol, 10% Tyloxapol   
  
2. MB-7H9 media:   
4.7 g MB-7H9 broth; 100 ml OADC, 0.025% v/v tyloxapol, 0.25% w/v glycerol). Made up to 1litre 
of sterile H2O   
  
3. MB-7H10 agar:   




Appendix 2   
 
Formulations of murine splenocyte suspension solutions for immunology   
  
1. R10 complete media   
RPMI medium 1640, 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin   
  
2. Blocking solution for antibody binding   
0.12μl normal mouse serum, 0.12μl normal rat serum, 0.16μg CD16/32   
  
3. FACS buffer   
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